<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Injection sclerotherapy for varicose veins - de Ávila Oliveira, R - 2021 | Cochrane Library</title> <meta content="Injection sclerotherapy for varicose veins - de Ávila Oliveira, R - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001732.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Injection sclerotherapy for varicose veins - de Ávila Oliveira, R - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001732.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001732.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Injection sclerotherapy for varicose veins" name="citation_title"/> <meta content="Ricardo de Ávila Oliveira" name="citation_author"/> <meta content="Universidade Federal de Uberlândia" name="citation_author_institution"/> <meta content="avila@ufu.br" name="citation_author_email"/> <meta content="Rachel Riera" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Vladimir Vasconcelos" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Jose CC Baptista-Silva" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD001732.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001732.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001732.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001732.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Sclerotherapy [adverse effects]; *Varicose Ulcer; *Varicose Veins [therapy]; Veins; *Venous Insufficiency" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001732.pub3&amp;doi=10.1002/14651858.CD001732.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001732\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001732\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ko","ms","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001732.pub3",title:"Injection sclerotherapy for varicose veins",firstPublishedDate:"Dec 10, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001732.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001732.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001732.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001732.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001732.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001732.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001732.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001732.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001732.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001732.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4427 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001732.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0139"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-sec-0118"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/appendices#CD001732-sec-0144"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/supinfo/CD001732StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/supinfo/CD001732StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Injection sclerotherapy for varicose veins</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#CD001732-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Ricardo de Ávila Oliveira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#CD001732-cr-0005">Rachel Riera</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#CD001732-cr-0006">Vladimir Vasconcelos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information#CD001732-cr-0007">Jose CC Baptista-Silva</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information/en#CD001732-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001732.pub3">https://doi.org/10.1002/14651858.CD001732.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001732-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001732-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001732-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001732-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001732-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001732-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD001732-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001732-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001732-abs-0001" lang="en"> <section id="CD001732-sec-0001"> <h3 class="title" id="CD001732-sec-0001">Background</h3> <p>Varicose veins are enlarged and tortuous veins, affecting up to one‐third of the world's population. They can be a cause of chronic venous insufficiency, which is characterised by oedema, pigmentation, eczema, lipodermatosclerosis, atrophie blanche, and healed or active venous ulcers. Injection sclerotherapy (liquid or foam) is widely used for treatment of varicose veins aiming to transform the varicose veins into a fibrous cord. However, there is limited evidence regarding its effectiveness and safety, especially in patients with more severe disease. This is the second update of the review first published in 2002. </p> </section> <section id="CD001732-sec-0002"> <h3 class="title" id="CD001732-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of injection sclerotherapy for the treatment of varicose veins. </p> </section> <section id="CD001732-sec-0003"> <h3 class="title" id="CD001732-sec-0003">Search methods</h3> <p>For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, AMED, CINAHL, and LILACS databases, and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registries, on 20 July 2021. </p> </section> <section id="CD001732-sec-0004"> <h3 class="title" id="CD001732-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) (including cluster‐randomised trials and first phase cross‐over studies) that used injection sclerotherapy for the treatment of varicose veins. </p> </section> <section id="CD001732-sec-0005"> <h3 class="title" id="CD001732-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed, selected and extracted data. Disagreements were cross‐checked by a third review author. We used Cochrane's Risk of bias tool to assess the risk of bias. The outcomes of interest were cosmetic appearance, complications, residual varicose veins, quality of life (QoL), persistence of symptoms, and recurrent varicose veins. We calculated risk ratios (RRs) or mean difference (MD) with 95% confidence intervals (CIs). We used the worst‐case‐scenario for dichotomous data imputation for intention‐to‐treat analyses. For continuous outcomes, we used the 'last‐observation‐carried‐forward' for data imputation if there was balanced loss to follow‐up. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD001732-sec-0006"> <h3 class="title" id="CD001732-sec-0006">Main results</h3> <p>We included 23 new RCTs for this update, bringing the total to 28 studies involving 4278 participants. The studies differed in their design, and in which sclerotherapy method, agent or concentration was used. None of the included RCTs compared sclerotherapy to no intervention or to any pharmacological therapy. The certainty of the evidence was downgraded for risk of bias, low number of studies providing information for each outcome, low number of participants, clinical differences between the study participants, and wide CIs. </p> <p><b>Sclerotherapy versus placebo</b> </p> <p>Foam sclerotherapy may improve cosmetic appearance as measured by IPR‐V (independent photography review ‐ visible varicose veins scores) compared to placebo (polidocanol 1%: mean difference (MD) ‐0.76, 95% CI ‐0.91 to ‐0.60; 2 studies, 223 participants; very low‐certainty evidence); however, deep vein thrombosis (DVT) rates may be slightly increased in this intervention group (RR 5.10, 95% CI 1.30 to 20.01; 3 studies, 302 participants; very low‐certainty evidence). Residual varicose vein rates may be decreased following polidocanol 1% compared to placebo (RR 0.19, 95% CI 0.13 to 0.29; 2 studies, 225 participants; very low‐certainty evidence). Following polidocanol 1% use, there may be a possible improvement in QoL as assessed using the VEINES‐QOL/Sym questionnaire (MD 12.41, 95% CI 9.56 to 15.26; 3 studies, 299 participants; very low‐certainty evidence), and possible improvement in varicose vein symptoms as assessed using the Venous Clinical Severity Score (VCSS) (MD ‐3.25, 95% CI ‐3.90 to ‐2.60; 2 studies, 223 participants; low‐certainty evidence). Recurrent varicose veins were not reported for this comparison. </p> <p><b>Foam sclerotherapy versus foam sclerotherapy with different concentrations</b> </p> <p>Three individual RCTs reported no evidence of a difference in cosmetic appearance after comparing different concentrations of the intervention; data could not be pooled for two of the three studies (RR 1.11, 95% CI 0.84 to 1.47; 1 study, 80 participants; very low‐certainty evidence). Similarly, there was no clear difference in rates of thromboembolic complications when comparing one foam concentration with another (RR 1.47, 95% CI 0.41 to 5.33; 3 studies, 371 participants; very low‐certainty evidence). Three RCTs investigating higher concentrations of polidocanol foam indicated the rate of residual varicose veins may be slightly decreased in the polidocanol 3% foam group compared to 1% (RR 0.67, 95% CI 0.43 to 1.04; 3 studies, 371 participants; moderate‐certainty evidence). No clear improvement in QoL was detected. Two RCTs reported improved VCSS scores with increasing concentrations of foam. Persistence of symptoms were not reported for this comparison. There was no clear difference in recurrent varicose vein rates (RR 0.91, 95% CI 0.62 to 1.32; 1 study, 148 participants; low‐certainty evidence). </p> <p><b>Foam sclerotherapy versus liquid sclerotherapy</b> </p> <p>One RCT reported on cosmetic appearance with no evidence of a difference between foam or liquid sclerotherapy (patient satisfaction scale MD 0.2, 95% CI ‐0.27 to 0.67; 1 study, 126 participants; very low‐certainty evidence). None of the RCTs investigated thromboembolic complications, QoL or persistence of symptoms. Six studies individually showed there may be a benefit to polidocanol 3% foam over liquid sclerotherapy in reducing residual varicose vein rate; pooling data from two studies showed a RR of 0.51, with 95% CI 0.41 to 0.65; 203 participants; very low‐certainty evidence. One study reported no clear difference in recurrent varicose vein rates when comparing sodium tetradecyl sulphate (STS) foam or liquid (RR 1.10, 95% CI 0.86 to 1.42; 1 study, 286 participants; very low‐certainty evidence). </p> <p><b>Sclerotherapy versus sclerotherapy with different substances</b> </p> <p>Four RCTs compared sclerotherapy versus sclerotherapy with any other substance. We were unable to combine the data due to heterogeneity or assess the certainty of the evidence due to insufficient data. </p> </section> <section id="CD001732-sec-0007"> <h3 class="title" id="CD001732-sec-0007">Authors' conclusions</h3> <p>There is a very low to low‐certainty evidence that, compared to placebo, sclerotherapy is an effective and safe treatment for varicose veins concerning cosmetic appearance, residual varicose veins, QoL, and persistence of symptoms. Rates of DVT may be slightly increased and there were no data concerning recurrent varicose veins. There was limited or no evidence for one concentration of foam compared to another; foam compared to liquid sclerotherapy; foam compared to any other substance; or one technique compared to another. There is a need for high‐quality trials using standardised sclerosant doses, with clearly defined core outcome sets, and measurement time points to increase the certainty of the evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001732-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001732-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001732-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001732-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001732-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD001732-abs-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001732-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001732-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001732-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001732-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001732-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001732-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001732-abs-0002" lang="en"> <h3>Injection sclerotherapy for varicose veins</h3> <p><b>Background</b> </p> <p>Varicose veins are enlarged, visibly lumpy knotted veins, usually found in the legs. They can cause pain, burning discomfort, aching, and itching as well as generalised aching, heaviness or swelling in the legs. However, some people do not attribute all symptoms to varicose veins, as there is little correlation between these symptoms and the extent or size of the varicose veins. Varicose vein disease can affect quality of life as it is cosmetically unattractive, can cause phlebitis, bleeding, skin pigmentation, and ulcers. </p> <p>Injection sclerotherapy can be used to treat varicose veins. Sclerotherapy is achieved by injection of an irritating liquid or foam into the blood vessels, leading to transformation of varicose veins into a fibrous cord. Possible complications include the formation of blood clots, skin pigmentation, inflammation, ulceration with tissue damage, and reactions to the sclerosing agent. </p> <p>This review aimed to investigate how effective and safe sclerotherapy is by comparing it to no treatment or placebo (sham) treatment; comparing different ways to perform sclerotherapy (including different doses, liquid versus foam, injection techniques, different substances) or comparing sclerotherapy to compression. </p> <p><b>Study characteristics and key findings</b> </p> <p>We searched for relevant studies and identified 28 randomised controlled trials, involving over 4278 participants (search current to 20 July 2021). We looked at cosmetic appearance, complications, residual varicose vein rates, quality of life, and symptomatic improvement related to sclerotherapy. There were no trials assessing treatment versus no interventions, sclerotherapy at different time intervals, or sclerotherapy compared with pharmacological therapy. </p> <p>Our results showed that, compared to placebo, sclerotherapy may improve cosmetic appearance and quality of life, and may reduce residual varicose veins and persistence of symptoms but the evidence is uncertain. Rates of deep vein thrombosis may be slightly increased but the evidence is uncertain. There were no data for recurrent varicose veins. There was not enough Information to conclude if one concentration of foam was better than another, or if foam was better than liquid or any other substance; or if there was any benefit of one injection technique compared to another. </p> <p><b>Reliability of the evidence</b> </p> <p>The evidence was graded as very low to moderate for all outcomes. The reliability of the evidence was downgraded due to concerns about how the studies were designed (risk of bias), the low number of studies providing information for each outcome, the low number of participants, clinical differences between the study participants, and wide confidence intervals. There is a need for more high‐quality trials using standardised methods to increase our confidence in the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001732-sec-0139" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001732-sec-0139"></div> <h3 class="title" id="CD001732-sec-0140">Implications for practice</h3> <section id="CD001732-sec-0140"> <p>There is a very low‐ to low‐certainty evidence that, compared to placebo, sclerotherapy is an effective and safe treatment for varicose veins concerning cosmetic appearance, residual varicose veins, QoL, and persistence of symptoms. Rates of DVT may be slightly increased and there were no data concerning recurrent varicose veins. There was limited or no evidence for one concentration of foam compared to another; foam compared to liquid sclerotherapy; foam compared to any other substance; or one technique compared to another. </p> </section> <h3 class="title" id="CD001732-sec-0141">Implications for research</h3> <section id="CD001732-sec-0141"> <p>The cost‐effectiveness of the treatment of varicose veins has significant implications for healthcare. Although there are some undesirable residual varicose veins, additional sclerotherapy sessions could be performed to resolve them (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). Sclerotherapy is a cheaper procedure when compared to any other surgical intervention for varicose veins, despite the issue of increasing costs with newer sessions; it might be the most cost‐effective treatment available (<a href="./references#CD001732-bbs2-0049" title="CarrollC , HummelS , LeavissJ , RenS , StevensJW , Everson-HockE , et al. Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. Health Technology Assessment2013;17(48):1–141. [DOI: 10.3310/hta17480]">Carrol 2013</a>). Sclerotherapy reaches veins which are impossible for treatment by other methods, so it could always be used as the main or the complementary choice of treatment. Possibly there is a dose‐response effect, and an increase in the concentrations of polidocanol foam decreased residual varicose veins up to polidocanol 3%. We do not know if increasing the polidocanol concentration even more could produce better results or if it could increase risks to patients. This question still needs to be answered with new studies. </p> <p>There is a need for high‐quality RCTs with a large number of participants, with comparable CEAP clinical classification, standardised sclerosant dose, clearly defined outcomes and time points to measure. A core outcome set for varicose veins would be helpful in defining the best outcomes to be studied. Adverse events should be better evaluated, mainly for higher concentrations of polidocanol foam (e.g. 3%). There is a need for studies comparing varicose vein interventions versus no interventions to understand if the natural history of the disease is worse than the risks of the treatment. </p> <p>There is a lack of RCTs using the same time point to reproduce results from cosmetic appearance after sclerotherapy. Ideally, cosmetic appearance should be evaluated after three to six months since this period is sufficient for phlebitis to disappear and to reabsorb the sclerosis material. One RCT described the same success rates at six months, with a need for new sclerotherapy sessions (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). Probably, as described in another study, recanalisation occurrence is high and should be reviewed at six months (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). It is essential to avoid limiting the diameter of the vein studied. Instead, there should be strict criteria for varicose vein definition. We propose that only dilated, tortuous veins with loss of function are included. It is possible that a considerable number of veins treated with a low diameter and with reflux detected are not varicose veins. Greater diameter varicose veins are subject to events influencing sclerosing: 1) effect of Archimedes (greater veins depend on higher volumes to occupy the lumen); and 2) floating phenomenon (foam tends to fluctuate and treat the upper wall of the vein leaving the base untreated). These effects should be considered for a subgroup analysis using foam sclerotherapy in larger varicose veins. </p> <p>Complications are rare events associated with sclerotherapy. The low number of events contributed to downgrading the certainty of the evidence. Therefore, RCTs focussing on complications should include a larger number of participants. There are complications limited to a short period of follow‐up (e.g. DVT and PE), and time points should have a rationale for those events. We propose time points for evaluating thromboembolic events up to 30 days after the last injection and between 30 days to six months. One other single source of bias is the amount of sclerosant injected in a single puncture or multiple ones. There is a lack of RCTs evaluating if the amount of sclerosant is important in ensuring the sclerosant agent reaches the deep venous system, providing a source of deep vein thrombosis. Comparing different volumes injected in each puncture could reduce the risk of including another source of bias for DVT, thrombophlebitis, and cerebrovascular complications. Skin pigmentation, on the other hand, should be better described at three, six, and 24 months since it appears later in the process and could also disappear later on. </p> <p>Evidence from residual varicose veins and recurrent varicose veins is confused due to differences in definitions and time point measures. To date, the spasm frequently does not lead to venous occlusion and recanalisation is not recurrent varicose veins. So, we propose one week to one month ideally to verify residual varicose veins and occluded veins after a sclerotherapy session. After this period, it is possible to develop recurrent varicose veins. Evidence of occlusion should lead to the diagnosis of recanalisation. These aspects introduce a necessity to clarify outcomes and time points to measure them. We also understand that time intervals between sclerotherapy sessions could have a substantial impact on residual and recurrent varicose veins. Time‐interval sclerotherapy is a particularly important issue since every treatment for varicose veins may have an influence on the rate of recanalisation and pigmentation. If necessary, new sessions of sclerotherapy should be performed without increasing risk but with increments in effectiveness (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). </p> <p>Despite the low number of RCTs describing quality of life, this is the critical factor for considering a varicose vein treatment. Quality of life is affected in many ways in the course of the disease. Indeed, we still need to know if different gases, substances, presentations (liquid versus foam), and many other comparisons could be the best way to treat varicose veins (e.g. using the same concentration of sclerosants which one would be the most effective to treat varicose veins?). Finally, further studies are needed to increase the number of events and so our confidence in the effect. </p> <p>Different techniques, including proximal versus distal treatment sclerotherapy, need to be studied since proximal sclerotherapy could have other effects (e.g. reducing the diameter of distal varicose veins for future new sessions) and risks (e.g. DVT and PE). </p> <p>There is a need for definitions of core outcome sets for varicose veins since some outcomes and the best way to measure them are still to be defined. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001732-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001732-sec-0008"></div> <div class="table" id="CD001732-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Foam sclerotherapy versus placebo for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam sclerotherapy (polidocanol 1%) compared to placebo for varicose veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>a</sup><br/><b>Setting:</b> clinical or hospital‐based study<br/><b>Intervention:</b> polidocanol 1% foam sclerotherapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 1% foam sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance (IPR‐V)</b> </p> <p>(Scale from: 0 to 4; 0 being the best appearance (0: none, 1: mild, 2: moderate, 3: severe, 4: very severe))<br/>follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The adjusted mean change from baseline in cosmetic appearance (IPR‐V) was ‐0.04</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 0.76 lower<br/>(0.91 lower to 0.6 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications ‐ DVT</b> </p> <p>follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.10<br/>(1.30 to 20.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>302<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c,d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(17 to 265) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/>(0.13 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>973 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000<br/>(127 to 282) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>(VEINES‐QOL/Sym;<br/>scale from: 0 to 50 with 0 being the worst and 50 better)<br/>follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in QoL (VEINES‐QOL/Sym score) was 9.60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 12.41 higher<br/>(9.56 higher to 15.26 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>f,g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> <p>(VCSS)</p> <p>follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in persistence of symptoms (VCSS score) was ‐1.14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 3.25 lower<br/>(3.9 lower to 2.6 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrent varicose veins</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated recurrent varicose veins in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DVT</b> : deep vein thrombosis; <b>IPR‐V:</b> independent photography review ‐ visible varicose veins scores;<b>MD</b> : mean difference; <b>QoL</b> : quality of life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VCSS</b> : venous clinical severity score; <b>VEINES‐QOL/Sym:</b> disease‐specific QoL instrument for chronic venous disorders of the leg </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> There were CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) participants included but there was no description of the proportion of these participants in the groups. <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> used the lower leg as the unit of analysis. In the remaining studies, the participant was the unit of analysis. </p> <p><sup>b</sup> We downgraded the certainty of the evidence two levels as neither personnel nor participants were blinded (risk of bias concerns). </p> <p><sup>c</sup> We downgraded one level for indirectness as <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> included 8.8% CEAP C5 and C6 in the placebo group and 3.4% CEAP C5 and C6 in the polidocanol 1% foam group. </p> <p><sup>d</sup> We downgraded one level due to inconsistency ‐ clinical heterogeneity among studies (severity of disease). </p> <p><sup>e</sup> We downgraded one level for imprecision due to low number of events; CI included both 'no difference' and a 'clinically important difference'. </p> <p><sup>f</sup> We downgraded one level due to a wide CI. </p> <p><sup>g</sup> We downgraded one level for imprecision ‐ low number of participants. </p> <p><sup>h</sup> We downgraded one level for indirectness (8.8% CEAP C5 and C6 participants in the placebo group). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001732-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Foam sclerotherapy versus foam sclerotherapy for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam sclerotherapy (polidocanol 3%) compared to foam sclerotherapy (polidocanol 1%) for treating varicose veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>a</sup><br/><b>Setting:</b> hospital or clinical setting<br/><b>Intervention:</b> polidocanol 3% foam sclerotherapy<br/><b>Comparison:</b> polidocanol 1% foam sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 1% foam sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 3% foam sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance</b> </p> <p>(self‐described cosmetic improvement)<br/>follow‐up: mean 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.84 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>675 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>749 per 1000<br/>(567 to 992) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications ‐ thromboembolic</b> </p> <p>follow‐up: range 3 weeks to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.47<br/>(0.41 to 5.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>371<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>d,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(7 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: range 6 months to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/>(0.43 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>371<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000<br/>(156 to 378) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated QoL for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated persistence of symptoms for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent varicose veins</b> </p> <p>follow‐up: mean 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.62 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>c,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>406 per 1000<br/>(276 to 589) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>QoL</b> : quality of life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> included 12.5% C1 participants. The studies included participants from C2 to C6 clinical classes without description of the proportions of C5 and C6 participants. </p> <p><sup>b</sup> We downgraded by one level as most risk of bias domains were judged as "unclear". </p> <p><sup>c</sup> We downgraded by one level due to imprecision ‐ single study. </p> <p><sup>d</sup> We downgraded by one level due to imprecision ‐ wide confidence interval. </p> <p><sup>e</sup> We downgraded by one level due to imprecision ‐ low number of participants. </p> <p><sup>f</sup> There were CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) participants included but there was no description of the proportion of these participants in the groups. <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>) used the lower leg as the unit of analysis. In the remaining studies, the participant was the unit of analysis. We downgraded by one level for indirectness. </p> <p><sup>g</sup> We downgraded by one level due to imprecision ‐ low number of events. </p> <p><sup>h</sup> There were participants from C5 and C6 clinical classes included (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) but there was no description of the proportion of these participants in the groups. We downgraded by one level for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001732-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Foam sclerotherapy versus liquid sclerotherapy for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam sclerotherapy compared to liquid sclerotherapy for varicose treating veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>a</sup><br/><b>Setting:</b> hospital or clinic‐based<br/><b>Intervention:</b> foam sclerotherapy using the same agent and concentration of the control<br/><b>Comparison:</b> liquid sclerotherapy using the same agent and concentration of the intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with liquid sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with foam sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance</b> </p> <p>(patient satisfaction scale, the higher the better)</p> <p>follow‐up: long‐term (365 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cosmetic appearance of the patient satisfaction scale was 7.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 0.2 higher (0.27 lower to 0.67 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a> reported no difference when using polidocanol 0.75% to 1.25% foam versus polidocanol 1.5% to 2.5% liquid. Different concentrations and different vein diameters were compared, reducing our confidence in these results </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complications ‐ DVT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated DVT or thromboembolic events for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: range 3 months to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/>(0.41 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>203<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>842 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000<br/>(345 to 547) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated QoLfor this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated persistence of symptoms for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent varicose veins</b> </p> <p>follow‐up: mean 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(0.86 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>286<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>477 per 1000<br/>(373 to 615) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DVT</b> ; deep vein thrombosis; <b>MD:</b> mean difference; <b>QoL:</b> quality of life;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Did not describe randomisation method. Due to the nature of the intervention was probably impossible to blind interventionist. We did not find a protocol. Risk of bias concerns </p> <p><sup>b</sup> Single study. We downgraded by one level for imprecision. </p> <p><sup>c</sup> Compared different concentration of the same substances for different vein diameter. Used different concentrations of the drug if liquid or foam </p> <p><sup>d</sup> We downgraded by one level for risk of bias concerns (query about randomisation method). </p> <p><sup>e</sup> We downgraded by one level for risk of bias concerns (intervention was presumably not blinded (foam vs liquid) due to the nature of the intervention). </p> <p><sup>f</sup> One study (<a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>) included participants from CEAP C2 to C6 without discriminating between them. <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a> included 1 CEAP C5 participant in the foam group (1.85%) and 4 CEAP C5 participants in the liquid group (7.69%). We downgraded by one level for indirectness. </p> <p><sup>h</sup><a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a> used a tensioactive substance (ultrasound contrast agent) to produce foam. This is not a standard way to produce foam. We downgraded by one level for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001732-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different substances for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy with STS 1% compared to sclerotherapy with polidocanol 1%<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>b</sup><br/><b>Setting:</b> clinical or hospital‐based study<br/><b>Intervention:</b> STS 1% sclerotherapy<br/><b>Comparison:</b> polidocanol 1% sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 1% sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with STS 1% sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance</b> </p> <p>follow‐up: 12 to 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two RCTs compared sclerotherapy with sclerotherapy with different substances but used a range of concentrations, formulations and drug volumes. We were unable to pool the data or draw conclusions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complications ‐ DVT</b> </p> <p>follow‐up: 16 weeks to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two RCTs reported on DVT but we were unable to pool the data or draw conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One RCT reported on residual varicose veins but we were unable to draw conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated QoL in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated persistence of symptoms in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrent varicose veins</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated recurrent varicose veins in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DVT</b> : deep vein thrombosis; <b>QoL</b> : quality of life; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>STS:</b> sodium tetradecyl sulphate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Four RCTs compared sclerotherapy with sclerotherapy with different substances but used a range of concentrations, formulations and drug volumes so we were not able to pool the data (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). None of these compared STS 1% sclerotherapy versus sclerotherapy with polidocanol 1% which we had planned to present in this table. </p> <p><sup>b</sup> Three studies did not describe CEAP classification of participants (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>). One study compared Varisolve with polidocanol 1% to any marketed sclerosant at any marketed concentration liquid or foam (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001732-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001732-sec-0009"></div> <section id="CD001732-sec-0010"> <h3 class="title" id="CD001732-sec-0010">Description of the condition</h3> <p>Varicose veins are enlarged and tortuous veins. They are subcutaneous and at least 3 mm in diameter (<a href="./references#CD001732-bbs2-0053" title="EklöfB , RutherfordRB , BerganJJ , CarpentierPH , Peter GloviczkiP , KistnerRL , et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40:1248-52. [DOI: 10.1016/j.jvs.2004.09.027]">Eklöf 2004</a>; <a href="./references#CD001732-bbs2-0055" title="HamdanA . Management of varicose veins and venous insufficiency. JAMA2012;308(24):2612-21. [DOI: 10.1001/jama.2012.111352]">Hamdan 2012</a>). It is difficult to find a satisfactory definition of varicose veins upon which consensus has been reached since reticular varicose veins can also be enlarged and tortuous. In 2012, the Vein Consult program cohort reported the epidemiology of chronic venous disease of a large international population of 91,545 adult patients' cohort across a diverse geographic area, including Europe, Latin America, the Middle East, and the Far East (<a href="./references#CD001732-bbs2-0072" title="RabeE , GuexJJ , PuskasA , ScuderiA , Fernandez QuesadaF . Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. International Angiology2012;31(2):105-15.">Rabe 2012</a>). Rabe and colleagues reported that 41.4% of these patients had early stage chronic venous disease (CEAP class C0s–C1) and 84% had any class of chronic venous disease greater than C0s (<a href="./references#CD001732-bbs2-0072" title="RabeE , GuexJJ , PuskasA , ScuderiA , Fernandez QuesadaF . Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. International Angiology2012;31(2):105-15.">Rabe 2012</a>). </p> <p>There are different prevalences of varicose vein disease described around the world, depending on factors such as personal lifestyle, obesity, and age (<a href="./references#CD001732-bbs2-0050" title="DaviesAH . The seriousness of chronic venous disease: a review of real-world evidence. Advances in Therapy2019;36 (Suppl 1):5-12. [DOI: 10.1007/s12325-019-0881-7]">Davies 2019</a>). </p> <p>The symptoms attributable to varicose veins, and their correlation with the extent of venous reflux (reversal of blood flow through the valves of veins during standing or sitting), are not clearly defined. Epidemiological evidence suggests that even in the presence of 'trunk' varicose veins, defined as varicose from great or short saphenous veins or their first or second order branches, most lower‐limb symptoms have a non‐venous cause (<a href="./references#CD001732-bbs2-0048" title="BradburyA , EvansC , AllanP , LeeA , RuckleyCV , FowkesFG . What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. BMJ1999;318(7180):353-6.">Bradbury 1999</a>). The Edinburgh Vein Study has demonstrated superficial venous reflux in 9% of randomly selected men and 15% of women as well as deep vein reflux in 22% of men and 11% of women (<a href="./references#CD001732-bbs2-0047" title="AllanPL , BradburyAW , EvansCJ , LeeAJ , RuckleyCV , FowkesFG . Patterns of reflux and severity of varicose veins in the general population - Edinburgh Vein Study. European Journal of Vascular and Endovascular Surgery2000;20(5):470-7.">Allan 2000</a>). Subjects with visible varicose veins have a higher incidence of reflux on Duplex ultrasound, although in many cases of documented reflux, there are no visible varicose veins. There is also little correlation between symptoms of varicose veins and their extent or size on examination. However, commonly reported symptoms include local discomfort of the varicose veins (pain, burning discomfort, aching and itching), generalised lower limb symptoms (aching, heaviness, and swelling), as well as complaints about cosmetic appearance. </p> <p>Swelling and night cramps are commonly reported signs and symptoms of varicose veins in pregnancy and the treatment options for pregnant women have been evaluated in another Cochrane Review (<a href="./references#CD001732-bbs2-0078" title="SmythRM , AflaifelN , BamigboyeAA . Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD001066. [DOI: 10.1002/14651858.CD001066.pub3]">Smyth 2015</a>; <a href="./references#CD001732-bbs2-0082" title="YoungGL , JewellD . Interventions for varicosities and leg oedema in pregnancy. Cochrane Database of Systematic Reviews1998, Issue 2. Art. No: CD001066. [DOI: 10.1002/14651858.CD001066]">Young 1998</a>). </p> <p>Clinicians use the classification system based on clinical manifestations (C), aetiologic factors (E), anatomic distribution (A), and underlying pathophysiology (P) (<a href="./references#CD001732-bbs2-0053" title="EklöfB , RutherfordRB , BerganJJ , CarpentierPH , Peter GloviczkiP , KistnerRL , et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40:1248-52. [DOI: 10.1016/j.jvs.2004.09.027]">Eklöf 2004</a>). </p> <p>The majority of outcome measures, following treatment of varicose veins, are assessed subjectively, i.e. symptomatic improvement, cosmetic appearance, and quality of life measures. Outcomes that can be objectively evaluated include varicose vein recurrence and complication rates. </p> <p>Varicose vein treatment options include conservative treatments (stockings, lifestyle modifications, sick leave, and medications) (<a href="./references#CD001732-bbs2-0055" title="HamdanA . Management of varicose veins and venous insufficiency. JAMA2012;308(24):2612-21. [DOI: 10.1001/jama.2012.111352]">Hamdan 2012</a>), and a variety of surgical interventions. Traditionally, surgery is commonly used to treat 'main stem' varicose veins (where the vein is stripped). Endovascular procedures (where the vein is treated but not stripped) include endovenous laser therapy, radiofrequency ablation therapy, and sclerotherapy. Endovenous laser therapy and radiofrequency ablation therapy use specific catheter devices to heat and cause thrombotic and fibrotic closure (<a href="./references#CD001732-bbs2-0069" title="PiazzaG . Varicose veins. Circulation2014;130:582-7. [DOI: 10.1161/CIRCULATIONAHA.113.008331.]">Piazza 2014</a>) damaging the endothelium and the inner media. Sclerotherapy is another endovascular procedure that aims to obliterate the varicose veins using liquid or foam preparations injected inside the lumen of the varicose vein. The option of treatment to use is driven by the patient preference for less invasive procedures, the location of the vein, the size, aetiology, and the costs of the treatment options (<a href="./references#CD001732-bbs2-0049" title="CarrollC , HummelS , LeavissJ , RenS , StevensJW , Everson-HockE , et al. Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. Health Technology Assessment2013;17(48):1–141. [DOI: 10.3310/hta17480]">Carrol 2013</a>; <a href="./references#CD001732-bbs2-0055" title="HamdanA . Management of varicose veins and venous insufficiency. JAMA2012;308(24):2612-21. [DOI: 10.1001/jama.2012.111352]">Hamdan 2012</a>; <a href="./references#CD001732-bbs2-0069" title="PiazzaG . Varicose veins. Circulation2014;130:582-7. [DOI: 10.1161/CIRCULATIONAHA.113.008331.]">Piazza 2014</a>). </p> </section> <section id="CD001732-sec-0011"> <h3 class="title" id="CD001732-sec-0011">Description of the intervention</h3> <p>Traditionally, sclerotherapy is defined as hardening of the vein. It is carried out by a needle puncture and injection of sclerosant (a substance that cause thrombosis and fibroses of the vein leading to reabsorption and resolution of the varicose vein). Vascular surgeons and dermatologists also use sclerotherapy to treat thread veins, telangiectasias, and reticular veins. In larger veins, it involves injecting liquid or foam medicines to cause sclerosing. Foam sclerotherapy is performed by mixing the liquid sclerosant agent with air. Despite presenting similar endpoints of other treatment options (for instance, phlebectomy, laser, radiofrequency), injection sclerotherapy can treat collateral veins which are sometimes difficult to treat with laser or radiofrequency and, probably, with lower costs (<a href="./references#CD001732-bbs2-0049" title="CarrollC , HummelS , LeavissJ , RenS , StevensJW , Everson-HockE , et al. Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. Health Technology Assessment2013;17(48):1–141. [DOI: 10.3310/hta17480]">Carrol 2013</a>). </p> </section> <section id="CD001732-sec-0012"> <h3 class="title" id="CD001732-sec-0012">How the intervention might work</h3> <p>The procedure of injecting sclerosants directly into the vessel damages the varicose vein without taking it out. This damage directly affects the endothelium and media wall causing inflammation and apoptosis (cell death) in up to 300 μm of the media vein wall (<a href="./references#CD001732-bbs2-0079" title="WhiteleyMS , Dos SantosSJ , Fernandez-HartTJ , LeeCTD , LiJM . Media damage following detergent sclerotherapy appears to be secondary to the induction of inflammation and apoptosis: an immunohistochemical study elucidating previous histological observations. European Journal of Vascular and Endovascular Surgery2016;51:421-8.">Whiteley 2016</a>). This produces a fibrous cord known as sclerosis with a functional result similar to surgery (<a href="./references#CD001732-bbs2-0071" title="RabeE , PannierF . Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology. Dermatologic Surgery2010;36:968-75.">Rabe 2010</a>), that is, occluding the varicose vein and eliminating the reflux (<a href="./references#CD001732-bbs2-0067" title="O’HareJL , EarnshawJJ . Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer. European Journal of Vascular and Endovascular Surgery2010;39:495-9.">O'Hare 2010</a>). </p> </section> <section id="CD001732-sec-0013"> <h3 class="title" id="CD001732-sec-0013">Why it is important to do this review</h3> <p>Currently, varicose veins may be treated by either conventional surgery, or newer techniques such as foam sclerotherapy, endovenous laser ablation (EVLT), and radiofrequency ablation (RFA). There is limited evidence to aid choice of which treatment is more effective. This update will provide the current evidence regarding injection sclerotherapy for varicose veins to inform health policymakers, health professional and consumers. </p> <p>This review is the second update of a systematic review first published in 2002 and updated in 2006. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001732-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001732-sec-0014"></div> <p>To assess the effectiveness and safety of injection sclerotherapy for the treatment of varicose veins. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001732-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001732-sec-0015"></div> <section id="CD001732-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001732-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) ‐ including cluster‐randomised trials and first phase cross‐over studies ‐ that used injection sclerotherapy for the treatment of varicose veins. Quasi‐randomised controlled trials, where the method of allocation was known but not considered truly random (e.g. alternation, date of birth), were excluded (<a href="./references#CD001732-bbs2-0057" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated March 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.">Higgins 2017a</a>). </p> </section> <section id="CD001732-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included all participants referred to a surgical outpatient clinic or primary care practitioner with symptomatic or cosmetic varicose veins, defined by clinical and/or ultrasound criteria as follows. </p> <p> <ul id="CD001732-list-0001"> <li> <p>Clinical criteria: CEAP C2, C3, and C4. CEAP C2 was defined as varicose veins more than 3 mm in diameter, C3 as a limb with oedema related to venous disease, and C4 as a limb with skin and subcutaneous changes (including pigmentation or eczema, and lipodermatosclerosis or atrophie blanche) related to venous disease (<a href="./references#CD001732-bbs2-0053" title="EklöfB , RutherfordRB , BerganJJ , CarpentierPH , Peter GloviczkiP , KistnerRL , et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40:1248-52. [DOI: 10.1016/j.jvs.2004.09.027]">Eklöf 2004</a>). </p> </li> <li> <p>Ultrasound criteria: handheld Doppler or duplex ultrasound defining varicose veins with or without the description of the depth of the vein related to the skin. </p> </li> </ul> </p> <p>We excluded people diagnosed as having CEAP C1 (including telangiectasias and reticular varicose veins), people with a healed venous leg ulcer (CEAP C5), and people with a venous leg ulcer (CEAP C6). </p> </section> <section id="CD001732-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies which used any injection sclerotherapy technique to treat varicose veins. We considered: </p> <p> <ul id="CD001732-list-0002"> <li> <p>Any sclerosant (e.g. sodium tetradecyl sulphate (STS), ethanolamine, polidocanol (Sclerovein, Aetoxysclerol, Aethoxysklerol, Aethoxysclerol, Atoxisclerol, Sotrauerix, Laureth 9), chrome alum (Scleremo), hypertonic saline (NaCl 17.55%); </p> </li> <li> <p>Any formulation (e.g. liquid, foam, and gas in foam (ambient air, O<sub>2</sub>, CO<sub>2</sub>)); </p> </li> <li> <p>Any dosage (e.g. STS 0.2%, 0.5%, 1%, 3%, polidocanol 1%, 3%);</p> </li> <li> <p>Using any technique (e.g. injection in empty veins, bandaging and compression techniques and repeat treatment intervals). </p> </li> </ul> </p> <p>We included studies comparing sclerotherapy with nonsurgical interventions (no intervention, conservative treatment including pharmacological therapy and/or graduated compression stockings, or sclerotherapy). Studies which compared sclerotherapy with an open surgical procedure (e.g. stripping), other endovascular approaches (laser or radiofrequency), and studies which investigated compression after sclerotherapy were not relevant for this review. They will be covered in other Cochrane Reviews. </p> <p>We included the following comparisons:</p> <p> <ul id="CD001732-list-0003"> <li> <p>Sclerotherapy versus no intervention or no active intervention (placebo);</p> </li> <li> <p>Sclerotherapy versus sclerotherapy (sclerosant versus different sclerosant/formulation/dose/technique);</p> </li> <li> <p>Sclerotherapy versus different conservative treatment (including pharmacological therapy and/or graduated compression stockings when sclerotherapy was the intervention being tested). We excluded studies investigating compression after sclerotherapy treatment. </p> </li> </ul> </p> </section> <section id="CD001732-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We considered RCTs that assessed at least one of the following outcomes.</p> <section id="CD001732-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001732-list-0004"> <li> <p>Cosmetic appearance (assessed by any validated tool)</p> </li> <li> <p>Complications (including haematoma formation, skin pigmentation, ulceration and necrosis, superficial thrombophlebitis, thromboembolic complications (deep vein thrombosis and pulmonary embolism as defined by the authors of primary studies), and anaphylactic reaction) </p> </li> </ul> </p> </section> <section id="CD001732-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001732-list-0005"> <li> <p>Frequency of residual varicose veins (number of veins that failed obliteration, assessed clinically and/or by ultrasound examination) </p> </li> <li> <p>Quality of life measures (measured as any specific and validated questionnaires such as Assessment of Burden in Chronic disease – Venous (ABC‐V), VEnous INsufficiency Epidemiological and Economic Study on Quality of Life (VEINES‐QOL), Freiburg Life Quality Assessment (FLQA), Specific Quality of life and Outcomes Response – Venous (SQOR‐V), ChronIc Venous Insufficiency Questionnaire (CIVIQ), and Aberdeen Varicose Vein Questionnaire (AVVQ) (<a href="./references#CD001732-bbs2-0064" title="LaunoisR . Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs. Journal of Vascular Surgery2015;3:219-27. [DOI: 10.1016/j.jvsv.2014.08.005]">Launois 2015</a>)) </p> </li> <li> <p>Frequency of persistence of symptoms (such as pain, burning discomfort, aching, itching, limb heaviness, oedema and nocturnal cramps) </p> </li> <li> <p>Frequency of recurrent varicose veins and venous flare formation</p> </li> </ul> </p> <p>We were guided by the time points reported in the individual studies.</p> </section> </section> </section> <section id="CD001732-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>There were no restrictions on language, date, or status of publication.</p> <section id="CD001732-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this update, the Cochrane Vascular Information Specialist (CIS) first searched the following databases for relevant trials (20 July 2021): </p> <p> <ul id="CD001732-list-0006"> <li> <p>Cochrane Vascular Specialised Register (20 July 2021);</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (20 July 2021) via the Cochrane Register of Studies Online. </p> </li> </ul> </p> <p>See <a href="./appendices#CD001732-sec-0145">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The CIS subsequently conducted systematic top‐up searches of the following databases for RCTs and CCTs without language, publication year or publication status restrictions: </p> <p> <ul id="CD001732-list-0007"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web) (20 July 2021); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Register of Studies Online (20 July 2021); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE) (20 July 2021); </p> </li> <li> <p>Embase via Ovid (20 July 2021);</p> </li> <li> <p>CINAHL via EBSCO (20 July 2021);</p> </li> <li> <p>AMED via Ovid (20 July 2021);</p> </li> <li> <p>LILACS (20 July 2021).</p> </li> </ul> </p> <p>The CIS modelled search strategies for the listed databases on the search strategy designed for CENTRAL. Where appropriate, they were combined with adaptations of the Cochrane highly sensitive search strategy for identifying reports of randomised controlled trials and controlled clinical trials (<a href="./references#CD001732-bbs2-0065" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.1.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD001732-sec-0146">Appendix 2</a>. </p> <p>The Information Specialist also performed searches of the following trials registries on 20 July 2021: </p> <p> <ul id="CD001732-list-0008"> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://who.int/trialsearch" target="_blank">who.int/trialsearch</a>). </p> </li> </ul> </p> </section> <section id="CD001732-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD001732-list-0009"> <li> <p>We searched the list of references from relevant studies to identify additional studies.</p> </li> <li> <p>We contacted pharmaceutical companies for information on any unpublished trials: Kreusller Pharma, Germany (polidocanol); BTG Pharma (polidocanol); LGM Pharma, USA (polidocanol); Shanghai T&amp;W Pharmaceutical Co. Ltd., China (polidocanol); Omega Laboratories Limited, Montreal, Canada (hypertonic saline, polidocanol); Medeva Pharma Limited, Leatherhead, UK (ethanolamine); STD Pharmaceutical, Hereford, UK (STD). </p> </li> <li> <p>We contacted experts in this area about further unpublished or ongoing trials.</p> </li> </ul> </p> </section> </section> <section id="CD001732-sec-0026"> <h3 class="title" id="CD001732-sec-0026">Data collection and analysis</h3> <section id="CD001732-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RAO and VV) independently assessed the search results. First, we screened titles and abstracts (if available). Additional review authors (RR and JCBS) resolved disagreements when necessary. We read the selected, potentially relevant trials in totality to check eligibility with the inclusion criteria. We recorded explanations/justifications for studies excluded at this second phase. If necessary, we contacted study authors for further information. To facilitate transparency, we presented a flow diagram showing the full list of included and excluded studies (PRISMA), as described by <a href="./references#CD001732-bbs2-0066" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. British Medical Journal2009;339:b2700.">Liberati 2009</a>. </p> </section> <section id="CD001732-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RAO and VV) extracted data from the included studies. We double‐checked that data were inserted correctly into the form. We used a standard form to collect the following information on study characteristics and outcome data. </p> <p> <ul id="CD001732-list-0010"> <li> <p>Publication details (i.e. year, country, authors)</p> </li> <li> <p>Study design and methods (inclusion/exclusion criteria, randomisation method, allocation concealment, blinding) </p> </li> <li> <p>Setting</p> </li> <li> <p>Population data (i.e. age, the severity of the disease, type of varicose vein)</p> </li> <li> <p>Details of intervention (i.e. the dose of the sclerosant, technique, duration)</p> </li> <li> <p>Outcome measures (including effectiveness and adverse effects)</p> </li> <li> <p>The number of dropouts</p> </li> <li> <p>Length of follow‐up</p> </li> <li> <p>Types of data analyses (e.g. intention‐to‐treat, modified intention‐to‐treat)</p> </li> <li> <p>Any potential risk of bias</p> </li> </ul> </p> <p>We discussed disagreements with the involvement of a third review author (RR or JCBS) until consensus was reached. Two review authors (RAO and VV) entered data into the Review Manager 5.3 software (<a href="./references#CD001732-bbs2-0075" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> </section> <section id="CD001732-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used Cochrane's Risk of bias tool for assessing the risk of bias, by evaluating the following criteria. </p> <p> <ul id="CD001732-list-0011"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other bias (bias due to problems not covered in the other domains)</p> </li> </ul> </p> <p>Two review authors (RAO and VV) independently evaluated the risk of bias for each included study. We resolved disagreements by discussion and consultation with a third review author (RR). We categorised the domains as 'high risk', 'low risk', or 'unclear risk' of bias according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001732-bbs2-0058" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017b</a>). For the domains 'Blinding of participants and personnel,' 'Blinding of outcome assessment' and 'Incomplete outcome data,' we judged each outcome separately. Where studies did not report on an outcome, this section remained blank in the risk of bias table. </p> <p>We considered the overall methodological quality of the studies as low risk if the sequence generation, allocation concealment and blinding (participants and personnel, and assessors) domains were all at low risk of bias. We considered the overall methodological quality of the studies as moderate if one of these domains was judged as being at unclear risk. Finally, we considered the overall methodological quality as 'high risk' if at least one of these domains was judged as 'high risk' of bias. </p> <p>In any case of 'unclear risk' of bias, we emailed the study contact author and asked to clarify any questions. When no answer was received from the study author, the judgement was assessed as 'unclear risk' of bias. </p> </section> <section id="CD001732-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We reported the results as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes. For continuous outcomes, we expressed the results as mean differences (MDs) with 95% CIs or as the standardised mean difference (SMD) with 95% CIs if different assessment tools were used by the included studies to report the same outcome. </p> </section> <section id="CD001732-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of randomisation analysed in the included studies was likely to be the individual patient. In some studies, for outcomes such as complications, residual varicose veins, recurrent varicose veins, for which bilateral procedures are possible, each treated limb or varicose vein was considered as an individual unit of analysis. We presented the data for such studies only where the disparity between the units of analysis and number of randomised participants was small. If we pooled data, we performed a sensitivity analysis to examine the effects of excluding any trials with analyses that had not been corrected for this unit of analysis issue. We avoided unit of analysis issues related to repeated observations of the same outcome, such as results presented for several periods of follow‐up. If encountered, we planned to evaluate each outcome at different follow‐up periods: at the end of the treatment, at short‐term and at long‐term follow‐up (<a href="./references#CD001732-bbs2-0052" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). </p> </section> <section id="CD001732-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We emailed the study authors for additional information when there were missing, incomplete or unavailable data. We performed a search for protocols and/or further articles related to the included trials. When relevant data were unavailable, we presented and discussed the results in the main text of the review. In the case of missing data or dropouts, intention‐to‐treat analyses were conducted by imputing data which considered the worst‐case scenario for dichotomous data. We also undertook an intention‐to‐treat analysis for continuous outcomes, by imputing the 'last‐observation‐carried‐forward'. This action is justified due to the balanced loss of follow‐up that did not change results with data imputation tested by sensitivity analyses. We followed the methods described in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> using the average of two units greater than the observed data in the intervention arm and decreasing two units in the control arm (<a href="./references#CD001732-bbs2-0057" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated March 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.">Higgins 2017a</a>). We did not find discrepancies in the trend of effect direction. Standard deviation imputation was used in one study (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>) using data from another included study (<a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) since there was no other source for data imputation. </p> </section> <section id="CD001732-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic, which indicates the degree of variation across studies related to heterogeneity rather than related to chance. We considered an I<sup>2</sup> value greater than 50% as substantial heterogeneity (<a href="./references#CD001732-bbs2-0052" title="DeeksJJ , HigginsJP , Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.2.">Deeks 2017</a>). We explored clinical and methodological differences as potential causes of heterogeneity. </p> </section> <section id="CD001732-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use funnel plots to explore possible reporting biases only if there were 10 or more included studies. </p> </section> <section id="CD001732-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We synthesised data using Review Manager 5.3 software (<a href="./references#CD001732-bbs2-0075" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Varicose vein conditions are heterogeneous by nature. Considering the heterogeneity of the disease and interventions used, we have used a random‐effects model for all meta‐analyses in the review. When a meta‐analysis was not possible, data were reported to measure effect size whenever possible. In all cases, we did a descriptive analysis of the study. </p> <p>As there is considerable variation in the time point measures of outcomes, a stratification into three time intervals was used to conduct a meta‐analysis. We considered a short‐term period from the intervention to up to one month, an intermediate‐term period from one month to three months, and a long‐term period that included any outcome measured after three months. This alternative was considered because some outcomes could not be appropriately measured at the short‐term period (for instance, staining) and others continued to be a risk (for instance, risks of pulmonary embolism (PE) in people with deep vein thrombosis (DVT) and superficial thrombophlebitis) (<a href="./references#CD001732-bbs2-0061" title="KearonC , AklEA , OrnelasJ , BlaivasA , JimenezD , BounameauxH , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest2016;149(2):315-52.">Kearon 2016</a>). </p> <p>We intended to present the results from the following comparisons:</p> <p> <ul id="CD001732-list-0012"> <li> <p>Sclerotherapy versus no intervention or no active intervention (placebo)</p> </li> <li> <p>Sclerotherapy versus sclerotherapy (sclerosant versus different sclerosant/formulation/dose/technique)</p> </li> <li> <p>Sclerotherapy versus different conservative treatment (including pharmacological therapy and/or graduated compression stockings when sclerotherapy was the intervention being tested). We excluded studies investigating compression sclerotherapy after treatment. </p> </li> </ul> </p> </section> <section id="CD001732-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to evaluate the following subgroups if sufficient data had been available.</p> <p> <ul id="CD001732-list-0013"> <li> <p>CEAP classification: CEAP C2 (varicose veins with no oedema or staining), CEAP C3 (varicose veins with oedema and no staining), and CEAP C4 (a limb with skin and subcutaneous changes (including pigmentation or eczema, and lipodermatosclerosis or atrophie blanche) related to venous disease) (<a href="./references#CD001732-bbs2-0053" title="EklöfB , RutherfordRB , BerganJJ , CarpentierPH , Peter GloviczkiP , KistnerRL , et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40:1248-52. [DOI: 10.1016/j.jvs.2004.09.027]">Eklöf 2004</a>), since we expected worse results for the higher categories. </p> </li> <li> <p>Presence or absence of truncal incompetence: superficial venous incompetence demonstrated on Duplex ultrasound scanning, (i.e. great saphenous vein, short saphenous vein, and thigh and calf vein perforators (veins connecting superficial and deep venous systems)) and varicose veins with no evidence of superficial venous incompetence, since there is different prognosis and we expect different effects for bigger diameters. </p> </li> <li> <p>The depth of the vein analysed assessed by Duplex ultrasound scanning: veins below 5 mm deep, and veins more than 5 mm deep, since we expected less pigmentation in deeper veins. </p> </li> <li> <p>Symptomatic versus nonsymptomatic participants, since we expected fewer symptoms after treatment. </p> </li> <li> <p>Sclerosant concentration for truncal incompetence (e.g. polidocanol 1% and 3%), since we expected to define the best concentration to use. </p> </li> <li> <p>Comparison of the gas used when foam sclerotherapy (e.g. CO<sub>2</sub> versus ambient air), since we expected to assess if a gas was better than another one. </p> </li> <li> <p>Previous complications (thrombophlebitis, DVT), since we expected different clinical evolution in participants with previous complications. </p> </li> </ul> </p> </section> <section id="CD001732-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned the following sensitivity analyses to investigate the robustness of our findings by: </p> <p> <ul id="CD001732-list-0014"> <li> <p>excluding studies with high risk of bias. The high risk of bias studies were defined as those presenting at least one of the following domains classified as 'high risk': selection, performance or detection; </p> </li> <li> <p>excluding studies funded by pharmaceuticals;</p> </li> <li> <p>excluding studies with data imputation (analysing by per‐protocol analysis).</p> </li> </ul> </p> </section> <section id="CD001732-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created Summary of findings (SoF) tables to present the main findings of this review using GRADEpro GDT software (<a href="./references#CD001732-bbs2-0054" title="GRADEpro GDT. Version (accessed 14 January 2019). Hamilton, ON: McMaster University (developed by Evidence Prime, Inc.)., 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We used the five GRADE criteria (risk of bias, inconsistency, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence as it related to the outcomes that contributed to the meta‐analyses. We used the methods and recommendations described in Section 8.5 (<a href="./references#CD001732-bbs2-0058" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017b</a>) and Chapter 12 (<a href="./references#CD001732-bbs2-0077" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration. Available from training.cochrane.org/handbook/archive/v5.2.">Schünemann 2017</a>) of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001732-bbs2-0057" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated March 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.">Higgins 2017a</a>). We explained all judgements to downgrade the certainty of the evidence in the footnotes, and we added comments to help readers understand the judgements of the review if necessary. We included the outcomes considered to be most clinically relevant in the Summary of findings tables. </p> <p> <ul id="CD001732-list-0015"> <li> <p>Cosmetic appearance</p> </li> <li> <p>Thromboembolic complications</p> </li> <li> <p>Residual varicose veins</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Persistence of symptoms</p> </li> <li> <p>Recurrent varicose veins</p> </li> </ul> </p> <p>We considered the following comparisons to be of the most clinical relevance and created a SoF table for each where data were available. </p> <p> <ul id="CD001732-list-0016"> <li> <p>Foam sclerotherapy (polidocanol 1%) versus placebo for treating varicose veins (<a href="./full#CD001732-tbl-0001">summary of findings Table 1</a>) </p> </li> <li> <p>Foam sclerotherapy (polidocanol 3%) versus foam sclerotherapy (polidocanol 1%) for treating varicose veins (<a href="./full#CD001732-tbl-0002">summary of findings Table 2</a>) </p> </li> <li> <p>Foam sclerotherapy versus liquid sclerotherapy for treating varicose veins (<a href="./full#CD001732-tbl-0003">summary of findings Table 3</a>) </p> </li> <li> <p>Sclerotherapy with STS 1% versus sclerotherapy with polidocanol 1% for treating varicose veins (<a href="./full#CD001732-tbl-0004">summary of findings Table 4</a>) </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001732-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001732-sec-0039"></div> <section id="CD001732-sec-0040"> <h3 class="title">Description of studies</h3> <p>Please see <a href="#CD001732-fig-0001">Figure 1</a> for the search results. </p> <div class="figure" id="CD001732-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001732-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <section id="CD001732-sec-0041"> <h4 class="title">Results of the search</h4> <p>We assessed the reports identified by the searches and cross‐checked these with the reports provided by BTG Pharma. No additional studies were identified in the reports provided by BTG Pharma. </p> <p>We reassessed the included and excluded studies from the previous version (<a href="./references#CD001732-bbs2-0084" title="TisiPV , BeverleyC , ReesA . Injection sclerotherapy for varicose veins. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD001732. [DOI: 10.1002/14651858.CD001732.pub2]">Tisi 2006</a>), as changes have been made to the inclusion criteria. See <a href="#CD001732-sec-0159">Differences between protocol and review</a>. Four studies excluded in the previous version of the review are now included as they met the inclusion criteria (<a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). Studies which were included in the previous version but which compared sclerotherapy with open surgery (e.g. stripping) or investigated compression after sclerotherapy were reassessed as not relevant for this update. </p> </section> <section id="CD001732-sec-0042"> <h4 class="title">Included studies</h4> <p>We identified 23 new studies for this update (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). This review includes a total of 28 RCTs (43 records), and they are described in the <a href="./references#CD001732-sec-0161" title="">Characteristics of included studies</a> tables (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). These studies have the following characteristics. </p> <p> <ul id="CD001732-list-0017"> <li> <p>Design: all included studies were randomised controlled trials (RCTs) with a parallel‐design intervention. </p> </li> <li> <p>Setting</p> <ul id="CD001732-list-0018"> <li> <p>Location of participants</p> <ul id="CD001732-list-0019"> <li> <p>Inpatients: seven RCTs (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>Outpatients: 10 RCTs (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>); </p> </li> <li> <p>Not specified: 11 RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). </p> </li> </ul> </li> </ul> </li> <li> <p>Country</p> <ul id="CD001732-list-0020"> <li> <p>Brazil: one RCT (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>); </p> </li> <li> <p>Chile: one RCT (<a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>); </p> </li> <li> <p>China: two RCTs (<a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>France: six RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>); </p> </li> <li> <p>Germany: three RCTs (<a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>); </p> </li> <li> <p>Japan: two RCTs (<a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>); </p> </li> <li> <p>South Africa: one RCT (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>); </p> </li> <li> <p>Spain: one RCT (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>); </p> </li> <li> <p>Thailand: one RCT (<a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>); </p> </li> <li> <p>The Netherlands: one RCT (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>); </p> </li> <li> <p>United States of America: seven RCTs (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>); </p> </li> <li> <p>Multicentre trials involving Belgium, France, Greece, Italy, South Africa, Sweden, The Netherlands, and United Kingdom: two RCTs (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). </p> </li> </ul> </li> <li> <p>Study duration (calculated by adding the time from start of recruitment to follow‐up duration), when described, ranged from 12 months (<a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>) to 10 years (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). The follow‐up ranged from three minutes (<a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>) to 10 years (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). </p> </li> <li> <p>Characteristics of the participants:</p> <ul id="CD001732-list-0021"> <li> <p>Age</p> <ul id="CD001732-list-0022"> <li> <p>Nine studies did not state the age of the participants (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>); </p> </li> <li> <p>Six described the mean age ranging from 41.9 to 59 years of age (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>); </p> </li> <li> <p>Twelve studies described the mean age for each intervention and control group, ranging from a minimum of 28 years to a maximum of 72 years of age (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>One study included people older than 18 years (group A: 44.8 (SD ± 11.33), group B: 47.5 (SD ± 13.47)) (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). </p> </li> </ul> </li> <li> <p>Gender</p> <ul id="CD001732-list-0023"> <li> <p>Nine studies did not state the gender of the participants (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>); </p> </li> <li> <p>One study included only women (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>); </p> </li> <li> <p>All other studies had groups with higher proportions of women than men. The lowest proportion of women included was 60% in two groups (<a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>), and the highest was 95% (<a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>). </p> </li> </ul> </li> <li> <p>CEAP classification</p> <ul id="CD001732-list-0024"> <li> <p>Two studies were published before or up to the first CEAP publication (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>). As the description of the studies matched with CEAP C2 or C3, both studies were included. </p> </li> <li> <p>13 studies did not clearly state the CEAP classification (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). All of these studies suggested the inclusion of people with CEAP C2 and/or C3 and so were included in the review. </p> </li> <li> <p>12 studies stated the CEAP classification without discriminating between subgroups ranging from C1 to C6 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> </li> <li> <p>Two studies also allocated people with CEAP C1 (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>), one study included people with CEAP C2 to C5 (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), and one study included people with CEAP C2 (<a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). </p> </li> <li> <p>One study included only people with CEAP C3 (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). </p> </li> <li> <p>Three studies included people with CEAP C2 to C4 (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). </p> </li> <li> <p>The remaining seven studies included people in CEAP groups C2 to C5 or C6 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> </li> </ul> </li> <li> <p>Sample size ranged from 10 participants (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>) to 877 participants (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). </p> </li> </ul> </li> <li> <p>Unit of analysis:</p> <ul id="CD001732-list-0025"> <li> <p>23 studies considered the individual as the unit of analysis (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>Two considered the lower leg (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>); </p> </li> <li> <p>Three considered the vein as the unit of analysis (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>). </p> </li> </ul> </li> <li> <p>Characteristics of the interventions/comparator and comparisons:</p> <ul id="CD001732-list-0026"> <li> <p>Injection technique: different techniques were used to inject the sclerosant. Most of them were described as traditional injection sclerotherapy where a traditional needle and syringe is used to inject the intravenous medicine. One study described the technique as one injection sclerotherapy (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>), and four studies used a catheter to deliver the medicine (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). We do not believe this intervention can be considered pharmacomechanical treatment since the catheter had the sole function to deliver the drug in this case. </p> </li> <li> <p>Interventions and comparisons:</p> <ul id="CD001732-list-0027"> <li> <p>Sclerotherapy versus compression: one RCT (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>); </p> </li> <li> <p>Sclerosant versus placebo: five RCTs (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>); </p> </li> <li> <p>Sclerosant versus sclerosant: 23 RCTs (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Two of these studies (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) also compared sclerosant to placebo and were included in both comparator groups; </p> </li> <li> <p>Foam versus liquid sclerotherapy: six RCTs (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>); </p> </li> <li> <p>Sodium tetradecyl sulphate (STS) liquid versus liquid plus foam: one RCT (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>); </p> </li> <li> <p>Polidocanol foam in different concentrations: five RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>); </p> </li> <li> <p>Polidocanol foam 1% versus any other sclerosant liquid or foam in any concentration: one RCT (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>); </p> </li> <li> <p>Single versus fractionated injection for sclerotherapy: two RCTs (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>); </p> </li> <li> <p>Ultrasound‐guided foam sclerotherapy versus visual‐foam sclerotherapy: one RCT (<a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>); </p> </li> <li> <p>Catheter directed sclerotherapy using antegrade versus retrograde approach to inject sclerosant: one RCT (<a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>Injection by needle versus microcatheter and catheter: one RCT (<a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>); </p> </li> <li> <p>Injection by needle versus catheter deliver of the foam associated with tumescent technique:one RCT (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>); </p> </li> <li> <p>STS versus polidocanol: three RCTs (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>); </p> </li> <li> <p>Addition of perfluropropane‐filled albumin microspheres of foam STS with air filled foam STS versus polidocanol foam sclerotherapy alone: one RCT (<a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>); </p> </li> <li> <p>Addition of low molecular weight synthetic protein (Gelufusine) to polidocanol foam versus polidocanol foam sclerotherapy alone: one RCT (<a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). </p> </li> </ul> </li> <li> <p>Sclerotherapy agent and dose:</p> <ul id="CD001732-list-0028"> <li> <p>Four studies described the sclerotherapy agent but not the volume of sclerosant administered using polidocanol (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>), or polidocanol and/or STS (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>); </p> </li> <li> <p>19 studies described the use of polidocanol (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>, <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>) ranging from 0.5 mL liquid (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>), to 60 mL foam sclerotherapy (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>); </p> </li> <li> <p>Seven studies used STS (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>) ranging from 0.5 mL liquid (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>) to up to 6 mL of foam (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>); </p> </li> <li> <p>One study (<a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>) described the use of 1 mL from the liquid form of polidocanol or STS to produce the foam in a ratio 1 to 4 to be injected. </p> </li> </ul> </li> </ul> </li> <li> <p>Outcomes ‐ time points used were variable depending on the outcome to be measured. These ranged from three minutes for venous spasm (<a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>) to 10 years for recurrent varicose veins (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). Outcomes measured are described: </p> <ul id="CD001732-list-0029"> <li> <p>Cosmetic appearance was assessed in seven RCTs (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). <a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a> described combined outcomes of symptomatic improvement and cosmetic results quoted as good, fair, and poor results. <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a> described cosmetic appearance as patient satisfaction using a scale from zero (minimum satisfaction) to ten (maximum satisfaction). <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> described cosmetic appearance as cosmetic improvement described by participants. <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> and <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a> described cosmetic appearance as disappearance scale and satisfaction scale ranging from 1 (worse than before treatment) to 5 (complete disappearance). <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a> pooled results as tolerability and satisfaction. <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> and <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> described by IPR‐V (Independent photography review: Visible Varicose veins; scale: 0 to 4; 0 being the best appearance (0: none, 1: mild, 2: moderate, 3: severe, 4: very severe)) and PA‐V (patient self‐assessment of visible varicose veins); </p> </li> <li> <p>At least one complication was described in 23 studies (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>Residual varicose veins were assessed in 25 studies (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); </p> </li> <li> <p>Recurrent varicose veins were described in six studies (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>); </p> </li> <li> <p>Quality of life (QoL) was measured in six studies (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a> and <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a> used the CIVIQ questionnaire (using a five‐point Likert scale in the items) to score QoL. <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a> used the modified venous insufficiency epidemiological and economic study QoL/symptoms (m‐VEINES‐QOL/Sym), Heavy legs, Achy legs, Swelling, Throbbing, and Itching (HASTI) questionnaire, and the chronic venous insufficiency questionnaire 2 (CIVIQ‐2). <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> used the modified venous insufficiency epidemiological and economic study QoL/symptoms (m‐VEINES‐QOL/Sym). <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> used the venous insufficiency epidemiological and economic study score (VEINES‐QOL). <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a> used Aberdeen Varicose Vein Questionnaire (AVVQ); </p> </li> <li> <p>Persistence of symptoms were described in seven studies (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>, <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> and <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a> used venous clinical severity score (VCSS). <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a> used Veines‐QOL/Sym and <a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>, <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> and <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a> reported this as 'clinical improvements'; and </p> </li> <li> <p>18 other studies described sclerosis or occlusion or venous shrinkage or venous spasm (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). The outcomes were evaluated by duplex ultrasound. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD001732-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 13 studies from this review update as they investigated sclerotherapy versus an intervention other than nonsurgical interventions (that is, no intervention, conservative treatment including pharmacological therapy and/or graduated compression stockings, or sclerotherapy) (<a href="./references#CD001732-bbs2-0029" title="AriyoshiH , KambayashiJ , TominagaS , HatanakaT . The possible risk of lower-limb sclerotherapy causing an extended hypercoagulable state. Surgery Today1996;26(5):323-7. ">Ariyoshi 1996</a>; <a href="./references#CD001732-bbs2-0030" title="BiemansAAM , KockaertM , AkkersdijkGP , Van den BosRR , De MaeseneerMGR , CuypersP , et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. Journal of Vascular Surgery2013;58(3):727-34. BiemansAAM , KockaertM , Van Den BosRR , CuypersP , NeumannHAM , NijstenTEC . A randomized comparative study of the three most commonly performed treatments for varicose veins, results after one year. Nederlands Tijdschrift voor Dermatologie en Venereologie2012;22(2):78-84. Van der VeldenSK , BiemansAA , De MaeseneerMG , KockaertMA , CuypersPW , HollesteinLM , et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. British Journal of Surgery2015;102(10):1184-94. ">Biemans 2013</a>; <a href="./references#CD001732-bbs2-0031" title="BrittendenJ , CottonSC , EldersA , RamsayCR , NorrieJ , BurrJ , et al. A randomized trial comparing treatments for varicose veins (CLASS). New England Journal of Medicine2014;371:1218-27. [DOI: 10.1056/NEJMoa1400781]BrittendenJ , CottonSC , EldersA , TassieE , ScotlandG , RamsayCR , et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. Health Technology Assessment2015;19(27):1-342. ISRCTN51995477. Randomised controlled trial comparing foam sclerotherapy, alone or in combination with endovenous laser therapy, with conventional surgery as a treatment for varicose veins. isrctn.com/ISRCTN51995477 (first received 25 February 2008). Lancet protocol 09PRT/2275. The CLASS Study: Comparison of LAser, Surgery and foam Sclerotherapy as a treatment for varicose veins (EudraCT 2008-001069-26). thelancet.com/protocol-reviews/09PRT-2275 (accessed 24 September 2020). ">Brittenden 2015</a>; <a href="./references#CD001732-bbs2-0032" title="ISRCTN03080206. Endovenous laser therapy (EVLT) versus ultrasound guided foam sclerotherapy (UGFS) for the treatment of varicose veins. isrctn.com/ISRCTN03080206 (first received 21 January 2010). KalodikiE , AzzamM , SchnatterbeckP , GeroulakosG , LattimerCR . The Discord Outcome Analysis (DOA) as a reporting standard at three months and five years in randomised varicose vein treatment trials. European Journal of Vascular and Endovascular Surgery2018;57(2):267-74. [DOI: 10.1016/j.ejvs.2018.09.013]LattimerCR , AzzamM , KalodikiE , ShawishE , TruemanP , GeroulakosG . Cost and effectiveness of laser with phlebectomies compared with foam sclerotherapy in superficial venous insufficiency. Early results of a randomised controlled trial. European Journal of Vascular and Endovascular Surgery2012;43:594-600. LattimerCR , KalodikiE , AzzamM , GeroulakosG . Responsiveness of individual questions from the venous clinical severity score and the Aberdeen varicose vein questionnaire. Phlebology2014;29:43-51. LattimerCR , KalodikiE , AzzamM , MakrisGC , SomiayajuluS , GeroulakosG . Interim results on abolishing reflux alongside a randomized clinical trial on laser ablation with phlebectomies versus foam sclerotherapy. International Angiology2013;32(4):394-403. ">Lattimer 2012</a>; <a href="./references#CD001732-bbs2-0033" title="LeungCC , CarradiceD , WallaceT , ChetterIC . Endovenous laser ablation versus mechanochemical ablation withClariVein(®) in the management of superficial venous insufficiency (LAMA trial): study protocol for a randomised controlled trial. Trials2016;17(1):421. ">Leung 2016</a>; <a href="./references#CD001732-bbs2-0034" title="MishraM , SoniR , MohilR , SinhaA . Comparative study of outcome of duplex ultrasound-guided,catheter-directed foam sclerotherapy and radio-frequency ablation in the management of great saphenous varicose veins. Indian Journal of Surgery2016;78(5):375-81. ">Mishra 2016</a>; <a href="./references#CD001732-bbs2-0035" title="NCT02462720 2015. COMFORT: multicenter study to evaluate pain following treatment of varicose vein with Varithena® compared to radiofrequency ablation. clinicaltrials.gov/show/NCT02462720 2015 (first received 4 June 2015). ">NCT02462720</a>; <a href="./references#CD001732-bbs2-0036" title="RaggJC . Initial and permanent vein lumen minimization obtained with endovenous occlusion techniques by using hyaluronan solution instead of tumescent fluid. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015; St Petersburg, Russia. Vol. 58. 2015. ">Ragg 2015a</a>; <a href="./references#CD001732-bbs2-0037" title="ISRCTN08060326. Endovenous laser ablation (EVLA), radio frequency (RF), foam sclerotherapy and stripping for treatment of varicose veins. isrctn.com/ISRCTN08060326 (first received 31 July 2009). [DOI: 10.1186/ISRCTN08060326]LawaetzM , RasmussenLH , BjoernL , BlemingsA , EklofB . Randomized trial comparing RF, laser, foam sclerotherapy and stripping in varicose veins. Phlebology2010;25:307. LawaetzM , SerupJ , LawaetzB , BjoernL , BlemingsA , EklofB , et al. Comparison of endovenous radiofrequency ablation, laser ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. Extended 5-year follow-up of a RCT. Phlebology2017;32(2):13-4. RasmussenL , LawaetzM , SerupJ , BjoernL , VennitsB , BlemingsA , et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy, and surgical stripping for great saphenous varicose veins with 3-year follow-up. Journal of Vascular Surgery2013;1(4):349-56. RasmussenLH , LawaetzM , BjoernL , VennitsB , BlemingsA , EklofB . Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins. British Journal of Surgery2011;98(8):1079-87. ">Rasmussen 2011</a>; <a href="./references#CD001732-bbs2-0038" title="TheivacumarNS , DellagrammaticasD , MavorAI , GoughMJ . Endovenous laser ablation: does standard above-knee great saphenous vein ablation provide optimum results in patients with both above-and below-knee reflux? A randomized controlled trial. Journal of Vascular Surgery2008;48(1):173-8. TheivacumarSN , DellagrammaticasD , DarwoodRJ , MavorAI , GoughMJ . Endovenous laser ablation (EVLA): is standard above-knee great saphenous vein (AK-GSV) ablation sufficient? A randomised controlled trial. Vascular Society of Great Britain &amp; Ireland Yearbook2007;71. ">Theivacumar 2008</a>; <a href="./references#CD001732-bbs2-0039" title="VahaahoS , AlbackA , HalmesmkiK , MahmoudO , VenermoM . RCT comparing the long-term results of UGFS, EVLA and open surgery in the treatment of GSV reflux. In: XXIX Annual Meeting European Society for Vascular Surgery; 2015. 2015. ">Vahaaho 2015</a>; <a href="./references#CD001732-bbs2-0040" title="NCT01298908. Comparison of treatments in venous insufficiency. clinicaltrials.gov/ct2/show/study/NCT01298908 (first received 18 February 2011). VenermoM , SaarinenJ , EskelinenE , VahaahoS , SaarinenE , RailoM , Finnish Venous Study Collaborators. Randomized clinical trial comparing surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy for the treatment of great saphenous varicose veins. British Journal of Surgery2016;103(11):1438-44. VenermoM . A randomised trial of three VV treatment strategies. ESVS 18-21 September 2013, Budapest, Hungary2013. ">Vernermo 2016</a>; <a href="./references#CD001732-bbs2-0041" title="ZafarghandiMR , FarsavianH , DavoudiM , FarsavianAA . Outcome of ultrasonography-guided foam sclerotherapy versus stab avulsion ambulatory phlebectomy in the treatment of varicosis in small veins of the leg: a single blinded randomized clinical triaI. Iranian Journal of Radiology2017;14(3):e21742. ">Zafarghandi 2017</a>). See the <a href="./references#CD001732-sec-0162" title="">Characteristics of excluded studies</a> tables. </p> <p>Studies which investigated compression after sclerotherapy or compared sclerotherapy with open surgery (e.g. stripping), other endovascular techniques (endolaser or radiofrequency), and compression therapy were assessed as not relevant as they clearly did not meet the inclusion criteria (<a href="#CD001732-sec-0016">Criteria for considering studies for this review</a>). </p> <section id="CD001732-sec-0044"> <h5 class="title">Ongoing studies</h5> <p>We did not identify any ongoing studies.</p> </section> <section id="CD001732-sec-0045"> <h5 class="title">Awaiting classification</h5> <p>Five studies were assessed as 'awaiting classification' as in all cases we were unable to contact authors and there was a lack of information to include or exclude them (<a href="./references#CD001732-bbs2-0042" title="LabasP , OhrádkaB , CambalM , RingelbandR . The results of compression sclerotherapy. Comparative study of two techniques and two sclerosants. Phlebologie2000;29:137-41. LabasP , OhradkaB , CambalM , ReisR , FilloJ . Long term results of compression sclerotherapy. Bratislavske Lekarske Listy2003;104(2):78-81. ">Labas 2003</a>; <a href="./references#CD001732-bbs2-0043" title="SatokawaH , HoshinoS , SakaguchiS , YamadaC . The Japanese polidocanol (aethoxysclerol) clinical trial. Abstracts from the UIP World Congress Chapter Meeting2003. ">Satokawa 2003</a>; <a href="./references#CD001732-bbs2-0044" title="SchadeckM , AllaertFA . Post sclerosis recurrences of the great saphenous vein. In: NegusD , JantetG , Coleridge-SmithPD , editors(s). Phlebology '95. Vol. 1. Springer, 1995:614. ">Schadeck 1995b</a>; <a href="./references#CD001732-bbs2-0045" title="Anonymous. Sclerotherapy to the long saphenous vein-a less invasive alternative. slctr.lk/trials/slctr-2008-014 (first received 18 July 2008). [SLCTR/2008/014]">SLCTR/2008/014</a>; <a href="./references#CD001732-bbs2-0046" title="VarnagyR , MalaveG , TabordaJ , GabayN . Clinical trial of a new experimental sclerosant product. Current Therapeutic Research, Clinical and Experimental1985;38:960-5. ">Varnagy 1985</a>). In two of these studies, there was limited information (intervention groups were not clear) (<a href="./references#CD001732-bbs2-0043" title="SatokawaH , HoshinoS , SakaguchiS , YamadaC . The Japanese polidocanol (aethoxysclerol) clinical trial. Abstracts from the UIP World Congress Chapter Meeting2003. ">Satokawa 2003</a>; <a href="./references#CD001732-bbs2-0044" title="SchadeckM , AllaertFA . Post sclerosis recurrences of the great saphenous vein. In: NegusD , JantetG , Coleridge-SmithPD , editors(s). Phlebology '95. Vol. 1. Springer, 1995:614. ">Schadeck 1995b</a>). <a href="./references#CD001732-bbs2-0042" title="LabasP , OhrádkaB , CambalM , RingelbandR . The results of compression sclerotherapy. Comparative study of two techniques and two sclerosants. Phlebologie2000;29:137-41. LabasP , OhradkaB , CambalM , ReisR , FilloJ . Long term results of compression sclerotherapy. Bratislavske Lekarske Listy2003;104(2):78-81. ">Labas 2003</a> was included in the previous version of the review, and <a href="./references#CD001732-bbs2-0044" title="SchadeckM , AllaertFA . Post sclerosis recurrences of the great saphenous vein. In: NegusD , JantetG , Coleridge-SmithPD , editors(s). Phlebology '95. Vol. 1. Springer, 1995:614. ">Schadeck 1995b</a> was excluded in the previous version of the review. On reassessment, we did not find sufficient information to either include or exclude these two studies. We are not sure if one study is a randomised or quasi‐randomised trial (<a href="./references#CD001732-bbs2-0046" title="VarnagyR , MalaveG , TabordaJ , GabayN . Clinical trial of a new experimental sclerosant product. Current Therapeutic Research, Clinical and Experimental1985;38:960-5. ">Varnagy 1985</a>). Should further information be provided, we will include these studies in future updates. </p> </section> </section> </section> <section id="CD001732-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p>Two review authors (RAO, VV) independently assessed the included studies for risk of bias following the recommendations in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD001732-bbs2-0057" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated March 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2/.">Higgins 2017a</a>). Any disagreements were resolved by a third author (RR) in consensus with the group. Details of the risk of bias judgements can be found in the Risk of bias tables, within the <a href="./references#CD001732-sec-0161" title="">Characteristics of included studies</a> tables. A graphical presentation of the risk of bias is shown in <a href="#CD001732-fig-0002">Figure 2</a>. For the domains of 'Blinding of participants and personnel', 'Blinding of outcome assessment', and 'Incomplete outcome data' we have also assessed each study by outcome. We have also distinguished between studies comparing intervention versus intervention and intervention versus placebo as we believe this can impact the risk of bias. Not all studies reported on all outcomes and those sections were left blank where appropriate in the tables. </p> <div class="figure" id="CD001732-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001732-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001732-sec-0047"> <h4 class="title">Allocation</h4> <section id="CD001732-sec-0048"> <h5 class="title">Random sequence generation</h5> <p>The randomisation sequence generation was rated as low risk in 10 RCTs (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>) and unclear risk for 18 RCTs (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> </section> <section id="CD001732-sec-0049"> <h5 class="title">Allocation concealment</h5> <p>One RCT described opening the study randomisation code after deciding the intervention and was judged as having high risk of allocation concealment (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). None of the remaining RCTs described allocation concealment, so all were judged as having unclear risk of bias. </p> </section> </section> <section id="CD001732-sec-0050"> <h4 class="title">Blinding</h4> <section id="CD001732-sec-0051"> <h5 class="title">Performance bias</h5> <section id="CD001732-sec-0052"> <h6 class="title">Cosmetic appearance (assessed by any tool)</h6> <p>Seven RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Four were judged to be at low risk of bias because the blinding of participants and personnel was described and considered appropriate (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Two were judged to be at unclear risk because they did not describe the blinding method making judgement impossible (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), and one was judged to be at high risk of bias because the nature of the intervention precluded blinding (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>). Two RCTs compared sclerosant with sclerosant and with placebo (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). They were considered as being at high risk of bias when any comparison was made with placebo since, due to the nature of the intervention, it was impossible to blind the placebo group (placebos had different physical appearance). We added columns in the Risk of bias table to describe the risk of bias of these RCTs comparing intervention versus intervention and intervention versus placebo. </p> </section> <section id="CD001732-sec-0053"> <h6 class="title">Complications (at least one of the following complications: haematoma formation, skin pigmentation, ulceration and necrosis, superficial thrombophlebitis, deep vein thrombosis and anaphylactic reaction) </h6> <p>Twenty‐three RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Seven were judged as being at low risk of bias since blinding of participants and personnel was described, and we judged it as appropriate (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Seven RCTs were judged to be at unclear risk of bias because they did not describe the blinding method (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Nine RCTs were judged as being at high risk of bias as the nature of the intervention precluded blinding (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). As above, two RCTs were considered as having high risk of bias when any comparison was made with placebo (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). </p> </section> <section id="CD001732-sec-0054"> <h6 class="title">Residual varicose veins (veins that failed obliteration, assessed clinically and/or by ultrasound examination) </h6> <p>Twenty‐five RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Five studies described properly the blinding of participants and personnel and were judged to be at low risk of bias (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Nine studies were considered to be at unclear risk of bias because they did not describe the blinding method despite it being possible to blind due to the nature of the procedure (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Eleven RCTs were judged as being at high risk of bias (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). For ten of these RCTs, it was considered impossible to blind due to the nature of the intervention (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). One RCT was described as blinded but the method was not described. We believe that the nature of the intervention precluded blinding when comparing foam versus liquid sclerotherapy since even a small amount of the sclerosant may flow back to the injection site (<a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>). One RCT described blinding of the patient and ultrasonograph professional. We believe that the nature of the intervention (foam versus liquid) precluded blinding of the interventionist and the ultrasonography professional (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>). As before, <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> and <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> were considered as being at high risk of bias when any comparison was made with placebo. </p> </section> <section id="CD001732-sec-0055"> <h6 class="title">Recurrent varicose veins and venous flare formation</h6> <p>Six RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). One study was judged to be at low risk of bias because it described blinding of participants and personnel and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>). Three were judged to be at unclear risk of bias because they did not state the blinding method (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>). Two RCTs were considered to be at high risk of bias since the nature of the intervention precluded any blinding (<a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). </p> </section> <section id="CD001732-sec-0056"> <h6 class="title">Quality of life (using any specific, validated questionnaire)</h6> <p>Six RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Three of them were judged to be at low risk of bias because they described blinding of participants and personnel and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). As before, <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> and <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> were considered as being at high risk of bias when any comparison was made with placebo. Three RCTs were considered to be at high risk of bias since it was impossible to blind personnel due to the nature of the procedure (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). </p> </section> <section id="CD001732-sec-0057"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>Seven RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Two of these studies were considered to be at low risk of bias since blinding of participants and personnel was described and seemed to be appropriate (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Three studies were considered to be at unclear risk of bias since they did not state who was blinded or how the blinding was carried out (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>). Two studies were judged to be at high risk of bias due to the nature of the intervention preventing blinding of personnel (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). </p> </section> </section> <section id="CD001732-sec-0058"> <h5 class="title">Detection bias</h5> <section id="CD001732-sec-0059"> <h6 class="title">Cosmetic appearance (assessed by any tool)</h6> <p>From the seven RCTs reporting on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>), five RCTs were judged as being at low risk of bias since they described blinding the outcome assessment, and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Two RCTs did not describe the blinding of the assessors of the outcomes. We had no data to judge if they did or not. So, we judged the RCTs as having unclear risk of bias (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>). </p> </section> <section id="CD001732-sec-0060"> <h6 class="title">Complications (at least one of the following complications: haematoma formation, skin pigmentation, ulceration and necrosis, superficial thrombophlebitis, deep vein thrombosis and anaphylactic reaction) </h6> <p>Twenty‐three RCTs reported on this outcome, and ten studies were judged as having low risk of bias since they described the blinding of the outcome assessment and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Ten studies were judged as having unclear risk of bias since the authors did not include any text which enabled us to make an assessment. We preferred to judge them as having unclear risk of bias since some studies could have undertaken this task (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Three studies were declared as non‐blinded studies and were judged as having high risk of bias (<a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). </p> </section> <section id="CD001732-sec-0061"> <h6 class="title">Residual varicose veins (veins that failed obliteration, assessed clinically and/or by ultrasound examination) </h6> <p>Twenty‐five studies reported on this outcome. Eight studies were judged as having low risk of bias since they described blinding of the outcome assessment and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Fourteen studies did not describe any kind of the blinding of assessment (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). As we were not sure about the method, we judged these studies as having unclear risk of bias. Three studies were judged as having high risk of bias (<a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). One study stated that it was impossible to perform a 'double‐blind' study (<a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>). The second study was described as an 'open‐label' study (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). We decided to judge these as having high risk of bias as we had no response from the authors for further information. One study was reported as an unblinded study for the outcome assessment (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). </p> </section> <section id="CD001732-sec-0062"> <h6 class="title">Recurrent varicose veins and venous flare formation</h6> <p>Six studies reported on this outcome; three studies were judged as having low risk of bias since they described the blinding of outcome assessors and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>), and three studies were judged as having unclear risk of bias since they did not state any blinding for outcome assessment (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>). </p> </section> <section id="CD001732-sec-0063"> <h6 class="title">Quality of life (using any specific, validated questionnaire)</h6> <p>Six RCTs reported on this outcome. Three studies were judged as having low risk of bias as the authors described assessment blinding, and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>), and two RCTs were judged as having unclear risk of bias since they did not mention blinding of the assessors of the outcomes (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>). One study was described as not being able to undertake double‐blinding (<a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>). We believe that, even in this case, the blinding of outcome assessment was possible and we judged it as having high risk of bias. One RCT reported outcome assessors were unblinded and was judged as having high risk of bias (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). </p> </section> <section id="CD001732-sec-0064"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>Seven RCTs reported on this outcome. Three studies were judged as having low risk of bias since the authors described blinding of outcome assessment and it seemed to be appropriate (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>), and four RCTs were judged as having unclear risk of bias since they did not describe any blinding of the assessors (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>). </p> </section> </section> </section> <section id="CD001732-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <section id="CD001732-sec-0066"> <h5 class="title">Cosmetic appearance</h5> <p>Seven studies reported on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Five were judged to be at low risk of bias because they described all proposed outcomes and there was no indication of incomplete outcome data (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). One study had 50% of dropouts in the control group and was judged as having unclear risk of bias (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>). One study was judged to be at unclear risk because there was no description of the dropouts (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>). No study was judged to be at high risk of bias. </p> </section> <section id="CD001732-sec-0067"> <h5 class="title">Complications</h5> <p>Twenty‐three RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Thirteen were considered to be at low risk of bias because they reported all the proposed outcomes, there were a low number of dropouts (less than 20%), and so were considered as appropriate (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Eight RCTs were judged to be at unclear risk of bias due to lack of dropout data to judge (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>), one RCT had 50% of dropouts in the control group and was judged as having unclear risk of bias (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>), and one RCT was considered to be at high risk of bias because six participants in the intervention group were removed by the sponsor and reasons for that were not clear to us (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). </p> </section> <section id="CD001732-sec-0068"> <h5 class="title">Residual varicose veins</h5> <p>Twenty‐five RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Sixteen RCTs were considered to be at low risk of bias because they described all data and dropouts and were judged as having appropriate completeness of data (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Eight studies were judged to be at unclear risk of bias because they did not describe dropouts, and we did not know to what extent this could impact the results (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). One RCT was judged as having high risk of bias as there was an intervention by the sponsor (six participants removed and reasons for that were unclear) (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). </p> </section> <section id="CD001732-sec-0069"> <h5 class="title">Recurrent varicose veins and venous flare formation</h5> <p>Six RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Four RCTs were considered to be at low risk of bias since participants were described and reasons for dropouts reported (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Two RCTs provided data in pooled percentages, we were not able to use it to determine the impact of data in the study, and they did not describe dropouts, so were considered to be at unclear risk of bias (<a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>). </p> </section> <section id="CD001732-sec-0070"> <h5 class="title">Quality of life</h5> <p>Six RCTs reported on this outcome and all of them were judged as being at low risk of bias because all studies reported numbers and reasons for dropouts (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). </p> </section> <section id="CD001732-sec-0071"> <h5 class="title">Frequency of persistence of symptoms:</h5> <p>Seven RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Five RCTs were considered to be at low risk of bias since they described numbers and reasons for dropouts (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). Two RCTs were judged to be at high risk of bias because they did not describe dropouts, and we did not know how this could impact results (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>). </p> </section> </section> <section id="CD001732-sec-0072"> <h4 class="title">Selective reporting</h4> <p>Seven RCTs were judged as being at low risk of reporting bias since the protocol was available and reporting was done according to what was planned (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). None of the remaining RCTs provided a protocol. These RCTs were judged as being at unclear risk of bias (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> </section> <section id="CD001732-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>It is estimated that an increase of 48% of size effect occurs in RCTs with fewer than 50 participants (<a href="./references#CD001732-bbs2-0051" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ2013;346:f2304.">Dechartres 2013</a>). So we graded included studies with fewer than 50 participants as having unclear risk of bias since we could not estimate the impact of such studies in a systematic review and a meta‐analysis. We also considered the diameter chosen to be sclerosed. If there was restriction in the vein diameter, external validity would not be applicable to all varicose vein diameters. When there was no imbalance between intervention and control groups and these previous aspects were observed, the studies were judged as having low risk of other bias. Nine RCTs were therefore classified as having low risk (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). All remaining RCTs were judged as having unclear risk as 12 studies had fewer than 50 participants (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Nine RCTs did not describe baseline characteristics (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>); one RCT described imbalances between groups (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>); two RCTs provided insufficient data to judge any imbalance between groups (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>); one RCT provided insufficient data to evaluate (<a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>); and two RCTs did not provide any data regarding the baseline characteristics (<a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>). </p> </section> </section> <section id="CD001732-sec-0074"> <h3 class="title" id="CD001732-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD001732-tbl-0001"><b>Summary of findings 1</b> Foam sclerotherapy versus placebo for treating varicose veins</a>; <a href="./full#CD001732-tbl-0002"><b>Summary of findings 2</b> Foam sclerotherapy versus foam sclerotherapy for treating varicose veins</a>; <a href="./full#CD001732-tbl-0003"><b>Summary of findings 3</b> Foam sclerotherapy versus liquid sclerotherapy for treating varicose veins</a>; <a href="./full#CD001732-tbl-0004"><b>Summary of findings 4</b> Sclerotherapy versus sclerotherapy with different substances for treating varicose veins</a> </p> <section id="CD001732-sec-0075"> <h4 class="title">Sclerotherapy versus no intervention or placebo</h4> <section id="CD001732-sec-0076"> <h5 class="title">Comparison 1: Sclerotherapy versus no intervention</h5> <p>None of the included RCTs compared sclerotherapy with no intervention.</p> </section> <section id="CD001732-sec-0077"> <h5 class="title">Comparison 2: Foam sclerotherapy versus placebo</h5> <p>Five RCTs compared sclerosant with placebo (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). One study did not provide sufficient data regarding the number of participants included in each group or details on the concentration of polidocanol used, so we could not include it in the analysis (<a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). One study referred to the use of polidocanol 2% or 3% (<a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>). As the concentrations of polidocanol were different from the other studies, the data were not used in meta‐analysis. We have chosen polidocanol 1% foam to compare with placebo because one study considered this concentration to be necessary to achieve good sclerotherapy results (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>). We understand this concentration is clinically relevant for foam sclerotherapy. As described in <a href="#CD001732-sec-0035">Data synthesis</a>, we decided to use short‐, intermediate‐, and long‐term time periods according to the moment of the outcome measurement (up to one month, one to three months, and after three months, respectively). There were no available data to perform subgroup analysis by CEAP classification, presence or absence of truncal incompetence, depth of the vein, symptomatic versus nonsymptomatic participants, and previous complications (thrombophlebitis, DVT). Subgroup analysis from different foam concentrations was performed in the comparator 'Sclerotherapy versus sclerotherapy' in the subgroup of 'Foam sclerotherapy versus foam sclerotherapy with different concentrations' due to the importance of the issue. Care was taken to prevent double counting. Due to limitations in the blinding due to the nature of the intervention, all studies were at high risk of bias for participants and personnel. See <a href="./full#CD001732-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD001732-sec-0078"> <h6 class="title">Cosmetic appearance</h6> <p>Two RCTs reported on this outcome, both at intermediate‐term periods (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Cosmetic appearance was reported using independent photography review ‐ visible varicose veins scores (IPR‐V) or using patient self‐assessment of visible varicose veins scores (PA‐V). In both cases, there was a possible benefit in favour of foam sclerotherapy if polidocanol 1% or 2% foam was used: polidocanol 1%: IPR‐V mean difference (MD) ‐0.76, 95% CI ‐0.91 to ‐0.60; 2 studies, 223 participants; very low‐certainty evidence; polidocanol 2%: IPR‐V MD ‐0.90, 95% CI ‐1.11 to ‐0.69; 1 study, 119 participants; (<a href="./references#CD001732-fig-0003" title="">Analysis 1.1</a>); polidocanol 1%: PA‐V MD ‐1.46, 95% CI ‐1.72 to ‐1.20; 2 studies, 223 participants; and polidocanol 2%: PA‐V MD ‐1.60, 95% CI ‐1.95 to ‐1.25; 1 study, 119 participants; (<a href="./references#CD001732-fig-0004" title="">Analysis 1.2</a>) (see <a href="./full#CD001732-tbl-0001">summary of findings Table 1</a>). We have chosen IPR for grading the evidence since it is independent of participants and personnel. We downgraded the certainty of the evidence due to risk of bias concerns and indirectness (<a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> included 8.8% CEAP C5 and C6 participants in the placebo group compared to 3.4% CEAP C5 and C6 participants in the polidocanol 1% group). </p> </section> <section id="CD001732-sec-0079"> <h6 class="title">Complications</h6> <p>Four RCTs reported on complications including DVT, phlebitis or thrombophlebitis, haemorrhagic and neurologic complications (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). We assessed the outcome of DVT using the GRADE approach due to severity of the conditions related to this event. </p> <p>Deep vein thrombosis rates may be increased following polidocanol 1% in the short and intermediate term (RR 5.1, 95% CI 1.3 to 20.01; 3 studies, 302 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0005" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence due to risk of bias concerns, indirectness, inconsistency and imprecision (see <a href="./full#CD001732-tbl-0001">summary of findings Table 1</a>). </p> <p>Polidocanol foam may increase phlebitis or thrombophlebitis rates. The lowest number of cases of phlebitis or thrombophlebitis were found in the placebo group compared with the polidocanol foam group during the intermediate‐term periods (e.g. for polidocanol ≥ 1% foam: RR 3.12, 95% CI 1.1 to 8.83; 3 studies, 302 participants) (<a href="./references#CD001732-fig-0006" title="">Analysis 1.4</a>; <a href="./references#CD001732-fig-0007" title="">Analysis 1.5</a>). </p> <p>Haematoma formation was described as a haemorrhagic complication. There were no clear differences in haemorrhagic outcomes between polidocanol foam and placebo in the short term (polidocanol 1%: RR 1.83, 95 CI 0.75 to 4.47; 3 studies, 302 participants) (<a href="./references#CD001732-fig-0008" title="">Analysis 1.6</a>). </p> <p>There was no evidence of a difference in neurological complication rates between 1% or more concentrated polidocanol foam and placebo at the short term (polidocanol 1%: RR 1.03, 95 CI 0.22 to 4.91; 3 studies, 302 participants) (<a href="./references#CD001732-fig-0009" title="">Analysis 1.7</a>). <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a> used a different gas mixture (Varithena) in which there is a low proportion of nitrogen aiming to reduce cerebral side effects. A case of transient ischaemic attack was reported on day 13 and could not be related to the intervention. As the gas concentrations were different, we conducted a sensitivity analysis that did not change the effect direction. Aiming to evaluate whether the polidocanol foam concentration could change complication rates, we performed subgroup analysis comparing different concentrations of polidocanol foam (see the comparison 'Sclerotherapy versus sclerotherapy' in the analysis of 'Foam sclerotherapy versus foam sclerotherapy with different concentrations'). </p> </section> <section id="CD001732-sec-0080"> <h6 class="title">Residual varicose veins</h6> <p>Five RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0011" title="KahleB , LengK , BolzS . Efficacy of sclerotherapy in varicose veins: a blinded, placebo-controlled study. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#114); 2003. San Diego, 2003. KahleB , LengK . Efficacy of sclerotherapy in varicose veins - prospective, blinded, placebo-controlled study. Dermatologic Surgery2004;30(5):723-8. ">Kahle 2004</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). Residual varicose vein rates may be decreased in the 1% or more polidocanol foam group than in the placebo group (for polidocanol 1% foam: RR 0.19, 95% CI 0.13 to 0.29; 2 studies, 225 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0010" title="">Analysis 1.8</a>) at an intermediate‐term period. We downgraded the certainty of the evidence due to risk of bias concerns and indirectness (<a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> included 8.8% CEAP C5 and C6 participants in the placebo group and 3.4% CEAP C5 and C6 participants in the polidocanol 1% group). </p> </section> <section id="CD001732-sec-0081"> <h6 class="title">Quality of life</h6> <p>Three RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Quality of life (QoL) was measured using QoL adjusted mean change VEINES‐QOL/Sym (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) in polidocanol foam versus placebo (for polidocanol 1%: MD 12.41; 95% CI 9.56 to 15.26; 3 studies, 299 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0011" title="">Analysis 1.9</a>), showing a possible improvement in the QoL in the foam group. Although <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> did not describe standard deviations, we used standard deviations from <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> to perform the meta‐analysis following recommendations for standard deviation data imputation from Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001732-bbs2-0059" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Review of interventions Version 5.2.0 (updated March 2017), The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017c</a>). The certainty of the evidence was downgraded due to wide confidence intervals, low number of participants, and indirectness (participants with CEAP C5 and C6 included in the studies). <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a> used a different gas mixture (Varithena) in which there is a low proportion of nitrogen aiming to reduce cerebral side effects. A sensitivity analysis did not show any difference in effect. </p> </section> <section id="CD001732-sec-0082"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>Three RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Persistence of symptoms was evaluated by <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a> using the VEINES‐QOL/Sym score to evaluate the patient perspective using polidocanol 1% foam versus placebo. In this case, polidocanol foam was superior to placebo in improving symptoms (MD ‐14.00; 95% CI ‐15.39 to ‐12.61; 1 study, 77 participants) (<a href="./references#CD001732-fig-0012" title="">Analysis 1.10</a>). The remaining two RCTs also evaluated VEINES‐QOL/Sym but we did not have access to sufficient data to conduct a meta‐analysis (missing standard deviations). These RCTs (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) also described VCSS; we used this outcome to grade the certainty of the evidence. Both studies reported an improvement in symptoms at intermediate‐term periods after sclerotherapy (eight weeks), and pooling the data for polidocanol 1% versus placebo showed: MD ‐3.25, 95% CI ‐3.90 to ‐2.60; 2 studies, 223 participants; low‐certainty evidence (<a href="./references#CD001732-fig-0013" title="">Analysis 1.11</a>). We downgraded the certainty of the evidence due to the low number of participants and indirectness (participants with CEAP C5 and C6 included in the RCTs). </p> </section> <section id="CD001732-sec-0083"> <h6 class="title">Recurrent varicose veins</h6> <p>None of the RCTs reporting on this comparison described recurrent varicose veins.</p> </section> </section> </section> <section id="CD001732-sec-0084"> <h4 class="title">Sclerotherapy versus sclerotherapy</h4> <p>Twenty‐two RCTs investigated this comparison. We were able to pool results from the comparison 'foam sclerotherapy versus foam sclerotherapy with different concentrations'; 'Foam versus liquid sclerotherapy'; and from the comparison 'different techniques'. Three RCTs compared 'different substances' (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>), two RCTs compared addition of substances including perfluropropane‐filled albumin microspheres of foam STS with air‐filled foam STS (<a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>) or a low molecular weight synthetic protein (Gelufusine) to polidocanol foam versus polidocanol foam sclerotherapy alone (<a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>), and we considered it inappropriate to pool results due to indirect comparisons (different concentrations of the substances). Three RCTs did not supply data to measure the size effect (<a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). </p> <p>No RCT compared different time intervals as part of their injection technique.</p> <section id="CD001732-sec-0085"> <h5 class="title">Comparison 3: Foam sclerotherapy versus foam sclerotherapy with different concentrations</h5> <p>Five RCTs reported on this comparison (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Different concentrations of polidocanol foam were used for comparison and they were categorised and described as polidocanol &lt; 1% versus ≥ 1% or the most concentrated polidocanol foam described. We adopted this approach based on data representing an increased efficacy of polidocanol foam to occlude varicose veins at 1% concentration (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>). </p> <p>For polidocanol foam concentrations at 1% to 2%, there was no clear difference in venous occlusion rates (80.4% for polidocanol 1% foam and 82.5% for polidocanol 2% foam) (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>). On the other hand, we are not confident that more concentrated foams could show an increase in success rates. So polidocanol 1% was used as a comparator against more concentrated foam preparations whenever there was a possibility to compare in order to investigate if concentrations greater than 1% could improve sclerotherapy effects. When there was an uncertainty of effect size, a subgroup analysis was performed. Care was taken to avoid double counting of participants. Although two authors (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) used polidocanol 0.125% foam as the smallest concentration permitting a stable foam as a control with other polidocanol concentrations, this sclerosant concentration showed a pharmacologic action, capable of producing objective outcomes (e.g. common femoral vein thrombus extension) as well as subjective outcomes (e.g. QoL improvements); and so is described in this session as an intervention group and not as the inactive placebo group. </p> <p>We used polidocanol 3% versus 1% to grade the certainty of the evidence and to look for any additional effect with the increase of the concentration of the sclerosant. See <a href="./full#CD001732-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD001732-sec-0086"> <h6 class="title">Cosmetic appearance</h6> <p>Three RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). </p> <p>One RCT described self‐related cosmetic improvement over a long‐term period (complete cosmetic satisfaction) when comparing polidocanol 3% foam with polidocanol 1% foam (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>). There were no clear differences in cosmetic appearance in this analysis at a short‐term period (RR 1.31, 95% CI 0.81 to 2.12; 1 study, 80 participants) (<a href="./references#CD001732-fig-0014" title="">Analysis 2.1</a>), or at long‐term period (RR 1.11, 95% CI 0.84 to 1.47; 1 study, 80 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0015" title="">Analysis 2.2</a>). The certainty of the evidence was downgraded due to concerns over risk of bias, indirectness (study authors included participants with CEAP C1, C5 and C6), and imprecision (low number of participants, wide confidence intervals, and single study). </p> <p>Two RCTs evaluated the PA‐V (patient‐visible varicose vein instrument) and the IPR‐V (independent expert panel rating scale) of photographs according to <a href="./references#CD001732-bbs2-0062" title="KingsleyJ , KingT , OrfeE , WrightD . Capturing the visual impact of varicose veins. Journal of Vascular Surgery2012;55(6 suppl):62S. [DOI: 10.1016/j.jvs.2012.03.163]">Kingsley 2012</a> (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Increased concentrations of polidocanol possibly increased the improvement in cosmetic appearance at intermediate‐term periods as seen with PA‐V: polidocanol 0.125% versus 1% (MD 0.45, 95% CI 0.03 to 0.87; 2 studies, 224 participants). Polidocanol 0.5% versus 1% showed no clear difference (MD 0.06, 95% CI ‐0.21 to 0.32; 2 studies, 221 participants; <a href="./references#CD001732-fig-0016" title="">Analysis 2.3</a>). A similar effect was seen with the IPR‐V (independent expert panel rating scale) of photographs: polidocanol 0.125% versus 1% (MD 0.19, 95% CI ‐0.01 to 0.40; 2 studies, 224 participants); polidocanol 0.5% versus 1% (MD ‐0.04, 95% CI ‐0.19 to 0.12; 2 studies, 221 participants; <a href="./references#CD001732-fig-0017" title="">Analysis 2.4</a>). If the concentration of test polidocanol foam was similar to the comparator (1%), there was no clear difference detected in cosmetic improvement, as is expected. We used the standard deviation from <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> to perform the meta‐analysis. Data imputation followed recommendations from the <i>Cochrane Handbook</i> to deal with missing data (<a href="./references#CD001732-bbs2-0059" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Review of interventions Version 5.2.0 (updated March 2017), The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017c</a>). </p> </section> <section id="CD001732-sec-0087"> <h6 class="title">Complications</h6> <p>Five RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Complications were described as DVT, skin pigmentation, phlebitis or thrombophlebitis rates, matting, thromboembolic complications, haemorrhagic complications, and neurologic complications. </p> <p>Thromboembolic complications (including DVT and PE) were described by three RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and there were no clear differences between polidocanol 3% versus 1% in foam (RR 1.47, 95% CI 0.41 to 5.33; 3 studies, 371 participants; very low‐certainty evidence <a href="./references#CD001732-fig-0018" title="">Analysis 2.5</a>). <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> used the lower leg as the unit of analysis and included 11.63% of participants with CEAP C1. <a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a> and <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a> used the individual as the unit of analysis. A sensitivity analysis was performed and it did not change the effect direction (<a href="./references#CD001732-fig-0019" title="">Analysis 2.6</a>). The certainty of the evidence was downgraded due to indirectness (inclusion of participants with CEAP C1, C5, and C6), and imprecision (low number of events). </p> <p>From polidocanol 0.125% to 2% foam, there was no evidence of increased DVT for the evaluated subgroups at short or intermediate‐term periods (for polidocanol foam 0.125% versus 2%: RR 1.81, 95% CI 0.17 to 19.43; 1 study, 120 participants) (<a href="./references#CD001732-fig-0020" title="">Analysis 2.7</a>) (for polidocanol 1% versus 2%: RR 0.83, 95% CI 0.12 to 5.66; 1 study, 115 participants) (<a href="./references#CD001732-fig-0020" title="">Analysis 2.7</a>). Analyses were carried out separately to dichotomise polidocanol concentrations lower than 1% versus higher or equal to 1%, and 1% compared to the higher concentrations of polidocanol foam. No differences were detected by the test for subgroup differences (P = 0.73). </p> <p>Two RCTs (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), investigated the frequency of PE at the short term comparing polidocanol 3% with 1% foam and there was no clear difference seen, with only one case of PE described in the 3% group (RR 3.00, 95% CI 0.13 to 71.51; 2 studies, 228 participants) (<a href="./references#CD001732-fig-0021" title="">Analysis 2.8</a>). </p> <p>Two RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>) described skin pigmentation at long‐term periods comparing polidocanol 3% with 1% foam and meta‐analysis showed no clear difference in skin pigmentation rates (RR 1.61, 95% CI 0.82 to 3.17; 2 studies, 223 participants) (<a href="./references#CD001732-fig-0022" title="">Analysis 2.9</a>). As <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> used the lower leg as the unit of analysis, a sensitivity analysis was conducted and there were no differences in the overall effect. </p> <p>A subgroup analysis was carried out to show the results of phlebitis or thrombophlebitis rates in two RCTs with a concentration of polidocanol ranging from 0.125% to 2% (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>); no clear differences in phlebitis and thrombophlebitis rates were seen in any subgroup despite the variation of sclerosant concentrations (polidocanol 0.5% versus 2%: RR 0.77, 95% CI 0.27 to 2.22; 1 study, 114 participants) (<a href="./references#CD001732-fig-0023" title="">Analysis 2.10</a>). No differences were detected by the test for subgroup differences (P = 0.3). Low thrombophlebitis rates were reported with polidocanol 0.125% in the <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> study (<a href="./references#CD001732-fig-0023" title="">Analysis 2.10</a>). </p> <p>Phlebitis and thrombophlebitis were also described by two other RCTs comparing polidocanol 3% with polidocanol 1% foam (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>). These studies were not included in the subgroup analysis above because we dichotomised data to polidocanol foam concentration less than 1% versus polidocanol foam concentration equal to or more than 1%. We assessed the effect size of the higher polidocanol foam concentration separately. There were no clear differences in thrombophlebitis rates in these foam concentrations (RR 1.46, 95% CI 0.88 to 2.41; 2 studies, 223 participants) (<a href="./references#CD001732-fig-0024" title="">Analysis 2.11</a>). </p> <p>Haematoma complications were described in two RCTs (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>), and no clear differences were detected between any investigated subgroups. For polidocanol 0.125% versus 1%: RR 0.61, 95% CI 0.20 to 1.83; 2 studies, 228 participants) (test for subgroup differences P = 0.18) (<a href="./references#CD001732-fig-0025" title="">Analysis 2.12</a>). </p> <p>Neurological complications were described as mild in two RCTs (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>), and no clear differences were detected between any of the polidocanol concentrations investigated (0.125% and 0.5% versus 1% and 2%) (<a href="./references#CD001732-fig-0026" title="">Analysis 2.13</a>); or polidocanol 1% versus 2% (RR 0.28, 95% CI 0.01 to 6.64; 1 study, 115 participants) (<a href="./references#CD001732-fig-0026" title="">Analysis 2.13</a>). </p> </section> <section id="CD001732-sec-0088"> <h6 class="title">Residual varicose veins</h6> <p>Five RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Residual varicose veins were described by two studies at an intermediate‐term period (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>), and three RCTs reported at a long‐term period (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). Subgroup analysis was used to compare concentrations of the foam sclerotherapy agent in reducing residual varicose veins (<a href="./references#CD001732-fig-0027" title="">Analysis 2.14</a>). Increasing the polidocanol foam concentration reduced the number of participants with residual varicose veins (for polidocanol 0.5% versus 2%: RR 2.36, 95% CI 1.26 to 4.42; 1 study, 114 participants) (<a href="./references#CD001732-fig-0027" title="">Analysis 2.14</a>). <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> compared polidocanol 1% versus 2% and there was no clear difference in residual varicose vein rates (RR 1.21, 95% CI 0.57 to 2.57; 1 study, 115 participants) (<a href="./references#CD001732-fig-0027" title="">Analysis 2.14</a>). Three studies evaluated higher concentrations of polidocanol foam at a long‐term period (3% versus 1% at 6, 12, and 24 months) (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). The rate of residual varicose veins may be slightly decreased in the polidocanol 3% foam group from six to 24 months (RR 0.67, 95% CI 0.43 to 1.04; 3 studies, 371 participants; moderate‐certainty evidence) (<a href="./references#CD001732-fig-0028" title="">Analysis 2.15</a>). The effect size was not changed following sensitivity analysis to exclude a study that included participants with CEAP C1(<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-fig-0029" title="">Analysis 2.16</a>). </p> <p>The evidence was downgraded due to indirectness (inclusion of participants with CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) but there was no description of the proportion of these participants in the groups). One study used the lower leg as the unit of analysis (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>). </p> </section> <section id="CD001732-sec-0089"> <h6 class="title">Quality of life</h6> <p>Two RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). </p> <p>Quality of life analysis was possible with data imputation using the standard deviations from <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> when using the VEINES‐QOL/Sym scores. The study authors reported a tendency for improvement of quality of life if more concentrated polidocanol foam was used. We were only able to conduct meta‐analysis comparing 0.125%, 0.5%, and 1% polidocanol foam (<a href="./references#CD001732-fig-0030" title="">Analysis 2.17</a>). Our analysis did not find a clear improvement in the quality of life when increasing polidocanol foam concentration up to 1% polidocanol foam (test for subgroup differences P = 0.11). </p> <p>No study evaluated polidocanol 3% versus 1%, so the certainty of the evidence was not graded. </p> </section> <section id="CD001732-sec-0090"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>Two RCTs reported the frequency of persistence of symptoms using the VCSS score (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Both reported an improvement in VCSS scores with increasing concentrations of polidocanol foam and this was confirmed by meta‐analysis: polidocanol 0.125% versus 0.5% (MD ‐0.87, 95% CI ‐1.52 to ‐0.21; 2 studies, 225 participants) (<a href="./references#CD001732-fig-0031" title="">Analysis 2.18</a>). Only polidocanol 0.5% versus 1% did not show a difference in VCSS scores (MD 0.10, 95% CI ‐0.56 to 0.75; 2 studies, 221 participants) (test for subgroup differences P = 0.08) (<a href="./references#CD001732-fig-0031" title="">Analysis 2.18</a>). </p> <p>The certainty of the evidence was not graded since no study compared polidocanol 3% versus 1%. </p> </section> <section id="CD001732-sec-0091"> <h6 class="title">Recurrent varicose veins and venous flare formation</h6> <p>One RCT reported on this outcome (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). There was no clear difference in the number of recurrent varicose veins when comparing polidocanol 3% versus 1% foam concentrations at a long‐term period (RR 0.91, 95% CI 0.62 to 1.32; 1 study, 148 participants; low‐certainty evidence) (<a href="./references#CD001732-fig-0032" title="">Analysis 2.19</a>). </p> <p>The certainty of the evidence was graded as low since data were from a single study with an indirect population (participants with CEAP C5 and C6). </p> </section> </section> <section id="CD001732-sec-0092"> <h5 class="title">Comparison 4: Foam sclerotherapy versus liquid sclerotherapy</h5> <p>Nine RCTs reported on this comparison (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). Three studies did not provide any usable data (<a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). One RCT used an ultrasound contrast agent to produce a foam (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). As this is not a standard way to produce a foam sclerotherapy agent, we believe it cannot be compared to any conventional foam in which the medicine is agitated with a gas. To grade the certainty of the evidence, we have tried to use similar or equal foam concentrations since it is not known if there is an ideal concentration. Using the same concentration will be more useful for clinicians. See <a href="./full#CD001732-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD001732-sec-0093"> <h6 class="title">Cosmetic appearance</h6> <p>One RCT reported on this outcome. Long‐term cosmetic appearance was reported by <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a> as patient satisfaction and there was no difference when using polidocanol 0.75% to 1.25% foam versus polidocanol 1.5% to 2.5% liquid (MD 0.20, 95% CI ‐0.27 to 0.67; 1 study, 126 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0033" title="">Analysis 3.1</a>). The unit of analysis was the vein. No other RCT included in this comparison reported on this outcome and there were differences in the concentrations compared. We downgraded the certainty of the evidence to very low due to risk of bias concerns, and indirectness (different concentrations of the polidocanol used). As the authors did not use similar or equal concentrations of sclerosant, we undertook a descriptive analysis and used this study to grade the certainty of the evidence in <a href="./full#CD001732-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD001732-sec-0094"> <h6 class="title">Complications</h6> <p>Seven RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>). Two studies did not report complications as an outcome (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>). There was a lack of reported information and interest in adverse events and complications, including thromboembolic events. Overall, complications were described as mild, and these included pain, phlebitis, haematomas, and skin pigmentation. One study described a case of allergy in the liquid intervention group and five cases of amaurosis in the foam intervention group using STS sclerosant agent (<a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>). <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a> described complications as pooled results including an event of vaso‐vagal response, one of sensation of heat in the mouth immediately after injection, persistent inflammation in the thigh, two cases of bruising, two of thrombophlebitis of the leg, one of asthenia, one patient with headache, and two cases of pain in the thigh and knee; with the study authors reporting that there was no difference between the two treatment groups. <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a> described four participants in the foam group as having severe pain as well as 25.3% of the participants from the foam group and 9.5% from the liquid group with local inflammation at 15 days post‐treatment. The RCT also described a greater number of pigmentations in the foam group (33%) compared to the liquid group (6.3%) at one year. However, this RCT included participants with CEAP C1 and we were unable to access individual patient data. Also, the sclerosant concentration was stratified for subgroups of vein diameter. For veins with 1 mm to 2 mm diameter, 1% liquid polidocanol or 0.5% for the foam group was used; veins with 1 mm to 3 mm used 1.25% liquid polidocanol versus 0.5% for foam; varicose veins with 3.1 mm to 4 mm used 1.5% liquid polidocanol and 0.75% for foam; 4.1 mm to 5 mm in diameter varicose veins used 2% liquid polidocanol versus 1% for foam; 5.1 mm to 6 mm in diameter veins used 2.5% liquid polidocanol versus 1.25% for foam sclerotherapy. As we had no access to subgroups of the participants, we decided not to calculate the effect size because it could result in bias. <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a> and <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a> described skin pigmentation as mild or moderate, with no clear difference detected between the foam and liquid sclerotherapy intervention groups (RR 1.75, 95% CI 0.81 to 3.80; 2 studies, 208 participants) (<a href="./references#CD001732-fig-0034" title="">Analysis 3.2</a>). One RCT described 0.2% of side effects for the foam group versus 2.4% for the liquid group but the study authors did not describe which side effects occurred (<a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>). One RCT described an increase in phlebitis rates in the air‐filled foam compared to microspheres filled (P = 0.01) (<a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>). </p> </section> <section id="CD001732-sec-0095"> <h6 class="title">Residual varicose veins</h6> <p>Six RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>). One study investigated the use of a tensioactive substance to produce a foam with STS 2% or 3% (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). The authors presented results as the reduction of ambulatory venous pressure, refilling time, and number of major sites of incompetence on duplex ultrasound, and using the duplex ultrasound demonstrated no differences in residual varicose veins after 10 years of follow‐up (1.1 points of major site incompetence in each treatment option). As the RCT used different medicine concentrations, different outcome measures, and time points to report the outcomes, we decided not to include it in the analysis. There was a benefit for the use of foam seen in all RCTs for occluding the varicose veins over a long time (<a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>). We did not think it was appropriate to pool overall, as different concentrations and sclerosants were used, so data have been presented as a subgroup analysis (<a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>). As <a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a> used different concentrations of sclerosant, a sensitivity analysis was conducted and it did not change the effect direction. We decided to report and assess results from polidocanol 3%, as this was most clinically relevant. For polidocanol 3%, there was an RR of 0.51 (95% CI 0.41 to 0.65; 2 studies, 203 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>). Two sclerotherapy products were included in this analysis: polidocanol and STS. There was also heterogeneity in the population due to differences in varicose vein diameter, type of vein treated (saphenous or collaterals), number of sessions necessary to treat, and the CEAP inclusion. Some of these data were difficult or impossible to recover and there were differences in results between different centres of the same RCTs (<a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>). Despite these limitations, sensitivity analysis showed a consistent benefit for the foam groups over the liquid groups. The certainty of the evidence was downgraded due to risk of bias concerns and indirectness: <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a> included participants with CEAP C2 to C6 without discriminating between them; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a> included one participant with CEAP C5 in the foam group (1.9%) and four participants with CEAP C5 in the liquid group (7.7%). </p> <p>Residual varicose veins were also investigated following STS 3%, and at a long‐term period showed a benefit of foam over liquid sclerotherapy (RR: 0.63, 95% CI 0.48 to 0.82; 1 study, 130 participants) (<a href="./references#CD001732-fig-0036" title="">Analysis 3.4</a>). </p> </section> <section id="CD001732-sec-0096"> <h6 class="title">Quality of life</h6> <p>None of the RCTs reporting on this comparison reported QoL.</p> </section> <section id="CD001732-sec-0097"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>None of the RCTs reporting on this comparison reported persistence of symptoms.</p> </section> <section id="CD001732-sec-0098"> <h6 class="title">Recurrent varicose veins</h6> <p>Two RCTs reported on recurrent varicose veins (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a>). <a href="./references#CD001732-bbs2-0013" title="MartimbeauPR . A randomized clinical trial comparing the sclerosing and side effects of foam vs. liquid formula for sclerotherapy of primary varicose veins. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#144); 2003. San Diego, 2003. ">Martimbeau 2003a</a> did not provide any data, but described no difference in recurrent varicose veins at 12 months (1.2% in foam group and 1.7% in liquid group). <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a> evaluated this outcome at five years comparing STS foam with liquid and reported recurrence as similar in both groups (RR 1.1, 95% CI 0.86 to 1.42; 1 study, 286 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0037" title="">Analysis 3.5</a>). </p> <p>The certainty of the evidence was downgraded due to the risk of bias (intervention probably impossible to blind due to the nature of the intervention), imprecision (single study), and indirectness (did not describe CEAP of the participants and used a tensioactive substance to produce foam ‐ not the standard way to use gas or room air). The study author described the participants as people with varicose veins with diameters larger than 3 mm. </p> </section> </section> <section id="CD001732-sec-0099"> <h5 class="title">Comparison 5: Sclerotherapy versus sclerotherapy with different substances</h5> <p>Four RCTs compared sclerotherapy versus sclerotherapy with any other substance (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). These studies investigated a range of concentrations, formulations, and drug volumes, so we were unable to pool all the data. <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> studied STS 1.5% versus polidocanol 3%. The same substances were investigated by <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a> but using STS 0.5% versus polidocanol 1%, and <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a> with STS 3% versus polidocanol 4%. <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a> compared polidocanol 1% with any market sclerosant in any presentation or concentration. Although we had planned to present a SoF table for the comparison sclerotherapy with STS 1% versus sclerotherapy with polidocanol 1% (see <a href="#CD001732-sec-0015">Methods</a> section), no included RCT considered this comparison. See <a href="./full#CD001732-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD001732-sec-0100"> <h6 class="title">Cosmetic appearance</h6> <p>Two RCTs reported on this outcome (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>). Cosmetic appearance was described by <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> as the disappearance of the varicose veins after treating the veins (diameter between 3 mm and 6 mm) using polidocanol 3% versus STS 1.5%. The scale to describe disappearance of the varicose veins ranged from 1 to 5: 1 = worse than before treatment; 2 = no change; 3 = minor disappearance; 4 = moderate disappearance; 5 = complete disappearance (MD 0.20, 95% CI ‐0.01 to 0.41; 1 study, 54 participants) (<a href="./references#CD001732-fig-0038" title="">Analysis 4.1</a>). As different polidocanol and STS concentrations were used, we were not able to draw conclusions about the benefit of one product over the other. <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a> described outcomes as clearance scores, tolerability, and patient satisfaction. It was not possible to estimate the effect size from <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a> since there were pooled data from CEAP C1 and C2 and different interventions (STS 0.25% or polidocanol 0.5% solution for vein diameters lower than 1 mm; STS 0.5% or polidocanol 1% solution for 1 mm to 3 mm veins, and STS 0.5% or polidocanol 1% foam for veins with diameter between 3 mm and 6 mm). We believe a sclerosant could reach veins with small or larger diameters once injected in a varicose vein, since reflux could drive sclerosant agent to that site, adding a confounding factor to analysis. We did not pool results to grade the certainty of the evidence. We decided not to grade the certainty of the evidence due to discrepancy in concentration of sclerosants and no discrimination of CEAP population. </p> </section> <section id="CD001732-sec-0101"> <h6 class="title">Complications</h6> <p>Two RCTs reported on complications but we were unable to pool the data due to differences in sclerosant concentrations used (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). One RCT compared a commercial polidocanol 1% foam (Varisolve) versus any market sclerosant liquid or foam and reported on skin pigmentation, DVT and haematoma at short‐ or intermediate‐term periods (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). No differences were seen in the occurrence of DVT (RR 0.97, 95% CI 0.09 to 10.54; 1 study, 384 participants) (<a href="./references#CD001732-fig-0039" title="">Analysis 4.2</a>); skin pigmentation (RR 1.01, 95% CI 0.80 to 1.27; 1 study, 384 participants; <a href="./references#CD001732-fig-0040" title="">Analysis 4.3</a>); or haematoma formation (RR 1.56, 95% CI 0.76 to 3.18; 1 study, 384 participants) (<a href="./references#CD001732-fig-0041" title="">Analysis 4.4</a>). <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> described complications without discriminating between participants with CEAP C1 and C2. Otherwise, intervention and control groups appeared to be balanced. The number of skin pigmentation events were not different between STS 1.5% versus polidocanol 3% (RR 1.21, 95% CI 0.95 to 1.55; 1 study, 167 participants) (<a href="./references#CD001732-fig-0042" title="">Analysis 4.5</a>). Skin necrosis numbers were not clearly different in the STS 1.5% group and in the polidocanol 3% group but no events were reported in the polidocanol 3% group resulting in a very wide CI (RR 14.12, 95% CI 0.81 to 246.76; 1 study, 167 participants) (<a href="./references#CD001732-fig-0043" title="">Analysis 4.6</a>). <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> also described thrombosis of the vein, probably related to thrombophlebitis or venous occlusion (superficial venous system). As the RCT compared different sclerosant concentrations, we considered it inappropriate to present the data in a SOF table. We decided not to grade the certainty of the evidence due to discrepancy in concentrations of sclerosants and no discrimination of CEAP population. </p> </section> <section id="CD001732-sec-0102"> <h6 class="title">Frequency of residual varicose veins</h6> <p><a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a> investigated polidocanol 1% (Varisolve) versus any market sclerosant liquid or foam. We considered the veins that had no occlusion or elimination of reflux as residual varicose veins. At 12 months, the rates of residual varicose veins were greater in any market sclerosant than in the intervention group (RR 0.64, 95% CI 0.42 to 0.97; 1 study, 373 participants) (<a href="./references#CD001732-fig-0044" title="">Analysis 4.7</a>). As the comparators were so discrepant (any concentrations and forms of liquid or foam), we decided not to grade the certainty of the evidence. </p> </section> <section id="CD001732-sec-0103"> <h6 class="title">Quality of life</h6> <p>None of the RCTs reporting on this comparison reported QoL.</p> </section> <section id="CD001732-sec-0104"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>None of the RCTs reporting on this comparison reported on persistence of symptoms.</p> </section> <section id="CD001732-sec-0105"> <h6 class="title">Frequency of recurrent varicose veins and venous flare formation</h6> <p><a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> investigated matting and there was no clinical difference in the STS 1.5% intervention group compared to polidocanol 3% (RR 1.53, 95% CI 0.58 to 4.02; 1 study, 167 participants) (<a href="./references#CD001732-fig-0045" title="">Analysis 4.8</a>). We did not grade the certainty of the evidence due to the different sclerosant concentrations. We believe that this concentration comparison does not represent a relevant clinical situation. </p> </section> </section> <section id="CD001732-sec-0106"> <h5 class="title">Comparison 6: Sclerotherapy versus sclerotherapy with different techniques</h5> <p>Six RCTs evaluated different techniques for injection sclerotherapy (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). There was important heterogeneity between comparisons due to the use of different interventions and time points assessed. These techniques included single versus multiple injections (with the same product and the same volume) (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>); polidocanol 1% to 3% foam injected in few injections versus in multiple injections (<a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>); and ultrasound‐guided foam sclerotherapy with visual foam sclerotherapy using polidocanol 1% foam (<a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>); polidocanol 1% foam sclerotherapy injected by a needle compared to polidocanol 1% foam catheter‐directed sclerotherapy, and with polidocanol 1% foam microcatheter‐directed sclerotherapy (<a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>); polidocanol 3% foam injected by needle versus delivered by a catheter associated with tumescent technique (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>); and antegrade versus retrograde technique with polidocanol 1% foam (<a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> <section id="CD001732-sec-0107"> <h6 class="title">Cosmetic appearance</h6> <p>None of the RCTs reporting on this comparison reported cosmetic appearance.</p> </section> <section id="CD001732-sec-0108"> <h6 class="title">Complications</h6> <p><a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a> compared antegrade versus retrograde techniques using polidocanol 1% foam and no DVT events were reported in either group. Similarly, no clear differences were detected in short‐term period thrombophlebitis rates (RR 2.00, 95% CI 0.54 to 7.45; 1 study, 80 participants) (<a href="./references#CD001732-fig-0046" title="">Analysis 5.1</a>); or long‐term period skin pigmentation rates (RR 1.5, 95% CI 0.26 to 8.50; 1 study, 80 participants) (<a href="./references#CD001732-fig-0047" title="">Analysis 5.2</a>); or in thrombophlebitis rates using catheter versus needle injection (RR 1.00, 95% CI 0.07 to 15.12; 1 study, 50 participants) (<a href="./references#CD001732-fig-0048" title="">Analysis 5.3</a>). </p> <p>There was more foam agent detected in the deep venous system by ultrasound when using fewer injections compared to more injections in <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a> (RR 2.12, 95% CI 1.36 to 3.30; 1 study, 112 participants) (<a href="./references#CD001732-fig-0049" title="">Analysis 5.4</a>). <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a> reported seven participants with pain, nine with phlebitis (described as "venulites"), and two with oedema. <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a> reported no adverse reaction, especially bleeding. <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a> described two cases of migraine in the few injections group, two cases of superficial thrombophlebitis in each group, and one case of pain in each group. <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a> reported one case of thrombophlebitis in each group, and one case of migraine in the visual foam sclerotherapy group. One RCT reported skin irritation in two participants, one case of migraine in the catheter foam‐delivered group, and hyperpigmentation in eight participants from the needle injection group, compared to four participants from the catheter group (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). As there was a co‐intervention (tumescent technique), we did not include these data in a meta‐analysis. </p> </section> <section id="CD001732-sec-0109"> <h6 class="title">Frequency of residual varicose veins</h6> <p>Six studies reported on this outcome but we were not able to pool data due to heterogeneity (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a> compared visual foam sclerotherapy with ultrasound‐guided foam sclerotherapy using polidocanol 1% foam and there were no clear differences in residual varicose vein rates in the long‐term period (RR 1.05, 95% CI 0.75 to 1.48; 1 study, 103 participants) (<a href="./references#CD001732-fig-0050" title="">Analysis 5.5</a>). Two studies reported on this outcome questioning if an increase in puncture number could impact residual varicose vein rates (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>). <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a> evaluated STS 3% injected in fractionated versus single injections with no differences detected in residual varicose vein rates (RR 1.08, 95% CI 0.79 to 1.49; 1 study, 150 participants) (<a href="./references#CD001732-fig-0051" title="">Analysis 5.6</a>). <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a> compared polidocanol 1% or 3% foam in multiple injections versus few injections showing no differences in the residual varicose vein rates (RR 1.17, CI 0.78 to 1.78; 1 study, 112 participants) (<a href="./references#CD001732-fig-0051" title="">Analysis 5.6</a>). The injection technique (retrograde versus antegrade) made no difference to the number of residual varicose veins at the intermediate‐term period (<a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>) (RR 1.80, 95% CI 0.66 to 4.90; 1 study, 80 participants) (<a href="./references#CD001732-fig-0052" title="">Analysis 5.7</a>). </p> <p><a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a> compared polidocanol 1% foam sclerotherapy injected by a needle with polidocanol 1% foam catheter‐directed sclerotherapy, and with polidocanol 1% foam microcatheter‐directed sclerotherapy. There were low numbers of participants in each group (10), and there was no difference in residual varicose veins at the intermediate‐term period between all comparable groups: microcatheter versus catheter (RR 5.00, 95% CI 0.27 to 92.62; 1 study, 20 participants; <a href="./references#CD001732-fig-0053" title="">Analysis 5.8</a>); or needle versus catheter with zero events in the catheter group leading to very wide CIs (RR 9.00, 95% CI 0.55 to 147.95; 1 study, 20 participants; <a href="./references#CD001732-fig-0054" title="">Analysis 5.9</a>); and needle sclerotherapy versus microcatheter (RR 2.00, 95% CI 0.47 to 8.56; 1 study, 20 participants; <a href="./references#CD001732-fig-0055" title="">Analysis 5.10</a>). <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a> compared polidocanol 3% foam injected by a catheter associated with tumescent technique versus needle and reported lower rates of residual varicose veins in the catheter‐delivered group at a short‐term period (RR 0.31, 95% CI 0.14 to 0.72; 1 study, 50 participants; <a href="./references#CD001732-fig-0056" title="">Analysis 5.11</a>). At a long‐term period, both groups had a similar number of participants requiring retreatments (RR 0.92, 95% CI 0.50 to 1.67; 1 study, 50 participants; <a href="./references#CD001732-fig-0057" title="">Analysis 5.12</a>). </p> </section> <section id="CD001732-sec-0110"> <h6 class="title">Frequency of recurrent varicose veins and venous flare formation</h6> <p>None of the RCTs reporting on this comparison reported on recurrent varicose veins and venous flare formation. </p> </section> <section id="CD001732-sec-0111"> <h6 class="title">Quality of life</h6> <p>One RCT reported QoL in this comparison (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). The authors reported an improvement in QoL without inter‐group differences but with intra‐group differences before and after six months of follow‐up. They used AVVQ (Aberdeen Varicose Vein Questionnaire) with the most favourable result being the lowest score. Our analysis did not show a clear improvement for either catheter‐directed or ultrasound‐guided sclerotherapy (MD ‐2.71, 95% CI ‐9.33 to 3.91; 1 study, 50 participants; <a href="./references#CD001732-fig-0058" title="">Analysis 5.13</a>). </p> </section> <section id="CD001732-sec-0112"> <h6 class="title">Frequency of persistence of symptoms</h6> <p>One RCT reported on this outcome. <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a> did not find clinical differences in VCSS in the long‐term period (MD 0.00, 95% CI ‐0.77 to 0.77; 1 study, 103 participants; <a href="./references#CD001732-fig-0059" title="">Analysis 5.14</a>). </p> </section> </section> </section> <section id="CD001732-sec-0113"> <h4 class="title">Sclerotherapy versus different conservative treatment</h4> <section id="CD001732-sec-0114"> <h5 class="title">Comparison 7: Sclerotherapy versus pharmacological therapy</h5> <p>No study compared sclerotherapy with any pharmacological therapy.</p> </section> <section id="CD001732-sec-0115"> <h5 class="title">Comparison 8: Sclerotherapy versus conservative compression treatment</h5> <p>One study compared sclerotherapy versus conservative management at six months to two years of follow‐up (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>). This study was conducted in pregnant women and reported a benefit with injection sclerotherapy compared to conservative management (compression) on the outcome of symptomatic improvement and cosmetic appearance (RR 7.96, 95% CI 3.38 to 18.76; 1 study, 101 participants) (<a href="./references#CD001732-fig-0060" title="">Analysis 6.1</a>). However, an increased number of ulcers were reported after sclerotherapy (RR 13.63, 95% CI 0.77 to 240.13; 1 study, 101 participants) (<a href="./references#CD001732-fig-0061" title="">Analysis 6.2</a>). It is also important to note that the outcomes, cosmetic appearance and symptomatic improvement, were described as pooled data and we were unable to discriminate data for each outcome. There were no other outcomes evaluated by the RCT. </p> </section> </section> <section id="CD001732-sec-0116"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis excluding studies which had data imputation. As the lost of follow‐up was balanced in all groups, this action did not change the effect direction. We preferred to present results using intention‐to‐treat analysis. </p> <p>Fourteen RCTs were judged as being at high risk of bias for at least one of the following domains: selection, performance, or detection (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a>; <a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). Two of these RCTs (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) were considered as having high risk of bias when placebo was the comparator, as it was impossible to blind placebo due to the nature of the intervention. <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a> declared that investigators opened the randomisation code after randomisation. <a href="./references#CD001732-bbs2-0014" title="MartimbeauPR . Perfluoropropane-filled albumin microspheres of sodium tetradecylsulphate versus air-filled sodium tetradecylsulphate for foam sclerotherapy of greater saphenous vein incompetence. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#145); 2003. San Diego, 2003. ">Martimbeau 2003b</a> did not describe the outcome assessment. All other studies were deemed as being at high risk of detection bias as it was not possible to blind participants and personnel. As planned, we conducted a sensitivity analysis </p> <p>any of these studies were included in a meta‐analysis. High risk of bias studies were combined in most meta‐analyses (e.g. foam versus placebo). One meta‐analysis evaluated residual varicose veins at a long‐term period comparing foam versus liquid sclerotherapy (<a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>). Only one RCT was not judged as being at high risk of bias (<a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>). A sensitivity analysis was performed and the effect direction was not changed (RR 0.63, 95% CI 0.48 to 0.82; 1 study, 300 participants; <a href="./references#CD001732-fig-0036" title="">Analysis 3.4</a>). To perform this analysis we evaluated only great saphenous veins (300 included, and 50% in each group) and considered recanalisation as residual varicose veins, since a duplex ultrasound image was presented in the paper showing the recanalised vein as an unresolved varicose vein, with sinals of thrombus in the lumen. So, with sensitivity analysis, foam appeared better than liquid to avoid residual varicose veins. Another analysis compared sclerotherapy versus sclerotherapy with different techniques and two studies in a subgroup analysis had different judgements for the risk of bias (<a href="./references#CD001732-fig-0051" title="">Analysis 5.6</a>). There was no change in the effect direction following sensitivity analysis, indicating residual varicose veins were not different with single versus fractionated doses of injection sclerotherapy. </p> <p>Six RCTs were funded by pharmaceutical companies (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). These RCTs were involved in six meta‐analyses (<a href="./references#CD001732-fig-0018" title="">Analysis 2.5</a>; <a href="./references#CD001732-fig-0019" title="">Analysis 2.6</a>; <a href="./references#CD001732-fig-0022" title="">Analysis 2.9</a>; <a href="./references#CD001732-fig-0024" title="">Analysis 2.11</a>; <a href="./references#CD001732-fig-0028" title="">Analysis 2.15</a>; <a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>). We performed a sensitivity analysis for all of these analyses and we did not find changes in the direction of the effect for any of the meta‐analyses. So, RCTs funded by industry did not appear to change the effect of the intervention. </p> <p>We expected to find the participant as the unit of analysis. However, in five RCTs, the unit of analysis was the vein (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0022" title="UkritmanoroatT . Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial. Journal of the Medical Association of Thailand2011;94(Suppl 2):S35-40. ">Ukritmanoroat 2011</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>) and, in four RCTs, the lower leg (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>). In these cases, whenever a meta‐analysis was performed, we did a sensitivity analysis. We did not find any change in effect direction in any of the analyses evaluated (<a href="./references#CD001732-fig-0018" title="">Analysis 2.5</a>; <a href="./references#CD001732-fig-0021" title="">Analysis 2.8</a>; <a href="./references#CD001732-fig-0022" title="">Analysis 2.9</a>; <a href="./references#CD001732-fig-0024" title="">Analysis 2.11</a>; <a href="./references#CD001732-fig-0025" title="">Analysis 2.12</a>; <a href="./references#CD001732-fig-0034" title="">Analysis 3.2</a>; <a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>; <a href="./references#CD001732-fig-0051" title="">Analysis 5.6</a>). </p> </section> <section id="CD001732-sec-0117"> <h4 class="title">Subgroup analysis</h4> <p>Planned subgroup analysis was not possible for CEAP clinical classes since we did not have data to discriminate participants from each clinical class. No RCT cited the depth of the vein or discriminated between symptomatic versus asymptomatic participants. </p> <p>RCTs comparing foam versus foam sclerotherapy evaluated only truncal incompetence, precluding subgroup analysis. </p> <p>Previous complications (e.g. thrombophlebitis) were exclusion criteria of the included studies, making subgroup analysis impossible. </p> <p>We used many comparators in the foam versus foam sclerotherapy dealing with subgroups. So, the 'Foam versus foam sclerotherapy' comparison was presented as subgroup analysis. <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> demonstrated that the best foam concentration to reduce residual varicose veins was at least polidocanol 1%. But polidocanol 3% foam was more effective at reducing residual varicose veins than 1% foam (RR 0.67, 95% CI 0.43 to 1.04; 3 studies, 371 participants; moderate‐certainty evidence) (<a href="./references#CD001732-fig-0028" title="">Analysis 2.15</a>). Polidocanol 1% foam versus 3% did not change cosmetic appearance, complications, QoL or symptoms (low‐ to moderate‐certainty evidence). </p> <p>Four RCTs investigated different gases (called physiologic gases including O<sub>2</sub> and CO<sub>2</sub> in Varithena and Varisolve) in the foam preparation (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). The study authors compared Varisolve with any market sclerosant liquid or foam (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>), precluding subgroup analysis. <a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a> compared foam sclerotherapy with placebo. The other proposed subgroup analysis involved the other three studies in the same meta‐analysis. </p> <p>We also performed subgroup analyses of the different sclerosant concentrations to simplify the data interpretation (<a href="./references#CD001732-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD001732-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD001732-fig-0006" title="">Analysis 1.4</a>; <a href="./references#CD001732-fig-0007" title="">Analysis 1.5</a>; <a href="./references#CD001732-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD001732-fig-0008" title="">Analysis 1.6</a>; <a href="./references#CD001732-fig-0009" title="">Analysis 1.7</a>; <a href="./references#CD001732-fig-0010" title="">Analysis 1.8</a>; <a href="./references#CD001732-fig-0011" title="">Analysis 1.9</a>; <a href="./references#CD001732-fig-0013" title="">Analysis 1.11</a>; <a href="./references#CD001732-fig-0016" title="">Analysis 2.3</a>; <a href="./references#CD001732-fig-0017" title="">Analysis 2.4</a>; <a href="./references#CD001732-fig-0020" title="">Analysis 2.7</a>; <a href="./references#CD001732-fig-0022" title="">Analysis 2.9</a>; <a href="./references#CD001732-fig-0023" title="">Analysis 2.10</a>; <a href="./references#CD001732-fig-0025" title="">Analysis 2.12</a>; <a href="./references#CD001732-fig-0026" title="">Analysis 2.13</a>; <a href="./references#CD001732-fig-0027" title="">Analysis 2.14</a>; <a href="./references#CD001732-fig-0030" title="">Analysis 2.17</a>; <a href="./references#CD001732-fig-0031" title="">Analysis 2.18</a>; <a href="./references#CD001732-fig-0034" title="">Analysis 3.2</a>; <a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>; <a href="./references#CD001732-fig-0051" title="">Analysis 5.6</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001732-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001732-sec-0118"></div> <section id="CD001732-sec-0119"> <h3 class="title" id="CD001732-sec-0119">Summary of main results</h3> <p>We included 28 RCTs involving 4278 participants. The studies varied in the interventions and comparisons used. </p> <section id="CD001732-sec-0120"> <h4 class="title">Sclerotherapy versus no intervention or placebo</h4> <section id="CD001732-sec-0121"> <h5 class="title">Comparison 1: Sclerotherapy versus no intervention</h5> <p>The review did not find any RCT comparing sclerotherapy with no intervention. This lack of information highlights the continuance of the disappointing gap of knowledge for this comparison, mainly for CEAP C2 varicose veins. </p> </section> <section id="CD001732-sec-0122"> <h5 class="title">Comparison 2: Sclerotherapy versus placebo</h5> <p><a href="./full#CD001732-tbl-0001">summary of findings Table 1</a> </p> <p>Foam sclerotherapy may improve cosmetic appearance compared to placebo (polidocanol 1%: independent photography review ‐ visible varicose veins scores (IPR‐V) mean difference (MD) ‐0.76, 95% CI ‐0.91 to ‐0.60; 2 studies, 223 participants; very low‐certainty evidence (<a href="./references#CD001732-fig-0003" title="">Analysis 1.1</a>)). </p> <p>Mild to moderate rates of complications were higher in the sclerotherapy group, including deep vein thrombosis (DVT) rates (polidocanol 1% foam: RR 5.10, CI 1.30 to 20.01; 3 studies, 302 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0005" title="">Analysis 1.3</a>); and thrombophlebitis (polidocanol 1% foam: RR 3.12, 95% CI 1.10 to 8.83; 3 studies, 302 participants) (<a href="./references#CD001732-fig-0007" title="">Analysis 1.5</a>). DVT occurrence is rare in sclerotherapy and can also occur in other modalities of treatment (<a href="./references#CD001732-bbs2-0060" title="JacobsCE , PinzonMM , OrozcoJ , HuntPJ , HiveraA , McCarthyWJ . Deep venous thrombosis after saphenous endovenous radiofrequency ablation: is it predictable?Annals of Vascular Surgery2014;28(3):679-85. [DOI: 10.1016/j.avsg.2013.08.012]">Jacobs 2014</a>; <a href="./references#CD001732-bbs2-0068" title="ParavastuSC , HorneM , DoddPD . Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD010878. [DOI: 10.1002/14651858.CD010878.pub2]">Paravastu 2016</a>). In this case, the occurrence of DVT is derived from usually small asymptomatic thrombus, and did not cause an increased rate in pulmonary embolism (PE) in most participants (no symptomatic PE events in any of the three studies were included in meta‐analysis) (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Most thrombi originated in the saphenous veins and extended to the femoral vein and there were no participants with signs or symptoms of DVT (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>). </p> <p>Sclerotherapy did not increase the rates of haemorrhagic (polidocanol 1%: RR 1.83, 95 CI 0.75 to 4.47; 3 studies, 302 participants) (<a href="./references#CD001732-fig-0008" title="">Analysis 1.6</a>) or neurologic complications (polidocanol 1%: RR 1.03, 95 CI 0.22 to 4.91; 3 studies, 302 participants) (<a href="./references#CD001732-fig-0009" title="">Analysis 1.7</a>). </p> <p>Sclerotherapy may reduce the rate of residual varicose veins (polidocanol 1% foam: RR 0.19, 95% CI 0.13 to 0.29; 2 studies, 225 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0010" title="">Analysis 1.8</a>); may improve quality of life (polidocanol 1%: MD 12.41, 95% CI 9.56 to 15.26; 2 studies, 222 participants; low‐certainty evidence) (<a href="./references#CD001732-fig-0011" title="">Analysis 1.9</a>); and may reduce varicose vein symptoms (MD ‐3.25, 95% CI ‐3.90 to ‐2.60; 2 studies, 223 participants; low‐certainty evidence) (<a href="./references#CD001732-fig-0013" title="">Analysis 1.11</a>). </p> </section> </section> <section id="CD001732-sec-0123"> <h4 class="title">Sclerotherapy versus sclerotherapy</h4> <p>Twenty‐two RCTs investigated sclerotherapy versus sclerotherapy, with four comparisons involved: </p> <p> <ul id="CD001732-list-0030"> <li> <p>Foam versus foam sclerotherapy with different concentrations</p> </li> <li> <p>Foam versus liquid sclerotherapy</p> </li> <li> <p>Sclerotherapy versus sclerotherapy with different substances</p> </li> <li> <p>Sclerotherapy versus sclerotherapy with different techniques</p> </li> </ul> </p> <section id="CD001732-sec-0124"> <h5 class="title">Comparison 3: Foam sclerotherapy versus foam sclerotherapy with different concentrations</h5> <p>Five RCTs reported on this comparison. See <a href="./full#CD001732-tbl-0002">summary of findings Table 2</a>. </p> <p>Increasing concentrations of polidocanol foam to 3% showed no clear differences in cosmetic appearance compared to polidocanol 1% foam in a single study at one month (RR 1.31, 95% CI 0.81 to 2.12; 1 study, 80 participants; <a href="./references#CD001732-fig-0014" title="">Analysis 2.1</a>); or one year (RR 1.11, 95% CI 0.84 to 1.47; 1 study, 80 participants; very low‐certainty evidence; <a href="./references#CD001732-fig-0015" title="">Analysis 2.2</a>). Lower concentrations of polidocanol foam sclerotherapy (0.125%) had a similar effect to placebo. Higher concentrations of polidocanol possibly increased the improvement in cosmetic appearance as assessed by the adjusted mean for patient visible varicose vein instrument (PA‐V) (polidocanol 0.125% versus 1% (MD 0.45, 95% CI 0.03 to 0.87; 2 studies, 224 participants).Polidocanol 0.5% versus 1% showed no clear difference (MD 0.06, 95% CI ‐0.21 to 0.32; 2 studies, 221 participants; <a href="./references#CD001732-fig-0016" title="">Analysis 2.3</a>). A similar effect was seen with IPR‐V (independent expert panel rating scale) of photographs:polidocanol 0.125% versus 1% (MD 0.19, 95% CI ‐0.01 to 0.40; 2 studies, 221 participants); polidocanol 0.5% versus 1% (MD ‐0.04, 95% CI ‐0.20 to 0.12; 2 studies, 224 participants; <a href="./references#CD001732-fig-0017" title="">Analysis 2.4</a>). However, improvement in cosmetic appearance was still uncertain for concentrations higher than 1%. </p> <p>No clear differences in the rates of thromboembolic complications were detected between polidocanol 3% and 1% (RR 1.47, 95% CI 0.41 to 5.33; 3 studies, 371 participants; very low‐certainty evidence; <a href="./references#CD001732-fig-0018" title="">Analysis 2.5</a>). Whenever there was a thrombus detected, it was clinically well manageable, and there were no severe clinical endpoints described after the event (<a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). Pulmonary embolism was diagnosed despite no detection of DVT in one study (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>). It was impossible to predict if the embolus could have derived from the superficial or deep venous system. No deaths or cardiac complications were described in the pooled studies. However, the number of events was small, with a need for more studies to better answer this concern. There was still imprecision due to the low number of events and participants. Skin pigmentation also impacts on worsening cosmetic appearance. Skin pigmentation rates did not increase when using polidocanol foam 3% compared to 1% (<a href="./references#CD001732-fig-0022" title="">Analysis 2.9</a>). Aspects associated with the relationship between the vein and the skin still need to be studied (vein depth, for example). We are not sure if the depth of the vein correlates with more pigmentation rates. </p> <p>One RCT demonstrated that a concentration of at least 1% polidocanol foam is necessary to reach the best effect for occluding veins (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>). There was no other similar finding for any other sclerotherapy agent, and the ideal polidocanol foam concentration is still not established. If the concentration of polidocanol foam was increased, the residual varicose vein rates may decrease (RR 0.67, 95% CI 0.43 to 1.04; 3 studies, 371 participants; moderate‐certainty evidence) (<a href="./references#CD001732-fig-0028" title="">Analysis 2.15</a>). </p> <p>Two RCTs investigated the improvements in QoL (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>), and no clear improvement was detected when increasing polidocanol foam concentration up to 1% polidocanol foam (<a href="./references#CD001732-fig-0030" title="">Analysis 2.17</a>). </p> <p>Increasing the foam concentration for sclerotherapy improved symptoms measured using change in VCSS from baseline (polidocanol 0.125% versus 0.5%, MD ‐0.87, 95% CI ‐1.52 to ‐0.21; 2 studies, 225 participants; <a href="./references#CD001732-fig-0031" title="">Analysis 2.18</a>). When polidocanol 0.5% foam was compared to 1% foam, there was no improvement in symptoms. There is a reasonable chance to improve the effect with increasing foam concentration if symptoms could be attributed to varicose vein disease. Therefore, there is a need to define which symptoms we could attribute to the varicose veins and which symptoms cannot be attributed to varicose veins. </p> <p>Only one RCT investigated the recurrence of varicose vein rates (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). No differences were detected (RR 0.91, 95% CI 0.62 to 1.32; 1 study, 148 participants; low‐certainty evidence; <a href="./references#CD001732-fig-0032" title="">Analysis 2.19</a>). Despite the low number of participants, recurrent varicose veins could have other factors driving the formation of new varicose veins. The recanalisation rate is another important issue to be studied. As described by <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>, the recanalisation event in sclerotherapy evolves into a smaller vein diameter. Those recanalised veins were successfully treated with a new sclerotherapy session. It is not clear if the recanalisation and reflux into a smaller vein diameter is a disease capable of producing chronic venous insufficiency in the long run since fibrous tissues in venous walls could limit newer diameter increments. <a href="./references#CD001732-bbs2-0063" title="LabropoulosN , DellsKT , NicolaidesAN . Venous reflux in symptom-flee vascular surgeons. Journal of Vascular Surgery1995;22(2):150-4.">Labropoulos 1995</a> demonstrated that saphenous veins were developing reflux after a working day in normal medical subjects (<a href="./references#CD001732-bbs2-0063" title="LabropoulosN , DellsKT , NicolaidesAN . Venous reflux in symptom-flee vascular surgeons. Journal of Vascular Surgery1995;22(2):150-4.">Labropoulos 1995</a>). Maybe, in this case, reflux is not the best outcome to be evaluated. The possible confusion sources drove the authors to consider technical success as occluded, fibrotic, or reabsorbed veins. </p> </section> <section id="CD001732-sec-0125"> <h5 class="title">Comparison 4: Foam sclerotherapy versus liquid sclerotherapy</h5> <p>Nine RCTs reported on this comparison. See <a href="./full#CD001732-tbl-0003">summary of findings Table 3</a>. </p> <p>The use of liquid or foam sclerotherapy for better cosmetic appearance results still needs to be answered since there were conflicting data due to the heterogeneity of sclerosant concentrations (polidocanol liquid concentrations ranged from 0.75% to 1.25% versus polidocanol foam 1.5% to 2.5%). In one study in the long‐term period, there was no difference in patient satisfaction (MD 0.20, 95% CI ‐0.27 to 0.67; 1 study, 126 participants; very low‐certainty evidence) (<a href="./references#CD001732-fig-0033" title="">Analysis 3.1</a>). It is necessary to consider that a liquid volume is converted to a higher volume in foam presentation, possibly being more efficient to occupy vessel lumen and to sclerose varicose veins using a smaller overall volume of sclerosant agent (<a href="./references#CD001732-bbs2-0070" title="PollakJS , White JrRI . Chapter 32: Peripheral vascular malformations. In: Peripheral vascular interventions. Philadelphia: Lippincott Williams &amp; Wilkins, 2008.">Pollak 2008</a>). Gas also causes floating phenomena that boost foam to the top part of the target vessels. In a lying patient, this floating phenomenon could cause damage only in the top portion of the venous lumen. These factors could explain more spasm in foam than in liquid intervention (<a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>), but it could drive sclerotherapy results in any effect direction since it can produce recanalisation with no success of occluding the varicose veins. </p> <p>Complications were described again as mild to moderate in foam versus liquid sclerotherapy and there were no DVTs described in the participants treated. An active search for DVT was not reported by the included studies. There were no differences in skin pigmentation rates between both interventions (RR 1.75, 95% CI 0.81 to 3.80; 2 studies, 208 participants) (<a href="./references#CD001732-fig-0034" title="">Analysis 3.2</a>). </p> <p>There was a consistent reduction in residual varicose vein rates at a long‐term period in the foam intervention group. We did not think it was appropriate to pool overall as different concentrations and sclerosants were used, so data have been presented as subgroup analyses. We decided to report and assess results from polidocanol 3% foam versus 3% liquid as this is the most clinically relevant: RR 0.51, 95% CI 0.41 to 0.65; 2 studies, 203 participants; very low‐certainty evidence (<a href="./references#CD001732-fig-0035" title="">Analysis 3.3</a>), indicating foam is more effective than liquid sclerotherapy in resolving residual varicose veins. </p> <p>No RCT reported on quality of life or persistence of symptoms.</p> <p>One additional RCT reported similar recurrence rates between the foam and liquid groups (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>) (RR 1.10, 95% CI 0.86 to 1.42; 1 study, 286 participants; very low‐certainty evidence, <a href="./references#CD001732-fig-0037" title="">Analysis 3.5</a>). Differently from conventional foams, the foam produced in this RCT used a tensioactive substance to enhance ultrasound vision (ultrasound contrast agent). Otherwise, factors that drive recurrence are related to the formation of new varicose veins and maybe not be influenced by the sclerosant used. </p> </section> <section id="CD001732-sec-0126"> <h5 class="title">Comparison 5: Sclerotherapy versus sclerotherapy with different substances</h5> <p>Four RCTs compared sclerotherapy versus sclerotherapy with any other substance. See <a href="./full#CD001732-tbl-0004">summary of findings Table 4</a>. </p> <p>Cosmetic appearance was evaluated by two RCTs but it was not possible to draw conclusions as different polidocanol and STS concentrations were used (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>), and different vein diameters for different concentrations compared (<a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>), so we were not able to draw conclusions about the benefit of one product over the other (<a href="./references#CD001732-fig-0038" title="">Analysis 4.1</a>). No other sclerosant was investigated, so, the best sclerotherapy agent still needs to be determined. </p> <p><a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a> and <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> described rare neurologic events as mild and completely recovered with observation in all participants using foam with room air or with CO<sub>2</sub> and O<sub>2</sub> gas mixture (Varisolve) (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>); but there was insufficient information to indicate any ideal gas mixture for sclerotherapy. The same RCT lacked congruency since comparison was with any market sclerosant liquid or foam and did not discriminate between participants with CEAP C1 and C2 (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). However, the RCTs found no differences in the occurrence of DVT (RR 0.97, 95% CI 0.09 to 10.54; 1 study, 384 participants; <a href="./references#CD001732-fig-0039" title="">Analysis 4.2</a>), skin pigmentation (RR 1.01, 95% CI 0.80 to 1.27; 1 study, 384 participants; <a href="./references#CD001732-fig-0040" title="">Analysis 4.3</a>), or haematoma formation (RR 1.56, 95% CI 0.76 to 3.18; 1 study, 384 participants; <a href="./references#CD001732-fig-0041" title="">Analysis 4.4</a>). <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> found no differences in skin pigmentation rates (RR 1.21, 95% CI 0.95 to 1.55; 1 study, 167 participants) (<a href="./references#CD001732-fig-0042" title="">Analysis 4.5</a>) and skin necrosis numbers (RR 14.12, 95% CI 0.81 to 246.76; 1 study, 167 participants) (<a href="./references#CD001732-fig-0043" title="">Analysis 4.6</a>). The study also described thrombosis of the vein, probably related to thrombophlebitis or venous occlusion (superficial venous system) and did not describe DVT. </p> <p><a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a> also investigated the rates of residual varicose veins at 12 months and found higher rates in any market sclerosant (RR 0.64, 95% CI 0.42 to 0.97; 1 study, 373 participants; <a href="./references#CD001732-fig-0044" title="">Analysis 4.7</a>). The incongruence in the comparator made it difficult to interpret results. </p> <p>No RCT investigated quality of life or persistence of symptoms. It is a disappointing finding for the systematic review since varicose vein treatment aims to improve quality of life and to reduce complication rates. </p> <p>Matting also was investigated by <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> and there were no clinical differences in the number of matting rates between the STS 1.5% group compared to polidocanol 3% (RR 1.53, 95% CI 0.58 to 4.02; 1 study, 167 participants; <a href="./references#CD001732-fig-0045" title="">Analysis 4.8</a>). There is also a need for congruency in objectives and outcomes in this comparison since varicose vein disease is probably incurable, and treatment is not directed to the aetiology of the disease (<a href="./references#CD001732-bbs2-0042" title="LabasP , OhrádkaB , CambalM , RingelbandR . The results of compression sclerotherapy. Comparative study of two techniques and two sclerosants. Phlebologie2000;29:137-41. LabasP , OhradkaB , CambalM , ReisR , FilloJ . Long term results of compression sclerotherapy. Bratislavske Lekarske Listy2003;104(2):78-81. ">Labas 2003</a>). Many factors that can produce varicose veins will drive the recurrence rates. Mainly, sclerotherapy alone or in association with any other intervention is essential for varicose vein treatment. Sclerotherapy is a unique and effective treatment in any varicose vein and with any diameter (<a href="./references#CD001732-bbs2-0042" title="LabasP , OhrádkaB , CambalM , RingelbandR . The results of compression sclerotherapy. Comparative study of two techniques and two sclerosants. Phlebologie2000;29:137-41. LabasP , OhradkaB , CambalM , ReisR , FilloJ . Long term results of compression sclerotherapy. Bratislavske Lekarske Listy2003;104(2):78-81. ">Labas 2003</a>). Sometimes, matting can be confused with a flare formation. Matting is formed by tiny vessels that usually disappear by themselves from weeks to months. As <a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a> described the outcome at 16 weeks, we decided to include these results as residual varicose veins in this section (considering, possibly, a flare formation or a residual telangiectasia). </p> </section> <section id="CD001732-sec-0127"> <h5 class="title">Comparison 6: Sclerotherapy versus sclerotherapy with different techniques</h5> <p>Six RCTs evaluated different techniques for injection sclerotherapy (<a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>; <a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>; <a href="./references#CD001732-bbs2-0025" title="YamakiT , HamahataA , SoejimaK , KonoT , NozakiM , SakuraiH . Prospective randomised comparative study of visual foam sclerotherapy alone or in combination with ultrasound-guided foam sclerotherapy for treatment of superficial venous insufficiency: preliminary report. European Journal of Vascular and Endovascular Surgery2012;43(3):343-7. ">Yamaki 2012</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> <p>Surprisingly, no RCT investigated cosmetic appearance using different techniques.</p> <p>There were no thromboembolic complications detected in the antegrade versus retrograde sclerotherapy comparison (<a href="./references#CD001732-fig-0046" title="">Analysis 5.1</a>) (<a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). Phlebitis and thrombophlebitis, and skin pigmentation rates were also not different (<a href="./references#CD001732-fig-0046" title="">Analysis 5.1</a>; <a href="./references#CD001732-fig-0047" title="">Analysis 5.2</a>). It is important to report that, in a study comparing few versus multiple injections for sclerotherapy, less foam was detected in the deep veins when using multiple injections (<a href="./references#CD001732-bbs2-0024" title="YamakiT , NozakiM , SakuraiH , TakeuchiM , SoejimaK , KonoT . Multiple small-dose injections can reduce the passage of sclerosant foam into deep veins during foam sclerotherapy for varicose veins. European Journal of Vascular and Endovascular Surgery2009;37(3):343-8. ">Yamaki 2009</a>) (<a href="./references#CD001732-fig-0049" title="">Analysis 5.4</a>). If an embolus originated from the superficial venous system, there is a better prognosis due to the smaller diameter of the veins (<a href="./references#CD001732-bbs2-0081" title="WuAR , GarryJ , LabropoulosN . Incidence of pulmonary embolism in patients with isolated calf deep vein thrombosis. Journal of Vascular Surgery2017;5(2):274-9.">Wu 2017</a>). On the other hand, the deep venous system has the potential to produce a bigger embolus increasing the risk of death to patients. Thromboembolic events were related to a proximal extension of a superficial thrombus usually derived from saphenous veins, or the extension of a perforator vein. DVT can also occur without an extension thrombus from the superficial venous system. So it is essential to investigate if foam in higher concentrations in the deep vein could cause any hazard to patients. </p> <p>Injection by a catheter associated with tumescent technique reduced residual varicose veins in the short‐term period compared to needle injection (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). However, other different sclerotherapy techniques did not show any benefit in reducing residual varicose vein rates, clinical severity scores, and complications (<a href="./references#CD001732-fig-0050" title="">Analysis 5.5</a>; <a href="./references#CD001732-fig-0051" title="">Analysis 5.6</a>; <a href="./references#CD001732-fig-0052" title="">Analysis 5.7</a>; <a href="./references#CD001732-fig-0053" title="">Analysis 5.8</a>; <a href="./references#CD001732-fig-0054" title="">Analysis 5.9</a>; <a href="./references#CD001732-fig-0055" title="">Analysis 5.10</a>; <a href="./references#CD001732-fig-0059" title="">Analysis 5.14</a>). After six months, participants from both groups (catheter‐delivered associated with tumescent technique versus needle‐delivered sclerotherapy) needed retreatment (<a href="./references#CD001732-bbs2-0019" title="NCT02753270. Catheter-directed foam sclerotherapy with tumescence. clinicaltrials.gov/ct2/show/NCT02753270 (first received 27 April 2016). SantosJB , JuniorWC , PortaRMP , PugginaJ , SilvaDFT , Puch-LeãoP , et al. Catheter-directed foam sclerotherapy with tumescence of the great saphenous vein versus ultrasound-guided foam sclerotherapy: a randomized controlled trial. Phlebology2019;35(2):84-91. [DOI: 10.1177/0268355519850651]">Santos 2019</a>). The studies need to be more congruent and with a larger number of participants to increase certainty. Despite incongruence, it does not appear that different techniques produce different outcomes. Concerns about outcomes remain related to proximal versus distal technique for sclerotherapy (if treating proximal saphenous vein versus distal saphenous vein). </p> </section> </section> <section id="CD001732-sec-0128"> <h4 class="title">Sclerotherapy versus different conservative treatment</h4> <section id="CD001732-sec-0129"> <h5 class="title">Comparison 7: Sclerotherapy versus pharmacological therapy</h5> <p>No RCT evaluated sclerotherapy with pharmacological therapy. It is important to note that this comparison involves expensive medication for some people. So, a study including a cost‐effectiveness analysis should be carried out to ensure there are more benefit than harms to patients since varicose veins impact quality of life more than they risk life. </p> </section> <section id="CD001732-sec-0130"> <h5 class="title">Comparison 8: Sclerotherapy versus conservative compression treatment</h5> <p>Only one RCT reported on this comparison (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>). The RCT was conducted in 1973 in South Africa and enrolled only pregnant women. It is of some importance since pregnant women are a subgroup of vulnerable patients at risk of complications (phlebitis, deep vein thrombosis, bleeding) (<a href="./references#CD001732-bbs2-0078" title="SmythRM , AflaifelN , BamigboyeAA . Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD001066. [DOI: 10.1002/14651858.CD001066.pub3]">Smyth 2015</a>). In the RCT, there was an improvement of pooled data from symptomatic and cosmetic improvement outcomes (RR 7.96, 95% CI 3.38 to 18.76; 1 study, 101 participants; <a href="./references#CD001732-fig-0060" title="">Analysis 6.1</a>), at the same time, producing more leg ulcer rates in the sclerotherapy group (RR 13.63, 95% CI 0.77 to 240.13; 1 study, 101 participants; <a href="./references#CD001732-fig-0061" title="">Analysis 6.2</a>). Despite the need to treat pregnant women, there are concerns related to the risks of DVT and PE produced by the procedure. As described by <a href="./references#CD001732-bbs2-0078" title="SmythRM , AflaifelN , BamigboyeAA . Interventions for varicose veins and leg oedema in pregnancy. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD001066. [DOI: 10.1002/14651858.CD001066.pub3]">Smyth 2015</a>, there is still a paucity of data in the literature. Ethical concerns will drive future research. </p> </section> </section> </section> <section id="CD001732-sec-0131"> <h3 class="title" id="CD001732-sec-0131">Overall completeness and applicability of evidence</h3> <p>Overall, 4278 participants were included in the RCTs, increasing the confidence that the procedure is a safe and an effective treatment. The aim of the review was to include CEAP C2, C3, and C4 criteria varicose veins. Due to differences in the vein diameter, the effects presented in this review are likely not relevant to people with CEAP C1, but possibly some results could also be applied to people with CEAP C5 and C6 (e.g. occlusion rates). Even in the cases of residual varicose veins, new sessions of sclerotherapy are feasible and acceptable procedures while other more invasive methods are related to patients' costs and risks. </p> <p>RCTs described cosmetic appearance and complications (including staining, DVT and PE). However, there is a lack of consistency between interventions, time points, and outcomes evaluated. There was variability and heterogeneity in participants, drugs, drug concentrations, varicose veins classification, and interventions (e.g. usage or non‐usage of stockings after sclerotherapy). The present systematic review did not investigate the role of co‐interventions. </p> <p>Overall, varicose veins are heterogeneous and, even when not described, there are likely to be smaller varicose veins (including CEAP C1) associated with the clinical classes described. Sclerosant agents may reach these veins, as noted in clinical practice. So it is important to have similar proportions of participants with C1, C5, and C6 between intervention and control groups. We described these proportions of CEAP C1, C5, and C6 in the footnotes of the meta‐analyses to assist with a critical analysis. It was not possible to estimate if the depth of the vein could result in different ratings of skin pigmentation due to the lack of information provided. </p> <p>Quality of life and symptoms were poorly reported. Some studies used VCSS to report symptoms; however, for VCSS, there is one attribute for symptoms and eight attributes for signs. So, there is a lack of data to increase confidence in the estimate of the effect. For symptoms, there is a need for establishing a cause‐effect relationship. </p> <p>It should be taken into account that it is not the aim of this review to evaluate injection sclerotherapy versus varicose vein surgery methods. This subject is the scope of another Cochrane Review. Applicability of the evidence is limited to injection sclerotherapy and their comparators with other types of sclerotherapy including other techniques of performing injection sclerotherapy. </p> <p>There was no evidence found for three interventions due to a lack of RCTs investigating these. </p> <p> <ul id="CD001732-list-0031"> <li> <p>Sclerotherapy versus no interventions for varicose veins</p> </li> <li> <p>Sclerotherapy versus sclerotherapy at different time intervals</p> </li> <li> <p>Sclerotherapy versus pharmacological therapy</p> </li> </ul> </p> </section> <section id="CD001732-sec-0132"> <h3 class="title" id="CD001732-sec-0132">Quality of the evidence</h3> <p>Overall, certainty of the evidence was very low to moderate. This is due to the heterogeneity of the interventions and population (including participants with CEAP class C1, C5, and C6 in the studies), variation in concentration of medicines, different time point measures, lack of core outcome set definitions (for instance: recurrent varicose veins and residual varicose veins), some outcomes evaluated by single RCTs, low number of events (e.g. DVT), wide confidence intervals including the line of no effect, most risk of bias domains judged as unclear, and different units of analysis studied. We decided to use the GRADE approach to assess our certainty of the evidence for the outcomes cosmetic appearance, complications (thromboembolic complications), residual varicose veins, quality of life, persistence of symptoms, and recurrent varicose veins. We created a summary of findings table for each of the four main comparisons. </p> <p> <ul id="CD001732-list-0032"> <li> <p>Foam sclerotherapy (1% polidocanol) versus placebo for treating varicose veins (<a href="./full#CD001732-tbl-0001">summary of findings Table 1</a>) </p> </li> <li> <p>Foam sclerotherapy (3% polidocanol) versus foam sclerotherapy (polidocanol 1%) for treating varicose veins (<a href="./full#CD001732-tbl-0002">summary of findings Table 2</a>) </p> </li> <li> <p>Foam sclerotherapy versus liquid sclerotherapy for treating varicose veins (<a href="./full#CD001732-tbl-0003">summary of findings Table 3</a>) </p> </li> <li> <p>Sclerotherapy with STS 1% versus sclerotherapy with polidocanol 1% (<a href="./full#CD001732-tbl-0004">summary of findings Table 4</a>) </p> </li> </ul> </p> <section id="CD001732-sec-0133"> <h4 class="title">Foam sclerotherapy (polidocanol 1%) versus placebo</h4> <p>See <a href="./full#CD001732-tbl-0001">summary of findings Table 1</a>. </p> <p>Five RCTs compared polidocanol foam sclerotherapy versus placebo but only three provided results from polidocanol 1% foam versus placebo to grade the certainty of the evidence (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>; <a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). There was a considerable variation of polidocanol concentration used, ranging from 0.125% (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) to 2% (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>). For grading certainty of the evidence, polidocanol 1% foam was chosen as the interventional group since there is a trend to increase occluded veins rates with up to 1% polidocanol foam (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>), and 1% concentration is clinically relevant. </p> <p>We understand that is impossible to blind personnel and participants for this comparison due to the nature of the intervention but we downgraded two levels for risk of bias concerns. </p> <p>For cosmetic appearance, the evidence was downgraded to very low‐certainty for risk of bias concerns and indirectness (one RCT (<a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>) included 8.8% participants with CEAP C5 and C6 in the placebo group and 3.4% participants with CEAP C5 and C6 in the 1% polidocanol foam group ‐ we planned to include CEAP C2, C3 or C4 participants. As the study authors included participants with other CEAP classes and we were unable to obtain information to exclude these data, we determined the population in the study as an indirect population). </p> <p>The evidence for thromboembolic complications was downgraded to very low‐certainty for risk of bias concerns and due to the indirectness, imprecision (low number of events, wide confidence intervals), and both clinical heterogeneity among studies (severity of the disease) and statistical heterogeneity (I<sup>2</sup> = 53%). </p> <p>The outcome, residual varicose veins, was downgraded to very low‐certainty evidence due to the same limitations observed in the cosmetic appearance outcome. </p> <p>Quality of life and the persistence of symptoms were both downgraded to very low‐certainty evidence due to indirectness (8.8% of participants in the placebo group had CEAP C5 or C6), imprecision (low number of participants, and wide confidence intervals). </p> <p>No RCT investigated recurrent varicose veins.</p> </section> <section id="CD001732-sec-0134"> <h4 class="title">Foam sclerotherapy (polidocanol 3%) versus foam sclerotherapy (polidocanol 1%)</h4> <p>See <a href="./full#CD001732-tbl-0002">summary of findings Table 2</a>. </p> <p>Polidocanol foam 3% versus 1% concentrations were chosen to evaluate the certainty of the evidence due to clinical relevance. </p> <p>Only <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> evaluated cosmetic appearance. As most of the risk of bias domains were unclear, inclusion of only a single study with a wide confidence interval (imprecision), and a low number of participants (imprecision); the evidence was downgraded to very low‐certainty. </p> <p>Thromboembolic complications were measured by three RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) and the evidence was judged as very low‐certainty due to indirectness (there were participants with CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) but the lower legs were equal in each group), imprecision (low number of events) and wide confidence intervals. <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> used the lower leg as the unit of analysis and there was a heterogeneous population (11.64% with CEAP C1), so a sensitivity analysis was carried out (<a href="./references#CD001732-fig-0019" title="">Analysis 2.6</a>). The effect direction was not changed. </p> <p>Residual varicose veins were evaluated by three RCTs (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), with indirectness (there were participants with CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) but these were equal in each group). Therefore, the evidence was rated as moderate‐certainty evidence. </p> <p>No RCT described the quality of life or the persistence of symptoms for this comparison.</p> <p>Recurrent varicose veins were investigated by one RCT (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>). We detected imprecision (single study), and indirectness (participants with CEAP C5 and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) without describing the proportion of these participants in the study arms). We downgraded by two levels and the evidence was judged as low‐certainty evidence. </p> </section> <section id="CD001732-sec-0135"> <h4 class="title">Foam sclerotherapy versus liquid sclerotherapy</h4> <p>See <a href="./full#CD001732-tbl-0003">summary of findings Table 3</a>. </p> <p>Ten RCTs reported on the comparison foam versus liquid sclerotherapy. There were outcomes that may not have correlated with clinical implications (immediate spasm after sclerotherapy) (<a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>) and substantial differences in sclerosant concentrations (ranging from 1.5% to 2.5% in liquid versus 0.75% to 1.25% in the foam group (<a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a>)), lacking congruency. </p> <p>For cosmetic appearance, the certainty of the evidence was downgraded to very low due to lack of description of the randomisation method, risk of bias concerns (the RCT probably not blinded due to the nature of the intervention), indirect population, single study, and comparing different concentrations of the same substances in different vein diameters in both arms of the study. </p> <p>No RCT investigated DVT, quality of life, or persistence of symptoms.</p> <p>There was a lack of data for the complications outcome, despite some RCTs describing complications such as thrombophlebitis and skin pigmentation as mild. No DVT events were described and we are not sure if the outcome was systematically investigated in the RCTs. </p> <p>Six RCTs reported on residual varicose veins and two of them compared polidocanol 3% liquid versus foam (<a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>; <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>). We assessed this outcome as having very low‐certainty evidence. The quality was downgraded since there was doubt about the randomisation method, the intervention was presumably not blinded due to the nature of the intervention, and one study (<a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>) included participants from CEAP C2 to C6 without discriminating between then. The other study (<a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a>) included one participant with CEAP C5 in the foam group (1.85%) and four participants with CEAP C5 in the liquid group intervention (7.69%). </p> <p>Recurrent varicose veins and flare formation was investigated by one RCT (<a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a>). There was some doubt about the randomisation method used. The intervention was presumably not blinded due to the nature of the intervention. There was a single RCT, and the author did not describe CEAP participants. <a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a> also used a tensioactive substance to enhance ultrasound vision (ultrasound contrast agent) to produce foam, which is not the usual way to produce foam. We judged the evidence as very low‐certainty. </p> </section> <section id="CD001732-sec-0136"> <h4 class="title">Sclerotherapy with STS 1% versus sclerotherapy with polidocanol 1%</h4> <p>Data were insufficient to allow assessment using the GRADE criteria. See <a href="./full#CD001732-tbl-0004">summary of findings Table 4</a>. </p> </section> </section> <section id="CD001732-sec-0137"> <h3 class="title" id="CD001732-sec-0137">Potential biases in the review process</h3> <p>We were unable to carry out a funnel plot analysis to investigate publication bias since there were fewer than 10 RCTs for each meta‐analysis. Due to unavailable data, it was impossible to perform a subgroup analysis between CEAP C2, C3, and C4 groups and symptomatic versus nonsymptomatic participants. Indeed, no RCTs evaluated the depth of the vein as a possible issue influencing pigmentation. Also, previous complications were exclusion criteria for the studies, limiting subgroup analysis. </p> <p>Authors were contacted to reduce bias in the review process. Most of them did not reply. Some RCTs were old, and others had no contact authors available (<a href="./references#CD001732-bbs2-0001" title="AbramowitzI . The treatment of varicose veins in pregnancy by empty vein compressive sclerotherapy. South African Medical Journal1973;47(14):607-10. ">Abramowitz 1973</a>; <a href="./references#CD001732-bbs2-0006" title="ChleirF , Cornu-ThenardA , SadounS , SchadeckM , Van CleefJF . Echosclerosis of the internal saphenous vein: single dose versus fractionated dose preliminary results of the Afcarp study [Echosclerose del la saphene l'interne: dose unique versus dose fractionne. Resultats preliminaries de l'etude Afcarp]. Phlébologie1997;50(2):275-80. ">Chleir 1997</a>; <a href="./references#CD001732-bbs2-0007" title="DemagnyA . Comparative study into the efficacy of a sclerosant product in the form of liquid or foam in echo-guided sclerosis of the arches of the long and short saphenous veins. Phlébologie2002;55:133-7. ">Demagny 2002</a>; <a href="./references#CD001732-bbs2-0017" title="RaggJC . Foam sclerotherapy of saphenous veins comparing the effect of injection via needles and catheters of different size. In: Scientific Programme and Book of Abstracts; 16th Meeting of the European Venous Forum; 2015 Jul 2-4; St Petersburg, Russia. 2015:57. ">Ragg 2015</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0026" title="ZehRG . Expanding sclerosing properties of polidocanol foam with Gelofusine. In: UIP World Congress Chapter Meeting (www.phlebology.org/AbstractUIP.htm#79); 2003. San Diego, 2003. ">Zeh 2003</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>; <a href="./references#CD001732-bbs2-0028" title="ZhangWG , YanRH , ZongHM , WangQC , ChenDQ , XuYP . Foam sclerotherapy of lauromacrogol for the treatment of lower extremity varicose veins: comparison study of two different injection ways. Journal of Interventional Radiology2014;23(5):392-6. ">Zhang 2014</a>). </p> <p>Two RCTs had heterogeneous populations including some participants with CEAP C1 (<a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a>). It was expected that there would be fewer thromboembolic and pigmentation rates in some of these subgroups. Differences from protocols were noted where participants with CEAP C1 should not be included. <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> included 12.8% of participants with CEAP C1, and <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a> did not discriminate between the proportions of the C1 class. Given this consideration, we included <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> in the meta‐analysis but <a href="./references#CD001732-bbs2-0027" title="ZhangJ , SchliephakeD , MaloufM , OttoJ , JingZ , GuY . Polidocanol/lauromacrogol 400 vs. placebo for sclerotherapy of C1 and C2 non-saphenous trunk varicose veins: a double-blind, randomized, controlled, multicenter clinical trial (Esachina study) performed in the P.R. of China. In: XVI World Congress of the Union Internationale de Phlebologie Abstract Book. 2009:54. ">Zhang 2009</a> was not included since the author did not describe the proportion of CEAP C1 included in each group. A sensitivity analysis was conducted to check the robustness of the results. Similarly, other RCTs considered CEAP C5 and C6 inclusions. All of them were described, with the proportions of the non‐proposed clinical classes included in each analysis and taken into consideration when interpreting the results. </p> <p>Three studies were assessed as 'awaiting classification'; there was a lack of data and we were unable to contact the authors for two of the studies (<a href="./references#CD001732-bbs2-0042" title="LabasP , OhrádkaB , CambalM , RingelbandR . The results of compression sclerotherapy. Comparative study of two techniques and two sclerosants. Phlebologie2000;29:137-41. LabasP , OhradkaB , CambalM , ReisR , FilloJ . Long term results of compression sclerotherapy. Bratislavske Lekarske Listy2003;104(2):78-81. ">Labas 2003</a>; <a href="./references#CD001732-bbs2-0043" title="SatokawaH , HoshinoS , SakaguchiS , YamadaC . The Japanese polidocanol (aethoxysclerol) clinical trial. Abstracts from the UIP World Congress Chapter Meeting2003. ">Satokawa 2003</a>; <a href="./references#CD001732-bbs2-0044" title="SchadeckM , AllaertFA . Post sclerosis recurrences of the great saphenous vein. In: NegusD , JantetG , Coleridge-SmithPD , editors(s). Phlebology '95. Vol. 1. Springer, 1995:614. ">Schadeck 1995b</a>); and we were unable to determine if one study was a randomised or quasi‐randomised controlled trial (<a href="./references#CD001732-bbs2-0046" title="VarnagyR , MalaveG , TabordaJ , GabayN . Clinical trial of a new experimental sclerosant product. Current Therapeutic Research, Clinical and Experimental1985;38:960-5. ">Varnagy 1985</a>). </p> <p>Co‐interventions were used during and after injection sclerotherapy (e.g. walking after injection sclerotherapy) (<a href="./references#CD001732-bbs2-0012" title="KingJT , O'ByrneM , VasquezM , WrightD , VANISH-1 investigator group. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. European Journal of Vascular and Endovascular Surgery2015;50(6):784-93. [DOI: 10.1016/j.ejvs.2015.06.111]NCT01072877. Efficacy and safety study of VarisolveT polidocanol endovenous microfoam (PEM) for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-1). clinicaltrials.gov/ct2/show/NCT01072877 (first received 22 February 2010). ">King 2015</a>; <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a>). These co‐interventions may have influenced the outcomes and there could be other confounders to consider. One crucial co‐intervention is the use or not of medical stockings after injection sclerotherapy. We suggest that this issue could be better evaluated in a further systematic review to evaluate sclerotherapy versus compression sclerotherapy for varicose veins. <a href="./references#CD001732-bbs2-0032" title="ISRCTN03080206. Endovenous laser therapy (EVLT) versus ultrasound guided foam sclerotherapy (UGFS) for the treatment of varicose veins. isrctn.com/ISRCTN03080206 (first received 21 January 2010). KalodikiE , AzzamM , SchnatterbeckP , GeroulakosG , LattimerCR . The Discord Outcome Analysis (DOA) as a reporting standard at three months and five years in randomised varicose vein treatment trials. European Journal of Vascular and Endovascular Surgery2018;57(2):267-74. [DOI: 10.1016/j.ejvs.2018.09.013]LattimerCR , AzzamM , KalodikiE , ShawishE , TruemanP , GeroulakosG . Cost and effectiveness of laser with phlebectomies compared with foam sclerotherapy in superficial venous insufficiency. Early results of a randomised controlled trial. European Journal of Vascular and Endovascular Surgery2012;43:594-600. LattimerCR , KalodikiE , AzzamM , GeroulakosG . Responsiveness of individual questions from the venous clinical severity score and the Aberdeen varicose vein questionnaire. Phlebology2014;29:43-51. LattimerCR , KalodikiE , AzzamM , MakrisGC , SomiayajuluS , GeroulakosG . Interim results on abolishing reflux alongside a randomized clinical trial on laser ablation with phlebectomies versus foam sclerotherapy. International Angiology2013;32(4):394-403. ">Lattimer 2012</a> described a lack of criteria between side effects and treatment effects, making it difficult to quantify in a meaningful way an effect size in a multi‐ethnic and multicultural population. <a href="./references#CD001732-bbs2-0032" title="ISRCTN03080206. Endovenous laser therapy (EVLT) versus ultrasound guided foam sclerotherapy (UGFS) for the treatment of varicose veins. isrctn.com/ISRCTN03080206 (first received 21 January 2010). KalodikiE , AzzamM , SchnatterbeckP , GeroulakosG , LattimerCR . The Discord Outcome Analysis (DOA) as a reporting standard at three months and five years in randomised varicose vein treatment trials. European Journal of Vascular and Endovascular Surgery2018;57(2):267-74. [DOI: 10.1016/j.ejvs.2018.09.013]LattimerCR , AzzamM , KalodikiE , ShawishE , TruemanP , GeroulakosG . Cost and effectiveness of laser with phlebectomies compared with foam sclerotherapy in superficial venous insufficiency. Early results of a randomised controlled trial. European Journal of Vascular and Endovascular Surgery2012;43:594-600. LattimerCR , KalodikiE , AzzamM , GeroulakosG . Responsiveness of individual questions from the venous clinical severity score and the Aberdeen varicose vein questionnaire. Phlebology2014;29:43-51. LattimerCR , KalodikiE , AzzamM , MakrisGC , SomiayajuluS , GeroulakosG . Interim results on abolishing reflux alongside a randomized clinical trial on laser ablation with phlebectomies versus foam sclerotherapy. International Angiology2013;32(4):394-403. ">Lattimer 2012</a> also concluded that pigmentation, inflammation, pain, and other side effects could be effects from the stockings rather than from sclerotherapy. These arguments contributed to deciding not to include compression stockings in this review. Despite that, the co‐intervention was common in the included studies, and the real effect of compression was not evaluated. </p> <p>Despite a proposed subgroup analysis to evaluate the different gases for foam sclerotherapy, there was no study comparing them. So, the issue of different gases to reduce incidence of neurological complications is still to be resolved (<a href="./references#CD001732-bbs2-0008" title="GibsonK , KabnickL , MorrisonN , MunavalliG , ReganJD . A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of varithena (Polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence. Phlebology2017;32(3):185-93. GibsonK , WrightD , RushJ , SuplickG , EvansE . Validating VeinesQOL/SYM: measuring changes following endovenous microfoam ablation of the great saphenous vein. Phlebology2010;25:308-9. NCT00758420. Randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol endovenous microfoam for treatment of symptomatic, visible varicose veins with SFJ incompetence (pilot). clinicaltrials.gov/ct2/show/NCT00758420 (first received 25 September 2008). ">Gibson 2010</a>). </p> <p>We considered it important to make a distinction between 'recurrent varicose veins' and 'residual varicose veins' because of the clinical relevance. The previous version of this review considered the time to measure the outcome and 'recurrent varicose veins' was defined as an outcome related to the time of the detection (described as 'long‐term patient follow‐up'). The previous version of the review included 'flare formation' in the same outcome. We believe these outcomes are quite different and they should not be measured together. Differences in definitions used by the study authors led us to consider the long‐term outcome as a 'recurrent varicose vein' and short‐term outcome as 'residual varicose vein'. This definition carries bias but we believe we need to be pragmatic. We will consider the subject again in a future update of this review. </p> <p>As with many other interventions, age is likely to increase heterogeneity between study groups. Despite balanced groups there could be different results in older and younger patients. This Cochrane review did not address this topic since we did not have data to investigate this. If possible, we will address this concern in a future update. </p> </section> <section id="CD001732-sec-0138"> <h3 class="title" id="CD001732-sec-0138">Agreements and disagreements with other studies or reviews</h3> <p>One systematic review described foam sclerotherapy as an effective and safe procedure similar to the findings of this review (<a href="./references#CD001732-bbs2-0074" title="RathbunS , NorrisA , StonerJ . Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders. Phlebology2012;27:105-17. [DOI: 10.1258/phleb.2011.011111]">Rathbun 2012</a>). It also described rare serious events like myocardial infarction and death related to sclerotherapy detected in case reports. Our update did not find any of these severe events. Death rates could be a result of the amount of sclerotherapy agent administered as well as anaphylactic reaction and the RCTs were perhaps aware of the injection volume. <a href="./references#CD001732-bbs2-0073" title="RabeE , BreuFX , CavezziA , Coleridge SmithP , FrulliniA , GilletJL , et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology2014;29(6):338-54. [DOI: 10.1177/0268355513483280]">Rabe 2014</a> recommended the maximum injection foam volume of 10 mL since complications like thrombosis and neurological symptoms tend to occur in higher volume injections. This updated review considered only randomised clinical trials while <a href="./references#CD001732-bbs2-0074" title="RathbunS , NorrisA , StonerJ . Efficacy and safety of endovenous foam sclerotherapy: meta-analysis for treatment of venous disorders. Phlebology2012;27:105-17. [DOI: 10.1258/phleb.2011.011111]">Rathbun 2012</a> considered other study types, including case reports, making it difficult to directly compare findings. However, it is important to report that most neurologic events are described in case reports since they are rare (<a href="./references#CD001732-bbs2-0076" title="SarvananthanT , ShepherdAC , WillenbergT , DaviesAH . Neurologicalcomplications of sclerotherapy for varicose veins. Journal of Vascular Surgery2012;55(1):243-51. [DOI: 10.1016/j.jvs.2011.05.093]">Sarvananthan 2012</a>; <a href="./references#CD001732-bbs2-0080" title="WillenbergT , SmithPC , ShepherdA , DaviesAH . Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review. Phlebology2013;28(3):123-31. [DOI: 10.1177/0268355513486745]">Willemberg 2013</a>). So, systematic reviews involving case reports could find more events than those described in the present update. </p> <p>A systematic review by <a href="./references#CD001732-bbs2-0056" title="Hammel-DesnosC , AllaertFA . Liquid versus foam sclerotherapy. Phlebology2009;24:240-246. [DOI: 10.1258/phleb.2009.009047]">Hammel‐Desnos 2009</a> found foam better than liquid for reducing rates of residual varicose veins. This review update confirmed this finding with very low‐certainty evidence. There is still a need for congruence in comparators and doses. </p> <p>No other systematic review involved only sclerotherapy, highlighting the importance of this update to answer clinical questions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001732-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001732-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001732-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 1: Cosmetic appearance: medical related IPR‐V adjusted mean change from baseline (intermediate term)" data-id="CD001732-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 1: Cosmetic appearance: medical related IPR‐V adjusted mean change from baseline (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 2: Cosmetic appearance: participant self assessment PA‐V adjusted mean change from baseline (intermediate term)" data-id="CD001732-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 2: Cosmetic appearance: participant self assessment PA‐V adjusted mean change from baseline (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 3: DVT (short and intermediate term)" data-id="CD001732-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 3: DVT (short and intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 4: Phlebitis or thrombophlebitis rates (intermediate term)" data-id="CD001732-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 4: Phlebitis or thrombophlebitis rates (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 5: Phlebitis or thrombophlebitis rates (intermediate term)" data-id="CD001732-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 5: Phlebitis or thrombophlebitis rates (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 6: Haemorrhagic complications (short term)" data-id="CD001732-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 6: Haemorrhagic complications (short term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 7: Neurologic complications (dizziness, TIA) (short term)" data-id="CD001732-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 7: Neurologic complications (dizziness, TIA) (short term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 8: Residual varicose veins (intermediate term)" data-id="CD001732-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 8: Residual varicose veins (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 9: Quality of life: VEINES‐QOL score change from baseline (intermediate term)" data-id="CD001732-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 9: Quality of life: VEINES‐QOL score change from baseline (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 10: Persistence of symptoms: absolute change from baseline score for the VVSymQ (total score) (intermediate term)" data-id="CD001732-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 10: Persistence of symptoms: absolute change from baseline score for the VVSymQ (total score) (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Foam sclerotherapy versus placebo, Outcome 11: Persistence of symptoms: mean change from baseline score for the VCSS (total score) (intermediate term)" data-id="CD001732-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Foam sclerotherapy versus placebo, Outcome 11: Persistence of symptoms: mean change from baseline score for the VCSS (total score) (intermediate term) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 1: Cosmetic appearance: number of participants with cosmetic improvement (short term) ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 1: Cosmetic appearance: number of participants with cosmetic improvement (short term) ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 2: Cosmetic appearance: number of participants with cosmetic improvement (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 2: Cosmetic appearance: number of participants with cosmetic improvement (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 3: Cosmetic appearance: adjusted mean PA‐V (intermediate term) ‐ polidocanol foam versus polidocanol foam" data-id="CD001732-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 3: Cosmetic appearance: adjusted mean PA‐V (intermediate term) ‐ polidocanol foam versus polidocanol foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 4: Cosmetic appearance: adjusted mean IPR‐V (intermediate term) ‐ polidocanol foam versus polidocanol foam" data-id="CD001732-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 4: Cosmetic appearance: adjusted mean IPR‐V (intermediate term) ‐ polidocanol foam versus polidocanol foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 5: Thromboembolic complications (intermediate term) ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 5: Thromboembolic complications (intermediate term) ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 6: Thromboembolic complications (intermediate term) ‐ polidocanol 3% foam versus polidocanol 1% foam (sensitivity analysis)" data-id="CD001732-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 6: Thromboembolic complications (intermediate term) ‐ polidocanol 3% foam versus polidocanol 1% foam (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 7: DVT (short and intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration" data-id="CD001732-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 7: DVT (short and intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 8: PE (short term) ‐ polidocanol 1% foam versus polidocanol 3% foam" data-id="CD001732-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 8: PE (short term) ‐ polidocanol 1% foam versus polidocanol 3% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 9: Skin pigmentation rates (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 9: Skin pigmentation rates (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 10: Phlebitis or thrombophlebitis rates (intermediate term) ‐ polidocanol &lt; 1% foam versus polidocanol ≥ 1% foam" data-id="CD001732-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 10: Phlebitis or thrombophlebitis rates (intermediate term) ‐ polidocanol &lt; 1% foam versus polidocanol ≥ 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 11: Phlebitis or thrombophlebitis ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 11: Phlebitis or thrombophlebitis ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 12: Haemorrhagic complications (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration" data-id="CD001732-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 12: Haemorrhagic complications (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 13: Neurologic complications (dizziness, TIA) (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration" data-id="CD001732-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 13: Neurologic complications (dizziness, TIA) (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 14: Residual varicose veins (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration" data-id="CD001732-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 14: Residual varicose veins (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 15: Residual varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 15: Residual varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 16: Residual varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam (sensitivity analysis)" data-id="CD001732-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 16: Residual varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 17: Quality of life: adjusted mean change VEINES‐QOL (intermediate term) ‐ polidocanol foam versus polidocanol foam" data-id="CD001732-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 17: Quality of life: adjusted mean change VEINES‐QOL (intermediate term) ‐ polidocanol foam versus polidocanol foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 18: Persistence of symptoms: adjusted mean change from baseline VCSS score (intermediate term) ‐ polidocanol foam versus polidocanol foam" data-id="CD001732-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 18: Persistence of symptoms: adjusted mean change from baseline VCSS score (intermediate term) ‐ polidocanol foam versus polidocanol foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 19: Recurrent varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam" data-id="CD001732-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Foam sclerotherapy versus foam sclerotherapy with different concentrations, Outcome 19: Recurrent varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 1: Cosmetic appearance: participant satisfaction (long term) ‐ polidocanol foam versus polidocanol liquid" data-id="CD001732-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 1: Cosmetic appearance: participant satisfaction (long term) ‐ polidocanol foam versus polidocanol liquid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 2: Skin pigmentation (long term) ‐ polidocanol foam versus polidocanol liquid" data-id="CD001732-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 2: Skin pigmentation (long term) ‐ polidocanol foam versus polidocanol liquid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 3: Residual varicose veins (long term) ‐ polidocanol foam versus polidocanol liquid" data-id="CD001732-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 3: Residual varicose veins (long term) ‐ polidocanol foam versus polidocanol liquid </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 4: Residual varicose veins (long term) ‐ polidocanol foam versus polidocanol liquid (sensitivity analysis)" data-id="CD001732-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 4: Residual varicose veins (long term) ‐ polidocanol foam versus polidocanol liquid (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 5: Recurrent varicose veins (long term) ‐ STS 3% liquid versus STS 3% foam" data-id="CD001732-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Foam sclerotherapy versus liquid sclerotherapy, Outcome 5: Recurrent varicose veins (long term) ‐ STS 3% liquid versus STS 3% foam </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 1: Cosmetic appearance: disappearance of varicose veins (long term) ‐ polidocanol 3% versus STS 1.5%" data-id="CD001732-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 1: Cosmetic appearance: disappearance of varicose veins (long term) ‐ polidocanol 3% versus STS 1.5% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 2: DVT (short and intermediate term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam)" data-id="CD001732-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 2: DVT (short and intermediate term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 3: Skin pigmentation (intermediate term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam)" data-id="CD001732-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 3: Skin pigmentation (intermediate term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 4: Haematoma (short term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam)" data-id="CD001732-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 4: Haematoma (short term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 5: Skin pigmentation (long term) ‐ STS 1.5% versus polidocanol 3%" data-id="CD001732-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 5: Skin pigmentation (long term) ‐ STS 1.5% versus polidocanol 3% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 6: Skin necrosis (long term) ‐ STS 1.5% versus polidocanol 3%" data-id="CD001732-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 6: Skin necrosis (long term) ‐ STS 1.5% versus polidocanol 3% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 7: Residual varicose veins (long term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam)" data-id="CD001732-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 7: Residual varicose veins (long term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 8: Matting (long term) ‐ STS 1.5% versus polidocanol 3%" data-id="CD001732-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy versus sclerotherapy with different substances, Outcome 8: Matting (long term) ‐ STS 1.5% versus polidocanol 3% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 1: Phlebitis or thrombophlebitis rates (short term) ‐ polidocanol 1% foam ‐ antegrade versus retrograde technique" data-id="CD001732-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 1: Phlebitis or thrombophlebitis rates (short term) ‐ polidocanol 1% foam ‐ antegrade versus retrograde technique </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 2: Skin pigmentation rates (long term) ‐ polidocanol 1% foam ‐ antegrade versus retrograde technique" data-id="CD001732-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 2: Skin pigmentation rates (long term) ‐ polidocanol 1% foam ‐ antegrade versus retrograde technique </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 3: Thrombophlebitis rates (short term) ‐ polidocanol 3% foam injected by catheter associated to tumescent technique versus polidocanol 3% foam injected by needle" data-id="CD001732-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 3: Thrombophlebitis rates (short term) ‐ polidocanol 3% foam injected by catheter associated to tumescent technique versus polidocanol 3% foam injected by needle </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 4: Detection of polidocanol foam in deep veins ‐ few injections versus multiple injections" data-id="CD001732-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 4: Detection of polidocanol foam in deep veins ‐ few injections versus multiple injections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 5: Residual varicose veins (long term) ‐ visual foam sclerotherapy versus ultrasound guided foam + visual foam sclerotherapy" data-id="CD001732-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 5: Residual varicose veins (long term) ‐ visual foam sclerotherapy versus ultrasound guided foam + visual foam sclerotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 6: Residual varicose veins (long term) ‐ multiple/fractionated injections versus few/single injections" data-id="CD001732-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 6: Residual varicose veins (long term) ‐ multiple/fractionated injections versus few/single injections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 7: Residual varicose veins (intermediate term) ‐ polidocanol 1% foam retrograde versus antegrade technique" data-id="CD001732-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 7: Residual varicose veins (intermediate term) ‐ polidocanol 1% foam retrograde versus antegrade technique </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 8: Residual varicose veins (intermediate term) ‐ microcatheter directed foam sclerotherapy versus catheter directed foam sclerotherapy" data-id="CD001732-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 8: Residual varicose veins (intermediate term) ‐ microcatheter directed foam sclerotherapy versus catheter directed foam sclerotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 9: Residual varicose veins (intermediate term) ‐ needle foam sclerotherapy versus catheter directed foam sclerotherapy" data-id="CD001732-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 9: Residual varicose veins (intermediate term) ‐ needle foam sclerotherapy versus catheter directed foam sclerotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 10: Residual varicose veins (intermediate term) ‐ needle foam sclerotherapy versus microcatheter directed foam sclerotherapy" data-id="CD001732-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 10: Residual varicose veins (intermediate term) ‐ needle foam sclerotherapy versus microcatheter directed foam sclerotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 11: Residual varicose veins (short term) ‐ polidocanol 3% foam injected by catheter versus polidocanol 3% foam injected by needle" data-id="CD001732-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 11: Residual varicose veins (short term) ‐ polidocanol 3% foam injected by catheter versus polidocanol 3% foam injected by needle </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 12: Participants not requiring retreatment (long term) ‐ polidocanol 3% foam injected by catheter versus polidocanol 3% foam injected by needle" data-id="CD001732-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 12: Participants not requiring retreatment (long term) ‐ polidocanol 3% foam injected by catheter versus polidocanol 3% foam injected by needle </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 13: QoL: AVVQ (long term) ‐ catheter‐directed foam sclerotherapy with tumescence versus ultrasound‐guided foam sclerotherapy" data-id="CD001732-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 13: QoL: AVVQ (long term) ‐ catheter‐directed foam sclerotherapy with tumescence versus ultrasound‐guided foam sclerotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 14: VCSS (long term) ‐ ultrasound guided foam + visual foam sclerotherapy versus visual foam sclerotherapy" data-id="CD001732-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy versus sclerotherapy with different techniques, Outcome 14: VCSS (long term) ‐ ultrasound guided foam + visual foam sclerotherapy versus visual foam sclerotherapy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sclerotherapy versus compression conservative treatment, Outcome 1: Cosmetic appearance: good symptomatic improvement and cosmetic result (long term) liquid STS versus compression" data-id="CD001732-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Sclerotherapy versus compression conservative treatment, Outcome 1: Cosmetic appearance: good symptomatic improvement and cosmetic result (long term) liquid STS versus compression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001732-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/urn:x-wiley:14651858:media:CD001732:CD001732-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sclerotherapy versus compression conservative treatment, Outcome 2: Ulcer (short, intermediate and long term) ‐ liquid STS versus compression" data-id="CD001732-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_t/tCD001732-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Sclerotherapy versus compression conservative treatment, Outcome 2: Ulcer (short, intermediate and long term) ‐ liquid STS versus compression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/media/CDSR/CD001732/image_n/nCD001732-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001732-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Foam sclerotherapy versus placebo for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam sclerotherapy (polidocanol 1%) compared to placebo for varicose veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>a</sup><br/><b>Setting:</b> clinical or hospital‐based study<br/><b>Intervention:</b> polidocanol 1% foam sclerotherapy<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 1% foam sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance (IPR‐V)</b> </p> <p>(Scale from: 0 to 4; 0 being the best appearance (0: none, 1: mild, 2: moderate, 3: severe, 4: very severe))<br/>follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The adjusted mean change from baseline in cosmetic appearance (IPR‐V) was ‐0.04</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 0.76 lower<br/>(0.91 lower to 0.6 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications ‐ DVT</b> </p> <p>follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 5.10<br/>(1.30 to 20.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>302<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c,d,e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(17 to 265) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.19<br/>(0.13 to 0.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>973 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000<br/>(127 to 282) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>(VEINES‐QOL/Sym;<br/>scale from: 0 to 50 with 0 being the worst and 50 better)<br/>follow‐up: 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in QoL (VEINES‐QOL/Sym score) was 9.60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 12.41 higher<br/>(9.56 higher to 15.26 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>f,g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> <p>(VCSS)</p> <p>follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in persistence of symptoms (VCSS score) was ‐1.14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 3.25 lower<br/>(3.9 lower to 2.6 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>g,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrent varicose veins</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated recurrent varicose veins in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DVT</b> : deep vein thrombosis; <b>IPR‐V:</b> independent photography review ‐ visible varicose veins scores;<b>MD</b> : mean difference; <b>QoL</b> : quality of life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>VCSS</b> : venous clinical severity score; <b>VEINES‐QOL/Sym:</b> disease‐specific QoL instrument for chronic venous disorders of the leg </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> There were CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) participants included but there was no description of the proportion of these participants in the groups. <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> used the lower leg as the unit of analysis. In the remaining studies, the participant was the unit of analysis. </p> <p><sup>b</sup> We downgraded the certainty of the evidence two levels as neither personnel nor participants were blinded (risk of bias concerns). </p> <p><sup>c</sup> We downgraded one level for indirectness as <a href="./references#CD001732-bbs2-0021" title="NCT01231373. Polidocanol endovenous microfoam (PEM) versus vehicle for the treatment of saphenofemoral junction (SFJ) incompetence (VANISH-2). clinicaltrials.gov/ct2/show/NCT01231373 (first received 1 November 2010). ToddKL , WrightDI . Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2). Journal of Vascular Surgery2015;3(3):258. ToddKL , WrightDI . The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology2014;29(9):608-18. [DOI: 10.1177/0268355513497709]">Todd 2014</a> included 8.8% CEAP C5 and C6 in the placebo group and 3.4% CEAP C5 and C6 in the polidocanol 1% foam group. </p> <p><sup>d</sup> We downgraded one level due to inconsistency ‐ clinical heterogeneity among studies (severity of disease). </p> <p><sup>e</sup> We downgraded one level for imprecision due to low number of events; CI included both 'no difference' and a 'clinically important difference'. </p> <p><sup>f</sup> We downgraded one level due to a wide CI. </p> <p><sup>g</sup> We downgraded one level for imprecision ‐ low number of participants. </p> <p><sup>h</sup> We downgraded one level for indirectness (8.8% CEAP C5 and C6 participants in the placebo group). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Foam sclerotherapy versus placebo for treating varicose veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001732-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Foam sclerotherapy versus foam sclerotherapy for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam sclerotherapy (polidocanol 3%) compared to foam sclerotherapy (polidocanol 1%) for treating varicose veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>a</sup><br/><b>Setting:</b> hospital or clinical setting<br/><b>Intervention:</b> polidocanol 3% foam sclerotherapy<br/><b>Comparison:</b> polidocanol 1% foam sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 1% foam sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 3% foam sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cosmetic appearance</b> </p> <p>(self‐described cosmetic improvement)<br/>follow‐up: mean 1 year </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.84 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>675 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>749 per 1000<br/>(567 to 992) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complications ‐ thromboembolic</b> </p> <p>follow‐up: range 3 weeks to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.47<br/>(0.41 to 5.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>371<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>d,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/>(7 to 86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: range 6 months to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.67<br/>(0.43 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>371<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>364 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000<br/>(156 to 378) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated QoL for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated persistence of symptoms for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent varicose veins</b> </p> <p>follow‐up: mean 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.62 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>148<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>c,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>446 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>406 per 1000<br/>(276 to 589) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>QoL</b> : quality of life; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a> included 12.5% C1 participants. The studies included participants from C2 to C6 clinical classes without description of the proportions of C5 and C6 participants. </p> <p><sup>b</sup> We downgraded by one level as most risk of bias domains were judged as "unclear". </p> <p><sup>c</sup> We downgraded by one level due to imprecision ‐ single study. </p> <p><sup>d</sup> We downgraded by one level due to imprecision ‐ wide confidence interval. </p> <p><sup>e</sup> We downgraded by one level due to imprecision ‐ low number of participants. </p> <p><sup>f</sup> There were CEAP C1 (11.63% in <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>), C5 (<a href="./references#CD001732-bbs2-0004" title="BlaiseS , BossonJL , DiamandJM . Ultrasound-guided sclerotherapy of the great saphenous vein with 1% vs. 3% polidocanol foam: a multicentre double-blind randomised trial with 3-year follow-up. European Journal of Vascular and Endovascular Surgery2010;39(6):779-86. NCT00348764. ESGVS: sclerotherapy with lauromacrogol. clinicaltrials.gov/ct2/show/NCT00348764 (first received 6 July 2006). ">Blaise 2010</a>; <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>; <a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>), and C6 (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) participants included but there was no description of the proportion of these participants in the groups. <a href="./references#CD001732-bbs2-0005" title="CeulenRP , Bullens-GoessensYI , Pi-Van De VenneSJ , NelemansPJ , VeraartJC , SommerA . Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatologic Surgery2007;33(3):276-81. ">Ceulen 2007</a>) used the lower leg as the unit of analysis. In the remaining studies, the participant was the unit of analysis. We downgraded by one level for indirectness. </p> <p><sup>g</sup> We downgraded by one level due to imprecision ‐ low number of events. </p> <p><sup>h</sup> There were participants from C5 and C6 clinical classes included (<a href="./references#CD001732-bbs2-0010" title='Hamel-DesnosC , AllaertFA , BenigniJP , BoitelleG , ChleirF , OuvryP , et al. Study 3/1. Polidocanol foam 3% versus 1% in the great saphenous vein: early results [Etdue 3/1. Mousse de polidocanol 3% versus 1% dans las grande veine saphene: premiers resultats]. Phlébologie2005;58(2):165-73. Hamel-DesnosC , OuvryP , Benigni J-P, BoitelleG , SchadeckM , DesnosP , et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". European Journal of Vascular and Endovascular Surgery2007;34(6):723-9. Hamel-DesnosC , OuvryP , DesnosP , AllaertFA . 3% versus 1% polidocanol foam in sclerotherapy of the great saphenous vein: randomised double-blind controlled trial with a 2-year follow-up. Study 3/1. Phlébologie2008;61(1):103-9. '>Hamel‐Desnos 2007</a>) but there was no description of the proportion of these participants in the groups. We downgraded by one level for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Foam sclerotherapy versus foam sclerotherapy for treating varicose veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001732-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Foam sclerotherapy versus liquid sclerotherapy for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam sclerotherapy compared to liquid sclerotherapy for varicose treating veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>a</sup><br/><b>Setting:</b> hospital or clinic‐based<br/><b>Intervention:</b> foam sclerotherapy using the same agent and concentration of the control<br/><b>Comparison:</b> liquid sclerotherapy using the same agent and concentration of the intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with liquid sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with foam sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance</b> </p> <p>(patient satisfaction scale, the higher the better)</p> <p>follow‐up: long‐term (365 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean cosmetic appearance of the patient satisfaction scale was 7.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The MD was 0.2 higher (0.27 lower to 0.67 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001732-bbs2-0002" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. ">Alos 2006</a> reported no difference when using polidocanol 0.75% to 1.25% foam versus polidocanol 1.5% to 2.5% liquid. Different concentrations and different vein diameters were compared, reducing our confidence in these results </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complications ‐ DVT</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated DVT or thromboembolic events for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: range 3 months to 2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/>(0.41 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>203<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>842 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000<br/>(345 to 547) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated QoLfor this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated persistence of symptoms for this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent varicose veins</b> </p> <p>follow‐up: mean 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.10<br/>(0.86 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>286<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,e,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>477 per 1000<br/>(373 to 615) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DVT</b> ; deep vein thrombosis; <b>MD:</b> mean difference; <b>QoL:</b> quality of life;<b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Did not describe randomisation method. Due to the nature of the intervention was probably impossible to blind interventionist. We did not find a protocol. Risk of bias concerns </p> <p><sup>b</sup> Single study. We downgraded by one level for imprecision. </p> <p><sup>c</sup> Compared different concentration of the same substances for different vein diameter. Used different concentrations of the drug if liquid or foam </p> <p><sup>d</sup> We downgraded by one level for risk of bias concerns (query about randomisation method). </p> <p><sup>e</sup> We downgraded by one level for risk of bias concerns (intervention was presumably not blinded (foam vs liquid) due to the nature of the intervention). </p> <p><sup>f</sup> One study (<a href="./references#CD001732-bbs2-0015" title="Hamel-DesnosC , DesnosP , OuvryP . New therapeutic methods in the management of varicose disease: echo-sclerotherapy and foam [Nouveautes therapeutiiques dans la prise en charge de la maladie variqueuse: echo-sclerotherapie et mousse]. Phlébologie2003;56(1):41-8. Hamel-DesnosC , DesnosP , WollmannJC , OuvryP , MakoS , AllaertFA . Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatologic Surgery2003;29(12):1170-5. Hamel-DesnosC , OuvryP , DesnosP , MakoS . Evaluation of the efficacy of polidocanol in the form of foam versus liquid form in sclerotherapy of the long saphenous vein. In: 16th Annual Congress of the American College of Phlebology; 7-10 Nov 2002; Fort Lauderdale, Florida. phlebology.org/AbstractsFTL.htm#19. 2002. OuvryP , AllaertFA , DesnosP , Hamel-DesnosC . Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up. European Journal of Vascular and Endovascular Surgery2008;36(3):366-70. ">Ouvry 2008</a>) included participants from CEAP C2 to C6 without discriminating between them. <a href="./references#CD001732-bbs2-0016" title="RabeE , OttoJ , SchliephakeD , PannierF . Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. European Journal of Vascular and Endovascular Surgery2008;35(2):238-45. ">Rabe 2008</a> included 1 CEAP C5 participant in the foam group (1.85%) and 4 CEAP C5 participants in the liquid group (7.69%). We downgraded by one level for indirectness. </p> <p><sup>h</sup><a href="./references#CD001732-bbs2-0003" title="BelcaroG , CesaroneM , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Treatments for varicose veins: surgery, sclerotherapy, foam sclerotherapy and combined (surgery + sclerotherapy) options. A 10-year, prospective, randomised, controlled, follow-up study. The VEDICO* trial and EST (European Sclerotherapy Trial). Angeiologie2003;55(1):29-36. BelcaroG , CesaroneMR , Di RenzoA , BrandoliniR , CoenL , AcerbiG , et al. Foam-sclerotherapy, surgery, sclerotherapy and combined treatment for varicose veins: a 10-year prospective, randomised, controlled trial (VEDICO Trial). Angiology2003;54(3):307-15. ">Belcaro 2003b</a> used a tensioactive substance (ultrasound contrast agent) to produce foam. This is not a standard way to produce foam. We downgraded by one level for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Foam sclerotherapy versus liquid sclerotherapy for treating varicose veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001732-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different substances for treating varicose veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy with STS 1% compared to sclerotherapy with polidocanol 1%<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with varicose veins<sup>b</sup><br/><b>Setting:</b> clinical or hospital‐based study<br/><b>Intervention:</b> STS 1% sclerotherapy<br/><b>Comparison:</b> polidocanol 1% sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with polidocanol 1% sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with STS 1% sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cosmetic appearance</b> </p> <p>follow‐up: 12 to 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two RCTs compared sclerotherapy with sclerotherapy with different substances but used a range of concentrations, formulations and drug volumes. We were unable to pool the data or draw conclusions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Complications ‐ DVT</b> </p> <p>follow‐up: 16 weeks to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two RCTs reported on DVT but we were unable to pool the data or draw conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual varicose veins</b> </p> <p>follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One RCT reported on residual varicose veins but we were unable to draw conclusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated QoL in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Persistence of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated persistence of symptoms in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Recurrent varicose veins</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study evaluated recurrent varicose veins in this comparison</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>DVT</b> : deep vein thrombosis; <b>QoL</b> : quality of life; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>STS:</b> sodium tetradecyl sulphate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Four RCTs compared sclerotherapy with sclerotherapy with different substances but used a range of concentrations, formulations and drug volumes so we were not able to pool the data (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>; <a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>). None of these compared STS 1% sclerotherapy versus sclerotherapy with polidocanol 1% which we had planned to present in this table. </p> <p><sup>b</sup> Three studies did not describe CEAP classification of participants (<a href="./references#CD001732-bbs2-0009" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxysklerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. ">Goldman 2002</a>; <a href="./references#CD001732-bbs2-0018" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5. ">Rao 2005</a>; <a href="./references#CD001732-bbs2-0020" title="SchadeckM . Aetoxisclerol 4% in the treatment of the saphenous veins. In: NegusD , JantetG , Coleridge-SmithP , editors(s). Phlebology. Vol. 1. Springer Verlag Inc, 1995:620. [ISBN: 3540199993]">Schadeck 1995a</a>). One study compared Varisolve with polidocanol 1% to any marketed sclerosant at any marketed concentration liquid or foam (<a href="./references#CD001732-bbs2-0023" title="WrightD , GobinJP , BradburyAW , Coleridge-SmithP , SpoelstraH , BerridgeD , et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology2006;21(4):180-90. WrightD . European randomized controlled trial of Varisolve PD microfoam compared with alternative therapy in management of moderate to severe varicose veins: preliminary results. In: UIP World Congress Chapter Meeting; 2003. San Diego, 2003. ">Wright 2006</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different substances for treating varicose veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/full#CD001732-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001732-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Foam sclerotherapy versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cosmetic appearance: medical related IPR‐V adjusted mean change from baseline (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐0.91, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.11, ‐0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cosmetic appearance: participant self assessment PA‐V adjusted mean change from baseline (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.46 [‐1.72, ‐1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐1.95, ‐1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 DVT (short and intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.08, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.08, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [1.30, 20.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.17, 19.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Phlebitis or thrombophlebitis rates (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [1.02, 19.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [1.09, 9.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Phlebitis or thrombophlebitis rates (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.10, 8.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.79, 16.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Haemorrhagic complications (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.42, 5.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.87, 8.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.75, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.23, 7.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Neurologic complications (dizziness, TIA) (short term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.08, 4.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.16, 7.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.22, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Residual varicose veins (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.34, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.11, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.13, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Polidocanol 2% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.11, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Quality of life: VEINES‐QOL score change from baseline (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.16 [6.17, 16.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.14 [11.02, 17.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.41 [9.56, 15.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Persistence of symptoms: absolute change from baseline score for the VVSymQ (total score) (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.00 [‐15.39, ‐12.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Persistence of symptoms: mean change from baseline score for the VCSS (total score) (intermediate term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Polidocanol 0.125% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.47 [‐3.12, ‐1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Polidocanol 0.5% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.35 [‐4.00, ‐2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Polidocanol 1% foam versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.25 [‐3.90, ‐2.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Foam sclerotherapy versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001732-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Foam sclerotherapy versus foam sclerotherapy with different concentrations</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Cosmetic appearance: number of participants with cosmetic improvement (short term) ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Cosmetic appearance: number of participants with cosmetic improvement (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Cosmetic appearance: adjusted mean PA‐V (intermediate term) ‐ polidocanol foam versus polidocanol foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.03, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.21, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Cosmetic appearance: adjusted mean IPR‐V (intermediate term) ‐ polidocanol foam versus polidocanol foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.01, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.19, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Thromboembolic complications (intermediate term) ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.41, 5.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Thromboembolic complications (intermediate term) ‐ polidocanol 3% foam versus polidocanol 1% foam (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.31, 5.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 DVT (short and intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.01, 14.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Polidocanol 0.125% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.17, 19.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.71 [0.59, 37.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.4 Polidocanol 0.5% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.15, 17.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.5 Polidocanol 1% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.12, 5.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 PE (short term) ‐ polidocanol 1% foam versus polidocanol 3% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Skin pigmentation rates (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.82, 3.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Phlebitis or thrombophlebitis rates (intermediate term) ‐ polidocanol &lt; 1% foam versus polidocanol ≥ 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.54, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 Polidocanol 0.125% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.17, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.3 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.55, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.4 Polidocanol 0.5% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.27, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Phlebitis or thrombophlebitis ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.88, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Haemorrhagic complications (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.20, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 Polidocanol 0.125% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.34, 6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.53, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.4 Polidocanol 0.5% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [0.92, 11.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.5 Polidocanol 1% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.11, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Neurologic complications (dizziness, TIA) (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.06, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.08, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 Polidocanol 0.125% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.31 [0.14, 79.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.4 Polidocanol 0.5% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.15 [0.30, 125.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.5 Polidocanol 1% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.01, 6.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Residual varicose veins (intermediate term) ‐ polidocanol foam lower concentration versus polidocanol foam higher concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [1.76, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 Polidocanol 0.125% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [1.92, 6.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.93, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.4 Polidocanol 0.5% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.26, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.5 Polidocanol 1% foam versus polidocanol 2% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.57, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Residual varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Residual varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.35, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Quality of life: adjusted mean change VEINES‐QOL (intermediate term) ‐ polidocanol foam versus polidocanol foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 Polidocanol 0.125% foam versus polidocanol 0.5% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [‐0.24, 5.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐2.50, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.3 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.82 [‐4.96, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Persistence of symptoms: adjusted mean change from baseline VCSS score (intermediate term) ‐ polidocanol foam versus polidocanol foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 Polidocanol 0.125% foam versus polidocanol 0.5% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐1.52, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 Polidocanol 0.125% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.42, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.3 Polidocanol 0.5% foam versus polidocanol 1% foam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.56, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Recurrent varicose veins (long term) ‐ polidocanol 3% foam versus polidocanol 1% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Foam sclerotherapy versus foam sclerotherapy with different concentrations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001732-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Foam sclerotherapy versus liquid sclerotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Cosmetic appearance: participant satisfaction (long term) ‐ polidocanol foam versus polidocanol liquid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Skin pigmentation (long term) ‐ polidocanol foam versus polidocanol liquid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.81, 3.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Polidocanol 3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.34, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Polidocanol liquid versus foam (unknown concentration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.82, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Residual varicose veins (long term) ‐ polidocanol foam versus polidocanol liquid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.33, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Polidocanol foam (0.75 to 1.25%) versus liquid (1.25 to 2.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.06, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Polidocanol 3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.41, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 Polidocanol (unknown concentration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.12, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 STS 3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Residual varicose veins (long term) ‐ polidocanol foam versus polidocanol liquid (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 STS 3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Recurrent varicose veins (long term) ‐ STS 3% liquid versus STS 3% foam <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Foam sclerotherapy versus liquid sclerotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001732-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different substances</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Cosmetic appearance: disappearance of varicose veins (long term) ‐ polidocanol 3% versus STS 1.5% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 DVT (short and intermediate term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Skin pigmentation (intermediate term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Haematoma (short term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Skin pigmentation (long term) ‐ STS 1.5% versus polidocanol 3% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Skin necrosis (long term) ‐ STS 1.5% versus polidocanol 3% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Residual varicose veins (long term) ‐ Varisolve polidocanol foam versus any market sclerosant (liquid or foam) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Matting (long term) ‐ STS 1.5% versus polidocanol 3% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different substances</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001732-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different techniques</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Phlebitis or thrombophlebitis rates (short term) ‐ polidocanol 1% foam ‐ antegrade versus retrograde technique <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Skin pigmentation rates (long term) ‐ polidocanol 1% foam ‐ antegrade versus retrograde technique <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Thrombophlebitis rates (short term) ‐ polidocanol 3% foam injected by catheter associated to tumescent technique versus polidocanol 3% foam injected by needle <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Detection of polidocanol foam in deep veins ‐ few injections versus multiple injections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Residual varicose veins (long term) ‐ visual foam sclerotherapy versus ultrasound guided foam + visual foam sclerotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Residual varicose veins (long term) ‐ multiple/fractionated injections versus few/single injections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 STS 3% single versus fractionated injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Polidocanol 1% or 3% low versus fractionated injections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Residual varicose veins (intermediate term) ‐ polidocanol 1% foam retrograde versus antegrade technique <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Residual varicose veins (intermediate term) ‐ microcatheter directed foam sclerotherapy versus catheter directed foam sclerotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Residual varicose veins (intermediate term) ‐ needle foam sclerotherapy versus catheter directed foam sclerotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Residual varicose veins (intermediate term) ‐ needle foam sclerotherapy versus microcatheter directed foam sclerotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Residual varicose veins (short term) ‐ polidocanol 3% foam injected by catheter versus polidocanol 3% foam injected by needle <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Participants not requiring retreatment (long term) ‐ polidocanol 3% foam injected by catheter versus polidocanol 3% foam injected by needle <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 QoL: AVVQ (long term) ‐ catheter‐directed foam sclerotherapy with tumescence versus ultrasound‐guided foam sclerotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 VCSS (long term) ‐ ultrasound guided foam + visual foam sclerotherapy versus visual foam sclerotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sclerotherapy versus sclerotherapy with different techniques</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001732-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sclerotherapy versus compression conservative treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Cosmetic appearance: good symptomatic improvement and cosmetic result (long term) liquid STS versus compression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Ulcer (short, intermediate and long term) ‐ liquid STS versus compression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sclerotherapy versus compression conservative treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001732.pub3/references#CD001732-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001732.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001732-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001732-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001732-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD001732-note-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="ko#CD001732-note-0012">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD001732-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001732-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001732-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001732-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001732-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001732\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001732\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001732\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001732\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001732\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001732.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001732.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001732.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001732.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001732.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713761920"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001732.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713761923"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001732.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d5e288d67936e',t:'MTc0MDcxMzc2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 